ICON plcG4705A100IE000571120907/23/2024Elect Director Ciaran MurrayDIRECTOR ELECTIONSISSUER285800.0000000FOR285800.000000FORS000002088ICON plcG4705A100IE000571120907/23/2024Elect Director Steve CutlerDIRECTOR ELECTIONSISSUER285800.0000000FOR285800.000000FORS000002088ICON plcG4705A100IE000571120907/23/2024Elect Director Ronan MurphyDIRECTOR ELECTIONSISSUER285800.0000000FOR285800.000000FORS000002088ICON plcG4705A100IE000571120907/23/2024Elect Director John ClimaxDIRECTOR ELECTIONSISSUER285800.0000000FOR285800.000000FORS000002088ICON plcG4705A100IE000571120907/23/2024Elect Director Julie O'NeillDIRECTOR ELECTIONSISSUER285800.0000000FOR285800.000000FORS000002088ICON plcG4705A100IE000571120907/23/2024Elect Director Eugene McCagueDIRECTOR ELECTIONSISSUER285800.0000000FOR285800.000000FORS000002088ICON plcG4705A100IE000571120907/23/2024Elect Director Linda GraisDIRECTOR ELECTIONSISSUER285800.0000000FOR285800.000000FORS000002088ICON plcG4705A100IE000571120907/23/2024Accept Financial Statements and Statutory ReportsCORPORATE GOVERNANCEISSUER285800.0000000FOR285800.000000FORS000002088ICON plcG4705A100IE000571120907/23/2024Authorise Board to Fix Remuneration of AuditorsAUDIT-RELATEDISSUER285800.0000000FOR285800.000000FORS000002088ICON plcG4705A100IE000571120907/23/2024Authorise Issue of EquityCAPITAL STRUCTUREISSUER285800.0000000FOR285800.000000FORS000002088ICON plcG4705A100IE000571120907/23/2024Authorise Issue of Equity without Pre-emptive RightsCAPITAL STRUCTUREISSUER285800.0000000FOR285800.000000FORS000002088ICON plcG4705A100IE000571120907/23/2024Authorize Issue of Equity without Pre-emptive Rights in Connection with an Acquisition or Other Capital InvestmentCAPITAL STRUCTUREISSUER285800.0000000FOR285800.000000FORS000002088ICON plcG4705A100IE000571120907/23/2024Authorise Market Purchase of Ordinary SharesCAPITAL STRUCTUREISSUER285800.0000000FOR285800.000000FORS000002088ICON plcG4705A100IE000571120907/23/2024Approve the Price Range for the Reissuance of SharesCAPITAL STRUCTUREISSUER285800.0000000FOR285800.000000FORS000002088Haemonetics Corporation405024100US405024100307/25/2024Election of Directors: Robert E. AbernathyDIRECTOR ELECTIONSISSUER265734.0000000FOR265734.000000FORS000002088Haemonetics Corporation405024100US405024100307/25/2024Election of Directors: Diane M. BryantDIRECTOR ELECTIONSISSUER265734.0000000FOR265734.000000FORS000002088Haemonetics Corporation405024100US405024100307/25/2024Election of Directors: Michael J. CoyleDIRECTOR ELECTIONSISSUER265734.0000000FOR265734.000000FORS000002088Haemonetics Corporation405024100US405024100307/25/2024Election of Directors: Charles J. DockendorffDIRECTOR ELECTIONSISSUER265734.0000000FOR265734.000000FORS000002088Haemonetics Corporation405024100US405024100307/25/2024Election of Directors: Lloyd E. JohnsonDIRECTOR ELECTIONSISSUER265734.0000000FOR265734.000000FORS000002088Haemonetics Corporation405024100US405024100307/25/2024Election of Directors: Mark W. KrollDIRECTOR ELECTIONSISSUER265734.0000000FOR265734.000000FORS000002088Haemonetics Corporation405024100US405024100307/25/2024Election of Directors: Claire PomeroyDIRECTOR ELECTIONSISSUER265734.0000000FOR265734.000000FORS000002088Haemonetics Corporation405024100US405024100307/25/2024Election of Directors: Christopher A. SimonDIRECTOR ELECTIONSISSUER265734.0000000FOR265734.000000FORS000002088Haemonetics Corporation405024100US405024100307/25/2024Election of Directors: Ellen M. ZaneDIRECTOR ELECTIONSISSUER265734.0000000FOR265734.000000FORS000002088Haemonetics Corporation405024100US405024100307/25/2024To approve, on an advisory basis, the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER265734.0000000FOR265734.000000FORS000002088Haemonetics Corporation405024100US405024100307/25/2024To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending March 29, 2025.AUDIT-RELATEDISSUER265734.0000000FOR265734.000000FORS000002088McKesson Corporation58155Q103US58155Q103107/31/2024Election of eleven directors for a one-year term: Richard H. Carmona, M.D.DIRECTOR ELECTIONSISSUER112809.0000000FOR112809.000000FORS000002088McKesson Corporation58155Q103US58155Q103107/31/2024Election of eleven directors for a one-year term: Dominic J. CarusoDIRECTOR ELECTIONSISSUER112809.0000000FOR112809.000000FORS000002088McKesson Corporation58155Q103US58155Q103107/31/2024Election of eleven directors for a one-year term: W. Roy DunbarDIRECTOR ELECTIONSISSUER112809.0000000FOR112809.000000FORS000002088McKesson Corporation58155Q103US58155Q103107/31/2024Election of eleven directors for a one-year term: Deborah Dunsire, M.D.DIRECTOR ELECTIONSISSUER112809.0000000FOR112809.000000FORS000002088McKesson Corporation58155Q103US58155Q103107/31/2024Election of eleven directors for a one-year term: James H. HintonDIRECTOR ELECTIONSISSUER112809.0000000FOR112809.000000FORS000002088McKesson Corporation58155Q103US58155Q103107/31/2024Election of eleven directors for a one-year term: Donald R. KnaussDIRECTOR ELECTIONSISSUER112809.0000000FOR112809.000000FORS000002088McKesson Corporation58155Q103US58155Q103107/31/2024Election of eleven directors for a one-year term: Bradley E. LermanDIRECTOR ELECTIONSISSUER112809.0000000FOR112809.000000FORS000002088McKesson Corporation58155Q103US58155Q103107/31/2024Election of eleven directors for a one-year term: Maria N. MartinezDIRECTOR ELECTIONSISSUER112809.0000000FOR112809.000000FORS000002088McKesson Corporation58155Q103US58155Q103107/31/2024Election of eleven directors for a one-year term: Kevin M. OzanDIRECTOR ELECTIONSISSUER112809.0000000FOR112809.000000FORS000002088McKesson Corporation58155Q103US58155Q103107/31/2024Election of eleven directors for a one-year term: Brian S. TylerDIRECTOR ELECTIONSISSUER112809.0000000FOR112809.000000FORS000002088McKesson Corporation58155Q103US58155Q103107/31/2024Election of eleven directors for a one-year term: Kathleen Wilson-ThompsonDIRECTOR ELECTIONSISSUER112809.0000000FOR112809.000000FORS000002088McKesson Corporation58155Q103US58155Q103107/31/2024Ratification of Appointment of Deloitte & Touche LLP as the Company's Independent Registered Public Accounting Firm for Fiscal Year 2025AUDIT-RELATEDISSUER112809.0000000FOR112809.000000FORS000002088McKesson Corporation58155Q103US58155Q103107/31/2024Advisory vote on Executive CompensationSECTION 14A SAY-ON-PAY VOTESISSUER112809.0000000FOR112809.000000FORS000002088McKesson Corporation58155Q103US58155Q103107/31/2024Approve Amendment to Certificate of Incorporation to Provide for Officer ExculpationCORPORATE GOVERNANCEISSUER112809.0000000FOR112809.000000FORS000002088McKesson Corporation58155Q103US58155Q103107/31/2024Shareholder Proposal on Independent Board ChairmanCORPORATE GOVERNANCESECURITY HOLDER112809.0000000AGAINST112809.000000FORS000002088McKesson Corporation58155Q103US58155Q103107/31/2024Shareholder Proposal on Report on Risks of State Policies Restricting Reproductive Health CareOTHER SOCIAL ISSUESSECURITY HOLDER112809.0000000AGAINST112809.000000FORS000002088Wave Life Sciences Ltd.Y95308105SG999901471608/06/2024The election of the nominees for director: Paul B. Bolno, M.D., MBADIRECTOR ELECTIONSISSUER1316941.0000000FOR1316941.000000FORS000002088Wave Life Sciences Ltd.Y95308105SG999901471608/06/2024The election of the nominees for director: Mark H. N. Corrigan, M.D.DIRECTOR ELECTIONSISSUER1316941.0000000FOR1316941.000000FORS000002088Wave Life Sciences Ltd.Y95308105SG999901471608/06/2024The election of the nominees for director: Christian HenryDIRECTOR ELECTIONSISSUER1316941.0000000AGAINST1316941.000000AGAINSTS000002088Wave Life Sciences Ltd.Y95308105SG999901471608/06/2024The election of the nominees for director: Peter Kolchinsky, Ph.D.DIRECTOR ELECTIONSISSUER1316941.0000000FOR1316941.000000FORS000002088Wave Life Sciences Ltd.Y95308105SG999901471608/06/2024The election of the nominees for director: Adrian RawcliffeDIRECTOR ELECTIONSISSUER1316941.0000000FOR1316941.000000FORS000002088Wave Life Sciences Ltd.Y95308105SG999901471608/06/2024The election of the nominees for director: Ken TakanashiDIRECTOR ELECTIONSISSUER1316941.0000000FOR1316941.000000FORS000002088Wave Life Sciences Ltd.Y95308105SG999901471608/06/2024The election of the nominees for director: Aik Na TanDIRECTOR ELECTIONSISSUER1316941.0000000FOR1316941.000000FORS000002088Wave Life Sciences Ltd.Y95308105SG999901471608/06/2024The election of the nominees for director: Gregory L. Verdine, Ph.D.DIRECTOR ELECTIONSISSUER1316941.0000000FOR1316941.000000FORS000002088Wave Life Sciences Ltd.Y95308105SG999901471608/06/2024The election of the nominees for director: Heidi L. Wagner, J.D.DIRECTOR ELECTIONSISSUER1316941.0000000FOR1316941.000000FORS000002088Wave Life Sciences Ltd.Y95308105SG999901471608/06/2024To approve the re-appointment of KPMG LLP to serve as our independent registered public accounting firm and independent Singapore auditor for the year ending December 31, 2024, and to authorize the Audit Committee of the Board of Directors to fix KPMG LLP's remuneration for services provided through the date of our 2025 Annual General Meeting of ShareholdersAUDIT-RELATEDISSUER1316941.0000000FOR1316941.000000FORS000002088Wave Life Sciences Ltd.Y95308105SG999901471608/06/2024To approve our payment of cash and equity-based compensation to non-employee directors for service on the Board of Directors and its committees, in the manner and on the basis set forth under "Proposal 3: Non-Employee Directors' Compensation" in the proxy statementCOMPENSATIONISSUER1316941.0000000FOR1316941.000000FORS000002088Wave Life Sciences Ltd.Y95308105SG999901471608/06/2024To approve a proposed amendment to our 2021 Equity Incentive Plan, as amended, in the manner and on the basis as set forth under "Proposal 4: Approval of an Amendment to the 2021 Equity Incentive Plan, as amended" in the proxy statementCOMPENSATIONISSUER1316941.0000000AGAINST1316941.000000AGAINSTS000002088Wave Life Sciences Ltd.Y95308105SG999901471608/06/2024To authorize the Board of Directors to allot and issue Ordinary Shares of Wave Life Sciences Ltd.CAPITAL STRUCTUREISSUER1316941.0000000AGAINST1316941.000000AGAINSTS000002088Wave Life Sciences Ltd.Y95308105SG999901471608/06/2024To approve, by a non-binding advisory vote, the compensation of our named executive officers as disclosed in the proxy statementSECTION 14A SAY-ON-PAY VOTESISSUER1316941.0000000FOR1316941.000000FORS000002088Ginkgo Bioworks Holdings, Inc.37611X209US37611X209908/14/2024To approve Article V, Section 1(c) of the Company's Amended and Restated Certificate of Incorporation to effect, at the discretion of the Company's Board of Directors, a reverse stock split of the issued and outstanding shares of Class A common stock and Class B common stock, which would combine a whole number of outstanding shares of the Class A common stock and Class B common stock in a range of not less than one-for-twenty (1:20) shares and not more than one-for-forty (1:40) shares into one share of Class A common stock or Class B common stock, as applicable, and reduce the number of outstanding shares of Class A common stock and Class B common stock.CAPITAL STRUCTUREISSUER1536635.0000000FOR1536635.000000FORS000002088Ginkgo Bioworks Holdings, Inc.37611X209US37611X209908/14/2024To approve Article VIII of the Company's Amended and Restated Certificate of Incorporation to permit officer exculpation.CORPORATE GOVERNANCEISSUER1536635.0000000AGAINST1536635.000000AGAINSTS000002088Ginkgo Bioworks Holdings, Inc.37611X209US37611X209908/14/2024To approve the Company's Amended and Restated Certificate of Incorporation, which has been updated to, among other things, remove provisions related to our merger with Soaring Eagle Acquisition Corp. and our domestication process, which are no longer relevant to our business.CORPORATE GOVERNANCEISSUER1536635.0000000FOR1536635.000000FORS000002088Replimune Group, Inc.76029N106US76029N106309/04/2024Election of Directors: Sushil PatelDIRECTOR ELECTIONSISSUER1623299.0000000FOR1623299.000000FORS000002088Replimune Group, Inc.76029N106US76029N106309/04/2024Election of Directors: Dieter WeinandDIRECTOR ELECTIONSISSUER1623299.0000000FOR1623299.000000FORS000002088Replimune Group, Inc.76029N106US76029N106309/04/2024Election of Directors: Madhavan BalachandranDIRECTOR ELECTIONSISSUER1623299.0000000FOR1623299.000000FORS000002088Replimune Group, Inc.76029N106US76029N106309/04/2024To ratify the selection of PricewaterhouseCoopers LLP as the independent registered public accounting firm for Replimune Group, Inc. for the fiscal year ending March 31, 2025.AUDIT-RELATEDISSUER1623299.0000000FOR1623299.000000FORS000002088Replimune Group, Inc.76029N106US76029N106309/04/2024To approve, on a non-binding advisory basis, the compensation of Replimune Group, Inc.'s named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER1623299.0000000FOR1623299.000000FORS000002088Replimune Group, Inc.76029N106US76029N106309/04/2024To approve, on a non-binding advisory basis, the preferred frequency of future advisory votes on the compensation of Replimune Group, Inc.'s named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER1623299.0000000ONE YEAR1623299.000000FORS000002088Rhythm Pharmaceuticals, Inc.76243J105US76243J105109/18/2024Election of the Class I directors, each to serve for a three year term until the 2027 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified: Stuart A. ArbuckleDIRECTOR ELECTIONSISSUER171902.0000000FOR171902.000000FORS000002088Rhythm Pharmaceuticals, Inc.76243J105US76243J105109/18/2024Election of the Class I directors, each to serve for a three year term until the 2027 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified: Christophe R. JeanDIRECTOR ELECTIONSISSUER171902.0000000FOR171902.000000FORS000002088Rhythm Pharmaceuticals, Inc.76243J105US76243J105109/18/2024Election of the Class I directors, each to serve for a three year term until the 2027 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified: Lynn A. TetraultDIRECTOR ELECTIONSISSUER171902.0000000FOR171902.000000FORS000002088Rhythm Pharmaceuticals, Inc.76243J105US76243J105109/18/2024Ratification of the appointment of Ernst & Young LLP as the independent registered public accounting firm for the Company for the fiscal year ending December 31, 2024.AUDIT-RELATEDISSUER171902.0000000FOR171902.000000FORS000002088Rhythm Pharmaceuticals, Inc.76243J105US76243J105109/18/2024Approval, on an advisory (non-binding) basis, of the compensation of the named executive officers of the Company.SECTION 14A SAY-ON-PAY VOTESISSUER171902.0000000FOR171902.000000FORS000002088Rhythm Pharmaceuticals, Inc.76243J105US76243J105109/18/2024Reapproval of the Rhythm Pharmaceuticals, Inc. 2017 Equity Incentive Plan.COMPENSATIONISSUER171902.0000000AGAINST171902.000000AGAINSTS000002088Legend Biotech Corporation52490G102US52490G102210/21/2024Accept Financial Statements and Statutory ReportsCORPORATE GOVERNANCEISSUER802871.0000000FOR802871.000000FORS000002088Legend Biotech Corporation52490G102US52490G102210/21/2024Ratify Ernst & Young LLP as AuditorsAUDIT-RELATEDISSUER802871.0000000FOR802871.000000FORS000002088Legend Biotech Corporation52490G102US52490G102210/21/2024Elect Director Ye WangDIRECTOR ELECTIONSISSUER802871.0000000AGAINST802871.000000AGAINSTS000002088Legend Biotech Corporation52490G102US52490G102210/21/2024Elect Director Darren Xiaohui JiDIRECTOR ELECTIONSISSUER802871.0000000FOR802871.000000FORS000002088Legend Biotech Corporation52490G102US52490G102210/21/2024Elect Director Ying HuangDIRECTOR ELECTIONSISSUER802871.0000000FOR802871.000000FORS000002088Legend Biotech Corporation52490G102US52490G102210/21/2024Elect Director Tomas HeymanDIRECTOR ELECTIONSISSUER802871.0000000FOR802871.000000FORS000002088Legend Biotech Corporation52490G102US52490G102210/21/2024Amend Restricted Stock PlanCOMPENSATIONISSUER802871.0000000FOR802871.000000FORS000002088Legend Biotech Corporation52490G102US52490G102210/21/2024Authorize Board to Ratify and Execute Approved ResolutionsCORPORATE GOVERNANCEISSUER802871.0000000FOR802871.000000FORS000002088Bio-Techne Corporation09073M104US09073M104510/24/2024To set the number of Directors at nine.CORPORATE GOVERNANCEISSUER1156885.0000000FOR1156885.000000FORS000002088Bio-Techne Corporation09073M104US09073M104510/24/2024Election of Directors: Robert V. BaumgartnerDIRECTOR ELECTIONSISSUER1156885.0000000FOR1156885.000000FORS000002088Bio-Techne Corporation09073M104US09073M104510/24/2024Election of Directors: Julie L. BushmanDIRECTOR ELECTIONSISSUER1156885.0000000FOR1156885.000000FORS000002088Bio-Techne Corporation09073M104US09073M104510/24/2024Election of Directors: Judith KlimovskyDIRECTOR ELECTIONSISSUER1156885.0000000FOR1156885.000000FORS000002088Bio-Techne Corporation09073M104US09073M104510/24/2024Election of Directors: John L. HigginsDIRECTOR ELECTIONSISSUER1156885.0000000FOR1156885.000000FORS000002088Bio-Techne Corporation09073M104US09073M104510/24/2024Election of Directors: Kim KeldermanDIRECTOR ELECTIONSISSUER1156885.0000000FOR1156885.000000FORS000002088Bio-Techne Corporation09073M104US09073M104510/24/2024Election of Directors: Alpna SethDIRECTOR ELECTIONSISSUER1156885.0000000FOR1156885.000000FORS000002088Bio-Techne Corporation09073M104US09073M104510/24/2024Election of Directors: Rupert VesseyDIRECTOR ELECTIONSISSUER1156885.0000000FOR1156885.000000FORS000002088Bio-Techne Corporation09073M104US09073M104510/24/2024Election of Directors: Joseph D. KeeganDIRECTOR ELECTIONSISSUER1156885.0000000FOR1156885.000000FORS000002088Bio-Techne Corporation09073M104US09073M104510/24/2024Election of Directors: Roeland NusseDIRECTOR ELECTIONSISSUER1156885.0000000FOR1156885.000000FORS000002088Bio-Techne Corporation09073M104US09073M104510/24/2024Approve, on an advisory basis, the compensation of our executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER1156885.0000000FOR1156885.000000FORS000002088Bio-Techne Corporation09073M104US09073M104510/24/2024Ratify the appointment of KPMG, LLP as the Company's independent registered public accounting firm for the 2025 fiscal year.AUDIT-RELATEDISSUER1156885.0000000FOR1156885.000000FORS000002088Cardinal Health, Inc.14149Y108US14149Y108211/06/2024Election of Directors: Robert W. AzelbyDIRECTOR ELECTIONSISSUER322341.0000000FOR322341.000000FORS000002088Cardinal Health, Inc.14149Y108US14149Y108211/06/2024Election of Directors: Michelle M. BrennanDIRECTOR ELECTIONSISSUER322341.0000000FOR322341.000000FORS000002088Cardinal Health, Inc.14149Y108US14149Y108211/06/2024Election of Directors: Sheri H. EdisonDIRECTOR ELECTIONSISSUER322341.0000000FOR322341.000000FORS000002088Cardinal Health, Inc.14149Y108US14149Y108211/06/2024Election of Directors: David C. EvansDIRECTOR ELECTIONSISSUER322341.0000000FOR322341.000000FORS000002088Cardinal Health, Inc.14149Y108US14149Y108211/06/2024Election of Directors: Patricia A. Hemingway HallDIRECTOR ELECTIONSISSUER322341.0000000FOR322341.000000FORS000002088Cardinal Health, Inc.14149Y108US14149Y108211/06/2024Election of Directors: Jason M. HollarDIRECTOR ELECTIONSISSUER322341.0000000FOR322341.000000FORS000002088Cardinal Health, Inc.14149Y108US14149Y108211/06/2024Election of Directors: Akhil JohriDIRECTOR ELECTIONSISSUER322341.0000000FOR322341.000000FORS000002088Cardinal Health, Inc.14149Y108US14149Y108211/06/2024Election of Directors: Gregory B. KennyDIRECTOR ELECTIONSISSUER322341.0000000FOR322341.000000FORS000002088Cardinal Health, Inc.14149Y108US14149Y108211/06/2024Election of Directors: Nancy KilleferDIRECTOR ELECTIONSISSUER322341.0000000FOR322341.000000FORS000002088Cardinal Health, Inc.14149Y108US14149Y108211/06/2024Election of Directors: Christine A. MundkurDIRECTOR ELECTIONSISSUER322341.0000000FOR322341.000000FORS000002088Cardinal Health, Inc.14149Y108US14149Y108211/06/2024To approve, on a non-binding advisory basis, the compensation of our named executive officersSECTION 14A SAY-ON-PAY VOTESISSUER322341.0000000FOR322341.000000FORS000002088Cardinal Health, Inc.14149Y108US14149Y108211/06/2024To ratify the appointment of Ernst & Young LLP as our independent auditor for the fiscal year ending June 30, 2025AUDIT-RELATEDISSUER322341.0000000FOR322341.000000FORS000002088Cardinal Health, Inc.14149Y108US14149Y108211/06/2024Shareholder proposal to prohibit re-nomination of any director who fails to receive a majority vote, if properly presentedCORPORATE GOVERNANCESECURITY HOLDER322341.0000000AGAINST322341.000000FORS000002088Oruka Therapeutics, Inc.687604108US687604108711/14/2024To approve, in accordance with Nasdaq Listing Rule 5635(d), the issuance of shares of the Company's common stock upon conversion of the Company's Series A Non-Voting Convertible Preferred Stock, par value $0.001 per share, issued in September 2024.CAPITAL STRUCTUREISSUER1125095.0000000FOR1125095.000000FORS000002088Oruka Therapeutics, Inc.687604108US687604108711/14/2024To approve an adjournment of the Special Meeting, if necessary or appropriate, to solicit additional proxies.CORPORATE GOVERNANCEISSUER1125095.0000000AGAINST1125095.000000AGAINSTS000002088Becton, Dickinson and Company075887109US075887109101/28/2025Election of Directors: William M. BrownDIRECTOR ELECTIONSISSUER688152.0000000FOR688152.000000FORS000002088Becton, Dickinson and Company075887109US075887109101/28/2025Election of Directors: Catherine M. BurzikDIRECTOR ELECTIONSISSUER688152.0000000FOR688152.000000FORS000002088Becton, Dickinson and Company075887109US075887109101/28/2025Election of Directors: Carrie ByingtonDIRECTOR ELECTIONSISSUER688152.0000000FOR688152.000000FORS000002088Becton, Dickinson and Company075887109US075887109101/28/2025Election of Directors: R. Andrew EckertDIRECTOR ELECTIONSISSUER688152.0000000FOR688152.000000FORS000002088Becton, Dickinson and Company075887109US075887109101/28/2025Election of Directors: Claire M. FraserDIRECTOR ELECTIONSISSUER688152.0000000FOR688152.000000FORS000002088Becton, Dickinson and Company075887109US075887109101/28/2025Election of Directors: Jeffrey W. HendersonDIRECTOR ELECTIONSISSUER688152.0000000FOR688152.000000FORS000002088Becton, Dickinson and Company075887109US075887109101/28/2025Election of Directors: Christopher JonesDIRECTOR ELECTIONSISSUER688152.0000000FOR688152.000000FORS000002088Becton, Dickinson and Company075887109US075887109101/28/2025Election of Directors: Thomas E. PolenDIRECTOR ELECTIONSISSUER688152.0000000FOR688152.000000FORS000002088Becton, Dickinson and Company075887109US075887109101/28/2025Election of Directors: Timothy M. RingDIRECTOR ELECTIONSISSUER688152.0000000FOR688152.000000FORS000002088Becton, Dickinson and Company075887109US075887109101/28/2025Election of Directors: Bertram L. ScottDIRECTOR ELECTIONSISSUER688152.0000000FOR688152.000000FORS000002088Becton, Dickinson and Company075887109US075887109101/28/2025Election of Directors: Joanne WaldstreicherDIRECTOR ELECTIONSISSUER688152.0000000FOR688152.000000FORS000002088Becton, Dickinson and Company075887109US075887109101/28/2025Ratification of the selection of the independent registered public accounting firm.AUDIT-RELATEDISSUER688152.0000000FOR688152.000000FORS000002088Becton, Dickinson and Company075887109US075887109101/28/2025Advisory vote to approve named executive officer compensation.SECTION 14A SAY-ON-PAY VOTESISSUER688152.0000000FOR688152.000000FORS000002088Hologic Inc.436440101US436440101202/26/2025Election of Directors: Stephen P. MacMillanDIRECTOR ELECTIONSISSUER471719.0000000FOR471719.000000FORS000002088Hologic Inc.436440101US436440101202/26/2025Election of Directors: Charles J. DockendorffDIRECTOR ELECTIONSISSUER471719.0000000FOR471719.000000FORS000002088Hologic Inc.436440101US436440101202/26/2025Election of Directors: Ludwig N. HantsonDIRECTOR ELECTIONSISSUER471719.0000000FOR471719.000000FORS000002088Hologic Inc.436440101US436440101202/26/2025Election of Directors: Martin MadausDIRECTOR ELECTIONSISSUER471719.0000000FOR471719.000000FORS000002088Hologic Inc.436440101US436440101202/26/2025Election of Directors: Nanaz MohtashamiDIRECTOR ELECTIONSISSUER471719.0000000FOR471719.000000FORS000002088Hologic Inc.436440101US436440101202/26/2025Election of Directors: Christiana StamoulisDIRECTOR ELECTIONSISSUER471719.0000000FOR471719.000000FORS000002088Hologic Inc.436440101US436440101202/26/2025Election of Directors: Stacey D. StewartDIRECTOR ELECTIONSISSUER471719.0000000FOR471719.000000FORS000002088Hologic Inc.436440101US436440101202/26/2025Election of Directors: Amy M. WendellDIRECTOR ELECTIONSISSUER471719.0000000FOR471719.000000FORS000002088Hologic Inc.436440101US436440101202/26/2025A non-binding advisory vote to approve executive compensation.SECTION 14A SAY-ON-PAY VOTESISSUER471719.0000000FOR471719.000000FORS000002088Hologic Inc.436440101US436440101202/26/2025Ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for fiscal 2025.AUDIT-RELATEDISSUER471719.0000000FOR471719.000000FORS000002088Hologic Inc.436440101US436440101202/26/2025Advisory approval of a stockholder proposal to replace the supermajority voting provisions in our charter and bylaws with a simple majority voting standard.CORPORATE GOVERNANCESECURITY HOLDER471719.0000000FOR471719.000000NONES000002088Cencora, Inc.03073E105US03073E105503/06/2025Election of eleven directors: Ornella BarraDIRECTOR ELECTIONSISSUER167452.0000000FOR167452.000000FORS000002088Cencora, Inc.03073E105US03073E105503/06/2025Election of eleven directors: Werner BaumannDIRECTOR ELECTIONSISSUER167452.0000000FOR167452.000000FORS000002088Cencora, Inc.03073E105US03073E105503/06/2025Election of eleven directors: Frank K. ClyburnDIRECTOR ELECTIONSISSUER167452.0000000FOR167452.000000FORS000002088Cencora, Inc.03073E105US03073E105503/06/2025Election of eleven directors: Steven H. CollisDIRECTOR ELECTIONSISSUER167452.0000000FOR167452.000000FORS000002088Cencora, Inc.03073E105US03073E105503/06/2025Election of eleven directors: D. Mark DurcanDIRECTOR ELECTIONSISSUER167452.0000000FOR167452.000000FORS000002088Cencora, Inc.03073E105US03073E105503/06/2025Election of eleven directors: Lon R. GreenbergDIRECTOR ELECTIONSISSUER167452.0000000FOR167452.000000FORS000002088Cencora, Inc.03073E105US03073E105503/06/2025Election of eleven directors: Lorence H. Kim, M.D.DIRECTOR ELECTIONSISSUER167452.0000000FOR167452.000000FORS000002088Cencora, Inc.03073E105US03073E105503/06/2025Election of eleven directors: Robert P. MauchDIRECTOR ELECTIONSISSUER167452.0000000FOR167452.000000FORS000002088Cencora, Inc.03073E105US03073E105503/06/2025Election of eleven directors: Redonda G. Miller, M.D.DIRECTOR ELECTIONSISSUER167452.0000000FOR167452.000000FORS000002088Cencora, Inc.03073E105US03073E105503/06/2025Election of eleven directors: Dennis M. NallyDIRECTOR ELECTIONSISSUER167452.0000000FOR167452.000000FORS000002088Cencora, Inc.03073E105US03073E105503/06/2025Election of eleven directors: Lauren M. TylerDIRECTOR ELECTIONSISSUER167452.0000000FOR167452.000000FORS000002088Cencora, Inc.03073E105US03073E105503/06/2025Advisory vote to approve the fiscal 2024 compensation of Cencora, Inc.'s named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER167452.0000000FOR167452.000000FORS000002088Cencora, Inc.03073E105US03073E105503/06/2025Ratify the appointment of Ernst & Young LLP as Cencora, Inc.'s independent registered public accounting firm for fiscal 2025.AUDIT-RELATEDISSUER167452.0000000FOR167452.000000FORS000002088Agilent Technologies, Inc.00846U101US00846U101603/13/2025Election of Directors: To elect two directors to a three-year term. At the annual meeting, the Board of Directors intends to present the following nominees for election as directors: Otis W. Brawley, M.D.DIRECTOR ELECTIONSISSUER481641.0000000FOR481641.000000FORS000002088Agilent Technologies, Inc.00846U101US00846U101603/13/2025Election of Directors: To elect two directors to a three-year term. At the annual meeting, the Board of Directors intends to present the following nominees for election as directors: Mikael Dolsten, M.D., Ph.D.DIRECTOR ELECTIONSISSUER481641.0000000FOR481641.000000FORS000002088Agilent Technologies, Inc.00846U101US00846U101603/13/2025To approve, on a non-binding advisory basis, the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER481641.0000000FOR481641.000000FORS000002088Agilent Technologies, Inc.00846U101US00846U101603/13/2025To ratify the Audit and Finance Committee's appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm.AUDIT-RELATEDISSUER481641.0000000FOR481641.000000FORS000002088Agilent Technologies, Inc.00846U101US00846U101603/13/2025To approve the amendments to Agilent's Second Amended and Restated Certificate of Incorporation to remove supermajority voting requirements.CORPORATE GOVERNANCEISSUER481641.0000000FOR481641.000000FORS000002088Agilent Technologies, Inc.00846U101US00846U101603/13/2025To elect each director annually.SHAREHOLDER RIGHTS AND DEFENSESSECURITY HOLDER481641.0000000FOR481641.000000NONES000002088Chugai Pharmaceutical Co., Ltd.J06930101JP351940000003/27/2025Approve Allocation of Income, with a Final Dividend of JPY 57CAPITAL STRUCTUREISSUER1546800.0000000FOR1546800.000000FORS000002088Chugai Pharmaceutical Co., Ltd.J06930101JP351940000003/27/2025Elect Director Okuda, OsamuDIRECTOR ELECTIONSISSUER1546800.0000000FOR1546800.000000FORS000002088Chugai Pharmaceutical Co., Ltd.J06930101JP351940000003/27/2025Elect Director Taniguchi, IwaakiDIRECTOR ELECTIONSISSUER1546800.0000000FOR1546800.000000FORS000002088Chugai Pharmaceutical Co., Ltd.J06930101JP351940000003/27/2025Elect Director Iikura, HitoshiDIRECTOR ELECTIONSISSUER1546800.0000000FOR1546800.000000FORS000002088Chugai Pharmaceutical Co., Ltd.J06930101JP351940000003/27/2025Elect Director Momoi, MarikoDIRECTOR ELECTIONSISSUER1546800.0000000FOR1546800.000000FORS000002088Chugai Pharmaceutical Co., Ltd.J06930101JP351940000003/27/2025Elect Director Tateishi, FumioDIRECTOR ELECTIONSISSUER1546800.0000000FOR1546800.000000FORS000002088Chugai Pharmaceutical Co., Ltd.J06930101JP351940000003/27/2025Elect Director Teramoto, HideoDIRECTOR ELECTIONSISSUER1546800.0000000FOR1546800.000000FORS000002088Chugai Pharmaceutical Co., Ltd.J06930101JP351940000003/27/2025Elect Director Thomas SchineckerDIRECTOR ELECTIONSISSUER1546800.0000000FOR1546800.000000FORS000002088Chugai Pharmaceutical Co., Ltd.J06930101JP351940000003/27/2025Elect Director Teresa A. GrahamDIRECTOR ELECTIONSISSUER1546800.0000000FOR1546800.000000FORS000002088Chugai Pharmaceutical Co., Ltd.J06930101JP351940000003/27/2025Elect Director Boris L. ZaitraDIRECTOR ELECTIONSISSUER1546800.0000000FOR1546800.000000FORS000002088Chugai Pharmaceutical Co., Ltd.J06930101JP351940000003/27/2025Appoint Statutory Auditor Higuchi, MasayoshiCOMPENSATIONCORPORATE GOVERNANCEISSUER1546800.0000000FOR1546800.000000FORS000002088The Cooper Companies, Inc.216648501US216648501904/02/2025Election of Directors: Robert S. WeissDIRECTOR ELECTIONSISSUER315197.0000000FOR315197.000000FORS000002088The Cooper Companies, Inc.216648501US216648501904/02/2025Election of Directors: Colleen E. JayDIRECTOR ELECTIONSISSUER315197.0000000FOR315197.000000FORS000002088The Cooper Companies, Inc.216648501US216648501904/02/2025Election of Directors: Lawrence E. KurziusDIRECTOR ELECTIONSISSUER315197.0000000FOR315197.000000FORS000002088The Cooper Companies, Inc.216648501US216648501904/02/2025Election of Directors: Cynthia L. LuccheseDIRECTOR ELECTIONSISSUER315197.0000000FOR315197.000000FORS000002088The Cooper Companies, Inc.216648501US216648501904/02/2025Election of Directors: Teresa S. MaddenDIRECTOR ELECTIONSISSUER315197.0000000FOR315197.000000FORS000002088The Cooper Companies, Inc.216648501US216648501904/02/2025Election of Directors: Maria Rivas, M.D.DIRECTOR ELECTIONSISSUER315197.0000000FOR315197.000000FORS000002088The Cooper Companies, Inc.216648501US216648501904/02/2025Election of Directors: Albert G. White IIIDIRECTOR ELECTIONSISSUER315197.0000000FOR315197.000000FORS000002088The Cooper Companies, Inc.216648501US216648501904/02/2025Approve an amendment to our Second Restated Certificate of Incorporation to provide for the exculpation of officers.CORPORATE GOVERNANCEISSUER315197.0000000FOR315197.000000FORS000002088The Cooper Companies, Inc.216648501US216648501904/02/2025Ratify the appointment of KPMG LLP as the Company's independent registered public accounting firm for the fiscal year ending October 31, 2025.AUDIT-RELATEDISSUER315197.0000000FOR315197.000000FORS000002088The Cooper Companies, Inc.216648501US216648501904/02/2025Approve, on a non-binding, advisory basis, the compensation of our Named Executive Officers.SECTION 14A SAY-ON-PAY VOTESISSUER315197.0000000FOR315197.000000FORS000002088AstraZeneca PLC046353108US046353108904/11/2025Accept Financial Statements and Statutory ReportsCORPORATE GOVERNANCEISSUER3968535.0000000FOR3968535.000000FORS000002088AstraZeneca PLC046353108US046353108904/11/2025Approve DividendsCAPITAL STRUCTUREISSUER3968535.0000000FOR3968535.000000FORS000002088AstraZeneca PLC046353108US046353108904/11/2025Reappoint PricewaterhouseCoopers LLP as AuditorsAUDIT-RELATEDISSUER3968535.0000000FOR3968535.000000FORS000002088AstraZeneca PLC046353108US046353108904/11/2025Authorise Board to Fix Remuneration of AuditorsAUDIT-RELATEDISSUER3968535.0000000FOR3968535.000000FORS000002088AstraZeneca PLC046353108US046353108904/11/2025Re-elect Michel Demare as DirectorDIRECTOR ELECTIONSISSUER3968535.0000000FOR3968535.000000FORS000002088AstraZeneca PLC046353108US046353108904/11/2025Re-elect Pascal Soriot as DirectorDIRECTOR ELECTIONSISSUER3968535.0000000FOR3968535.000000FORS000002088AstraZeneca PLC046353108US046353108904/11/2025Re-elect Aradhana Sarin as DirectorDIRECTOR ELECTIONSISSUER3968535.0000000FOR3968535.000000FORS000002088AstraZeneca PLC046353108US046353108904/11/2025Re-elect Philip Broadley as DirectorDIRECTOR ELECTIONSISSUER3968535.0000000FOR3968535.000000FORS000002088AstraZeneca PLC046353108US046353108904/11/2025Re-elect Euan Ashley as DirectorDIRECTOR ELECTIONSISSUER3968535.0000000FOR3968535.000000FORS000002088AstraZeneca PLC046353108US046353108904/11/2025Elect Birgit Conix as DirectorDIRECTOR ELECTIONSISSUER3968535.0000000FOR3968535.000000FORS000002088AstraZeneca PLC046353108US046353108904/11/2025Elect Rene Haas as DirectorDIRECTOR ELECTIONSISSUER3968535.0000000FOR3968535.000000FORS000002088AstraZeneca PLC046353108US046353108904/11/2025Elect Karen Knudsen as DirectorDIRECTOR ELECTIONSISSUER3968535.0000000FOR3968535.000000FORS000002088AstraZeneca PLC046353108US046353108904/11/2025Re-elect Diana Layfield as DirectorDIRECTOR ELECTIONSISSUER3968535.0000000FOR3968535.000000FORS000002088AstraZeneca PLC046353108US046353108904/11/2025Re-elect Anna Manz as DirectorDIRECTOR ELECTIONSISSUER3968535.0000000FOR3968535.000000FORS000002088AstraZeneca PLC046353108US046353108904/11/2025Re-elect Sheri McCoy as DirectorDIRECTOR ELECTIONSISSUER3968535.0000000FOR3968535.000000FORS000002088AstraZeneca PLC046353108US046353108904/11/2025Re-elect Tony Mok as DirectorDIRECTOR ELECTIONSISSUER3968535.0000000FOR3968535.000000FORS000002088AstraZeneca PLC046353108US046353108904/11/2025Re-elect Nazneen Rahman as DirectorDIRECTOR ELECTIONSISSUER3968535.0000000FOR3968535.000000FORS000002088AstraZeneca PLC046353108US046353108904/11/2025Re-elect Marcus Wallenberg as DirectorDIRECTOR ELECTIONSISSUER3968535.0000000FOR3968535.000000FORS000002088AstraZeneca PLC046353108US046353108904/11/2025Approve Remuneration ReportCOMPENSATIONISSUER3968535.0000000FOR3968535.000000FORS000002088AstraZeneca PLC046353108US046353108904/11/2025Authorise UK Political Donations and ExpenditureOTHER SOCIAL ISSUESISSUER3968535.0000000FOR3968535.000000FORS000002088AstraZeneca PLC046353108US046353108904/11/2025Authorise Issue of EquityCAPITAL STRUCTUREISSUER3968535.0000000FOR3968535.000000FORS000002088AstraZeneca PLC046353108US046353108904/11/2025Authorise Issue of Equity without Pre-emptive RightsCAPITAL STRUCTUREISSUER3968535.0000000FOR3968535.000000FORS000002088AstraZeneca PLC046353108US046353108904/11/2025Authorise Issue of Equity without Pre-emptive Rights in Connection with an Acquisition or Other Capital InvestmentCAPITAL STRUCTUREISSUER3968535.0000000FOR3968535.000000FORS000002088AstraZeneca PLC046353108US046353108904/11/2025Authorise Market Purchase of Ordinary SharesCAPITAL STRUCTUREISSUER3968535.0000000FOR3968535.000000FORS000002088AstraZeneca PLC046353108US046353108904/11/2025Authorise the Company to Call General Meeting with Two Weeks' NoticeCORPORATE GOVERNANCEISSUER3968535.0000000FOR3968535.000000FORS000002088Revvity, Inc.714046109US714046109304/22/2025To elect ten nominees for director for terms of one year each: Peter Barrett, PhDDIRECTOR ELECTIONSISSUER421963.0000000FOR421963.000000FORS000002088Revvity, Inc.714046109US714046109304/22/2025To elect ten nominees for director for terms of one year each: Samuel R. ChapinDIRECTOR ELECTIONSISSUER421963.0000000FOR421963.000000FORS000002088Revvity, Inc.714046109US714046109304/22/2025To elect ten nominees for director for terms of one year each: Michael A. KlobucharDIRECTOR ELECTIONSISSUER421963.0000000FOR421963.000000FORS000002088Revvity, Inc.714046109US714046109304/22/2025To elect ten nominees for director for terms of one year each: Michelle McMurry-Heath, MD, PhDDIRECTOR ELECTIONSISSUER421963.0000000FOR421963.000000FORS000002088Revvity, Inc.714046109US714046109304/22/2025To elect ten nominees for director for terms of one year each: Alexis P. MichasDIRECTOR ELECTIONSISSUER421963.0000000FOR421963.000000FORS000002088Revvity, Inc.714046109US714046109304/22/2025To elect ten nominees for director for terms of one year each: Prahlad R. Singh, PhDDIRECTOR ELECTIONSISSUER421963.0000000FOR421963.000000FORS000002088Revvity, Inc.714046109US714046109304/22/2025To elect ten nominees for director for terms of one year each: Sophie V. Vandebroek, PhDDIRECTOR ELECTIONSISSUER421963.0000000FOR421963.000000FORS000002088Revvity, Inc.714046109US714046109304/22/2025To elect ten nominees for director for terms of one year each: Michel VounatsosDIRECTOR ELECTIONSISSUER421963.0000000FOR421963.000000FORS000002088Revvity, Inc.714046109US714046109304/22/2025To elect ten nominees for director for terms of one year each: Frank Witney, PhDDIRECTOR ELECTIONSISSUER421963.0000000FOR421963.000000FORS000002088Revvity, Inc.714046109US714046109304/22/2025To elect ten nominees for director for terms of one year each: Pascale WitzDIRECTOR ELECTIONSISSUER421963.0000000FOR421963.000000FORS000002088Revvity, Inc.714046109US714046109304/22/2025To ratify the selection of Deloitte & Touche LLP as Revvity's independent registered public accounting firm for the current fiscal year.AUDIT-RELATEDISSUER421963.0000000FOR421963.000000FORS000002088Revvity, Inc.714046109US714046109304/22/2025To approve, by non-binding advisory vote, our executive compensation.SECTION 14A SAY-ON-PAY VOTESISSUER421963.0000000FOR421963.000000FORS000002088Revvity, Inc.714046109US714046109304/22/2025To approve amendments to Revvity's Restated Articles of Organization, as amended, and Amended and Restated By-laws to implement a majority voting standard for specified corporate actions.CORPORATE GOVERNANCEISSUER421963.0000000FOR421963.000000FORS000002088Revvity, Inc.714046109US714046109304/22/2025To approve the shareholder proposal regarding ability to call a special shareholder meeting, if properly presented at the annual meeting.CORPORATE GOVERNANCESECURITY HOLDER421963.0000000AGAINST421963.000000FORS000002088The Cigna Group125523100US125523100304/23/2025Election of Directors: David M. CordaniDIRECTOR ELECTIONSISSUER600695.0000000FOR600695.000000FORS000002088The Cigna Group125523100US125523100304/23/2025Election of Directors: Eric J. FossDIRECTOR ELECTIONSISSUER600695.0000000FOR600695.000000FORS000002088The Cigna Group125523100US125523100304/23/2025Election of Directors: Retired Maj. Gen. Elder Granger, M.D.DIRECTOR ELECTIONSISSUER600695.0000000FOR600695.000000FORS000002088The Cigna Group125523100US125523100304/23/2025Election of Directors: Neesha HathiDIRECTOR ELECTIONSISSUER600695.0000000FOR600695.000000FORS000002088The Cigna Group125523100US125523100304/23/2025Election of Directors: George KurianDIRECTOR ELECTIONSISSUER600695.0000000FOR600695.000000FORS000002088The Cigna Group125523100US125523100304/23/2025Election of Directors: Kathleen M. MazzarellaDIRECTOR ELECTIONSISSUER600695.0000000FOR600695.000000FORS000002088The Cigna Group125523100US125523100304/23/2025Election of Directors: Mark B. McClellan, M.D., Ph.D.DIRECTOR ELECTIONSISSUER600695.0000000FOR600695.000000FORS000002088The Cigna Group125523100US125523100304/23/2025Election of Directors: Philip O. Ozuah, M.D., Ph.D.DIRECTOR ELECTIONSISSUER600695.0000000FOR600695.000000FORS000002088The Cigna Group125523100US125523100304/23/2025Election of Directors: Kimberly A. RossDIRECTOR ELECTIONSISSUER600695.0000000FOR600695.000000FORS000002088The Cigna Group125523100US125523100304/23/2025Election of Directors: Eric C. WisemanDIRECTOR ELECTIONSISSUER600695.0000000FOR600695.000000FORS000002088The Cigna Group125523100US125523100304/23/2025Election of Directors: Donna F. ZarconeDIRECTOR ELECTIONSISSUER600695.0000000FOR600695.000000FORS000002088The Cigna Group125523100US125523100304/23/2025Advisory approval of executive compensationSECTION 14A SAY-ON-PAY VOTESISSUER600695.0000000FOR600695.000000FORS000002088The Cigna Group125523100US125523100304/23/2025Ratification of the appointment of PricewaterhouseCoopers LLP as The Cigna Group's independent registered public accounting firm for 2025AUDIT-RELATEDISSUER600695.0000000FOR600695.000000FORS000002088The Cigna Group125523100US125523100304/23/2025Shareholder proposal - Support Special Shareholder Meeting ImprovementCORPORATE GOVERNANCESECURITY HOLDER600695.0000000AGAINST600695.000000FORS000002088HCA Healthcare, Inc.40412C101US40412C101804/24/2025Election of Directors: Thomas F. Frist IIIDIRECTOR ELECTIONSISSUER311727.0000000FOR311727.000000FORS000002088HCA Healthcare, Inc.40412C101US40412C101804/24/2025Election of Directors: Samuel N. HazenDIRECTOR ELECTIONSISSUER311727.0000000FOR311727.000000FORS000002088HCA Healthcare, Inc.40412C101US40412C101804/24/2025Election of Directors: Robert J. DennisDIRECTOR ELECTIONSISSUER311727.0000000FOR311727.000000FORS000002088HCA Healthcare, Inc.40412C101US40412C101804/24/2025Election of Directors: Nancy-Ann DeParleDIRECTOR ELECTIONSISSUER311727.0000000FOR311727.000000FORS000002088HCA Healthcare, Inc.40412C101US40412C101804/24/2025Election of Directors: William R. FristDIRECTOR ELECTIONSISSUER311727.0000000FOR311727.000000FORS000002088HCA Healthcare, Inc.40412C101US40412C101804/24/2025Election of Directors: Hugh F. JohnstonDIRECTOR ELECTIONSISSUER311727.0000000FOR311727.000000FORS000002088HCA Healthcare, Inc.40412C101US40412C101804/24/2025Election of Directors: Michael W. MichelsonDIRECTOR ELECTIONSISSUER311727.0000000FOR311727.000000FORS000002088HCA Healthcare, Inc.40412C101US40412C101804/24/2025Election of Directors: Wayne J. Riley M.D.DIRECTOR ELECTIONSISSUER311727.0000000FOR311727.000000FORS000002088HCA Healthcare, Inc.40412C101US40412C101804/24/2025Election of Directors: Andrea B. SmithDIRECTOR ELECTIONSISSUER311727.0000000FOR311727.000000FORS000002088HCA Healthcare, Inc.40412C101US40412C101804/24/2025To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the year ending December 31, 2025.AUDIT-RELATEDISSUER311727.0000000FOR311727.000000FORS000002088HCA Healthcare, Inc.40412C101US40412C101804/24/2025Advisory vote to approve named executive officer compensation.SECTION 14A SAY-ON-PAY VOTESISSUER311727.0000000FOR311727.000000FORS000002088HCA Healthcare, Inc.40412C101US40412C101804/24/2025To approve the First Amendment to the 2020 Stock Incentive Plan for Key Employees of HCA Healthcare, Inc. and its Affiliates.COMPENSATIONISSUER311727.0000000FOR311727.000000FORS000002088HCA Healthcare, Inc.40412C101US40412C101804/24/2025To approve an amendment to our amended and restated certificate of incorporation to provide for the exculpation of officers as permitted by Delaware law.CORPORATE GOVERNANCEISSUER311727.0000000FOR311727.000000FORS000002088HCA Healthcare, Inc.40412C101US40412C101804/24/2025Stockholder proposal, if properly presented at the meeting, regarding lavish golden parachutes.COMPENSATIONSECURITY HOLDER311727.0000000AGAINST311727.000000FORS000002088HCA Healthcare, Inc.40412C101US40412C101804/24/2025Stockholder proposal, if properly presented at the meeting, regarding an amendment to Patient Safety and Quality of Care Committee charter.OTHER SOCIAL ISSUESSECURITY HOLDER311727.0000000AGAINST311727.000000FORS000002088HCA Healthcare, Inc.40412C101US40412C101804/24/2025Stockholder proposal, if properly presented at the meeting, regarding report on acquisition strategy.OTHER SOCIAL ISSUESSECURITY HOLDER311727.0000000AGAINST311727.000000FORS000002088UCB SAB93562120BE000373953004/24/2025Approve Financial Statements, Allocation of Income, and Dividends of EUR 1.39 per ShareCAPITAL STRUCTURECORPORATE GOVERNANCEISSUER40540.0000000FOR40540.000000FORS000002088UCB SAB93562120BE000373953004/24/2025Approve Remuneration ReportCOMPENSATIONISSUER40540.0000000FOR40540.000000FORS000002088UCB SAB93562120BE000373953004/24/2025Approve Remuneration PolicyCOMPENSATIONISSUER40540.0000000FOR40540.000000FORS000002088UCB SAB93562120BE000373953004/24/2025Approve Discharge of DirectorsCORPORATE GOVERNANCEISSUER40540.0000000FOR40540.000000FORS000002088UCB SAB93562120BE000373953004/24/2025Approve Discharge of AuditorsAUDIT-RELATEDCORPORATE GOVERNANCEISSUER40540.0000000FOR40540.000000FORS000002088UCB SAB93562120BE000373953004/24/2025Reelect Jonathan Peacock as DirectorDIRECTOR ELECTIONSISSUER40540.0000000FOR40540.000000FORS000002088UCB SAB93562120BE000373953004/24/2025Indicate Jonathan Peacock as Independent DirectorDIRECTOR ELECTIONSCORPORATE GOVERNANCEISSUER40540.0000000FOR40540.000000FORS000002088UCB SAB93562120BE000373953004/24/2025Elect Fiona Powrie as DirectorDIRECTOR ELECTIONSISSUER40540.0000000FOR40540.000000FORS000002088UCB SAB93562120BE000373953004/24/2025Indicate Fiona Powrie as Independent DirectorDIRECTOR ELECTIONSCORPORATE GOVERNANCEISSUER40540.0000000FOR40540.000000FORS000002088UCB SAB93562120BE000373953004/24/2025Elect Stefaan Heylen as DirectorDIRECTOR ELECTIONSISSUER40540.0000000FOR40540.000000FORS000002088UCB SAB93562120BE000373953004/24/2025Approve Change-of-Control Clause Re: EMTN Program RenewalSHAREHOLDER RIGHTS AND DEFENSESCAPITAL STRUCTUREISSUER40540.0000000FOR40540.000000FORS000002088Verona Pharma Plc925050106US925050106404/24/2025To re-elect Kenneth Cunningham, M.D. as a director of the Company.DIRECTOR ELECTIONSISSUER1403730.0000000FOR1403730.000000FORS000002088Verona Pharma Plc925050106US925050106404/24/2025To re-elect Vikas Sinha as a director of the Company.DIRECTOR ELECTIONSISSUER1403730.0000000FOR1403730.000000FORS000002088Verona Pharma Plc925050106US925050106404/24/2025To re-elect James Brady as a director of the Company.DIRECTOR ELECTIONSISSUER1403730.0000000FOR1403730.000000FORS000002088Verona Pharma Plc925050106US925050106404/24/2025To receive and adopt the U.K. statutory annual accounts and Directors' report for the year ended December 31, 2024.CORPORATE GOVERNANCEISSUER1403730.0000000FOR1403730.000000FORS000002088Verona Pharma Plc925050106US925050106404/24/2025To receive and approve, as a non-binding advisory resolution, the U.K. statutory Directors' Remuneration Report for the year ended December 31, 2024.COMPENSATIONISSUER1403730.0000000AGAINST1403730.000000AGAINSTS000002088Verona Pharma Plc925050106US925050106404/24/2025To re-appoint Ernst & Young LLP as the Company's auditors, to hold office until the conclusion of the next annual general meeting of shareholders.AUDIT-RELATEDISSUER1403730.0000000FOR1403730.000000FORS000002088Verona Pharma Plc925050106US925050106404/24/2025To authorize the Audit and Risk Committee to determine the auditors' remuneration for the year ending December 31, 2025.AUDIT-RELATEDISSUER1403730.0000000FOR1403730.000000FORS000002088Verona Pharma Plc925050106US925050106404/24/2025To approve, on an advisory (non-binding) basis, the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER1403730.0000000AGAINST1403730.000000AGAINSTS000002088Verona Pharma Plc925050106US925050106404/24/2025To authorize the Board of Directors to exercise all the powers of the Company to allot shares in the Company or grant rights to subscribe for or to convert any security into shares in the Company up to an aggregate nominal amount of pounds7,031,895 (being up to a maximum of 140,637,892 shares representing 20% of the Company's existing ordinary share capital as at the close of business on March 11, 2025 (being the latest practicable date prior to publication of this document)).CAPITAL STRUCTUREISSUER1403730.0000000FOR1403730.000000FORS000002088Verona Pharma Plc925050106US925050106404/24/2025To authorize the Board of Directors to allot equity securities for cash and/or to sell ordinary shares held by the Company as treasury shares for cash as if section 561(1) of the Companies Act does not apply to any such allotment.CAPITAL STRUCTUREISSUER1403730.0000000FOR1403730.000000FORS000002088BeiGene Ltd.07725L102US07725L102604/28/2025THAT a special resolution that the deregistration of the Company in the Cayman Islands and the continuation of the Company to Switzerland be and hereby is approved and authorized (the "Continuation").EXTRAORDINARY TRANSACTIONSCORPORATE GOVERNANCEISSUER792551.0000000FOR792551.000000FORS000002088BeiGene Ltd.07725L102US07725L102604/28/2025Subject to, and effective only upon, (i) the approval of Resolution 1, (ii) the de-registration of the Company from the Register of Companies in the Cayman Islands and (iii) the simultaneous registration of the Continuation with the Swiss Commercial Register, THAT: 1. The seventh amended and restated memorandum and articles of association be amended and restated in the form set forth in Exhibit A to the proxy statement/prospectus (the "Proposed Swiss Articles") to be effective from the effective date of the Continuation. 2. The holders of ordinary shares represented in person or by proxy at the EGM hereby waive the option to discuss each individual article of the Proposed Swiss Articles and hereby approve the Proposed Swiss Articles in the form set forth in Exhibit A to the proxy statement/prospectus.CORPORATE GOVERNANCEISSUER792551.0000000FOR792551.000000FORS000002088BeiGene Ltd.07725L102US07725L102604/28/2025Subject to the approval of the Continuation and as required by Swiss law, THAT the election of Ernst & Young AG to serve as the Company's statutory auditor (for Swiss legal purposes) until the Company's first annual general meeting following the completion of the Continuation and provide the related audit services and the authorization to board of directors to fix the remuneration of Ernst & Young AG be and hereby is approved and authorized.AUDIT-RELATEDISSUER792551.0000000FOR792551.000000FORS000002088Masimo Corporation574795100US574795100304/29/2025Election of Directors: William JellisonDIRECTOR ELECTIONSISSUER218381.0000000FOR218381.000000FORS000002088Masimo Corporation574795100US574795100304/29/2025Election of Directors: Wendy LaneDIRECTOR ELECTIONSISSUER218381.0000000FOR218381.000000FORS000002088Masimo Corporation574795100US574795100304/29/2025Election of Directors: Timothy ScannellDIRECTOR ELECTIONSISSUER218381.0000000FOR218381.000000FORS000002088Masimo Corporation574795100US574795100304/29/2025Election of Directors: Darlene SolomonDIRECTOR ELECTIONSISSUER218381.0000000FOR218381.000000FORS000002088Masimo Corporation574795100US574795100304/29/2025Election of Directors: Catherine SzymanDIRECTOR ELECTIONSISSUER218381.0000000FOR218381.000000FORS000002088Masimo Corporation574795100US574795100304/29/2025To ratify the selection of Grant Thornton LLP as the Company's independent registered public accounting firm for the fiscal year ending January 3, 2026.AUDIT-RELATEDISSUER218381.0000000FOR218381.000000FORS000002088Masimo Corporation574795100US574795100304/29/2025An advisory vote to approve the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER218381.0000000FOR218381.000000FORS000002088Molina Healthcare, Inc.60855R100US60855R100504/30/2025To elect nine directors to hold office until the 2026 Annual Meeting: Barbara L. BrasierDIRECTOR ELECTIONSISSUER270671.0000000FOR270671.000000FORS000002088Molina Healthcare, Inc.60855R100US60855R100504/30/2025To elect nine directors to hold office until the 2026 Annual Meeting: Leo P. GrohowskiDIRECTOR ELECTIONSISSUER270671.0000000FOR270671.000000FORS000002088Molina Healthcare, Inc.60855R100US60855R100504/30/2025To elect nine directors to hold office until the 2026 Annual Meeting: Stephen H. LockhartDIRECTOR ELECTIONSISSUER270671.0000000FOR270671.000000FORS000002088Molina Healthcare, Inc.60855R100US60855R100504/30/2025To elect nine directors to hold office until the 2026 Annual Meeting: Steven J. OrlandoDIRECTOR ELECTIONSISSUER270671.0000000FOR270671.000000FORS000002088Molina Healthcare, Inc.60855R100US60855R100504/30/2025To elect nine directors to hold office until the 2026 Annual Meeting: Ronna E. RomneyDIRECTOR ELECTIONSISSUER270671.0000000FOR270671.000000FORS000002088Molina Healthcare, Inc.60855R100US60855R100504/30/2025To elect nine directors to hold office until the 2026 Annual Meeting: Richard M. SchapiroDIRECTOR ELECTIONSISSUER270671.0000000FOR270671.000000FORS000002088Molina Healthcare, Inc.60855R100US60855R100504/30/2025To elect nine directors to hold office until the 2026 Annual Meeting: Dale B. WolfDIRECTOR ELECTIONSISSUER270671.0000000FOR270671.000000FORS000002088Molina Healthcare, Inc.60855R100US60855R100504/30/2025To elect nine directors to hold office until the 2026 Annual Meeting: Richard C. ZoreticDIRECTOR ELECTIONSISSUER270671.0000000FOR270671.000000FORS000002088Molina Healthcare, Inc.60855R100US60855R100504/30/2025To elect nine directors to hold office until the 2026 Annual Meeting: Joseph M. ZubretskyDIRECTOR ELECTIONSISSUER270671.0000000FOR270671.000000FORS000002088Molina Healthcare, Inc.60855R100US60855R100504/30/2025To consider and approve, on a non-binding, advisory basis, the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER270671.0000000FOR270671.000000FORS000002088Molina Healthcare, Inc.60855R100US60855R100504/30/2025To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for 2025.AUDIT-RELATEDISSUER270671.0000000FOR270671.000000FORS000002088Molina Healthcare, Inc.60855R100US60855R100504/30/2025To consider and approve the Company's 2025 Equity Incentive Plan.COMPENSATIONISSUER270671.0000000FOR270671.000000FORS000002088Molina Healthcare, Inc.60855R100US60855R100504/30/2025Stockholder proposal regarding stockholders ability to call a special stockholders meeting, if properly presented.CORPORATE GOVERNANCESECURITY HOLDER270671.0000000AGAINST270671.000000FORS000002088Sanofi80105N105US80105N105404/30/2025Approve Financial Statements and Statutory ReportsCORPORATE GOVERNANCEISSUER2681675.0000000FOR2681675.000000FORS000002088Sanofi80105N105US80105N105404/30/2025Approve Consolidated Financial Statements and Statutory ReportsCORPORATE GOVERNANCEISSUER2681675.0000000FOR2681675.000000FORS000002088Sanofi80105N105US80105N105404/30/2025Approve Allocation of Income and Dividends of EUR 3.92 per ShareCAPITAL STRUCTUREISSUER2681675.0000000FOR2681675.000000FORS000002088Sanofi80105N105US80105N105404/30/2025Approve Transaction with l'Oreal Re: Share Repurchase AgreementCORPORATE GOVERNANCEISSUER2681675.0000000FOR2681675.000000FORS000002088Sanofi80105N105US80105N105404/30/2025Ratify Appointment of Jean-Paul Kress as DirectorDIRECTOR ELECTIONSISSUER2681675.0000000FOR2681675.000000FORS000002088Sanofi80105N105US80105N105404/30/2025Reelect Carole Ferrand as DirectorDIRECTOR ELECTIONSISSUER2681675.0000000FOR2681675.000000FORS000002088Sanofi80105N105US80105N105404/30/2025Reelect Barbara Lavernos as DirectorDIRECTOR ELECTIONSISSUER2681675.0000000FOR2681675.000000FORS000002088Sanofi80105N105US80105N105404/30/2025Reelect Emile Voest as DirectorDIRECTOR ELECTIONSISSUER2681675.0000000FOR2681675.000000FORS000002088Sanofi80105N105US80105N105404/30/2025Reelect Antoine Yver as DirectorDIRECTOR ELECTIONSISSUER2681675.0000000FOR2681675.000000FORS000002088Sanofi80105N105US80105N105404/30/2025Approve Compensation Report of Corporate OfficersCOMPENSATIONISSUER2681675.0000000FOR2681675.000000FORS000002088Sanofi80105N105US80105N105404/30/2025Approve Compensation of Frederic Oudea, Chairman of the BoardSECTION 14A SAY-ON-PAY VOTESISSUER2681675.0000000FOR2681675.000000FORS000002088Sanofi80105N105US80105N105404/30/2025Approve Compensation of Paul Hudson, CEOSECTION 14A SAY-ON-PAY VOTESISSUER2681675.0000000FOR2681675.000000FORS000002088Sanofi80105N105US80105N105404/30/2025Approve Remuneration Policy of DirectorsCOMPENSATIONISSUER2681675.0000000FOR2681675.000000FORS000002088Sanofi80105N105US80105N105404/30/2025Approve Remuneration Policy of Chairman of the BoardCOMPENSATIONISSUER2681675.0000000FOR2681675.000000FORS000002088Sanofi80105N105US80105N105404/30/2025Approve Remuneration Policy of CEOCOMPENSATIONISSUER2681675.0000000FOR2681675.000000FORS000002088Sanofi80105N105US80105N105404/30/2025Authorize Repurchase of Up to 10 Percent of Issued Share CapitalCAPITAL STRUCTUREISSUER2681675.0000000FOR2681675.000000FORS000002088Sanofi80105N105US80105N105404/30/2025Authorize Decrease in Share Capital via Cancellation of Repurchased SharesCAPITAL STRUCTUREISSUER2681675.0000000FOR2681675.000000FORS000002088Sanofi80105N105US80105N105404/30/2025Authorize Issuance of Equity or Equity-Linked Securities with Preemptive Rights (Rights Issue) up to Aggregate Nominal Amount of EUR 997 MillionCAPITAL STRUCTUREISSUER2681675.0000000FOR2681675.000000FORS000002088Sanofi80105N105US80105N105404/30/2025Authorize Issuance of Equity or Equity-Linked Securities without Preemptive Rights up to Aggregate Nominal Amount of EUR 240 MillionCAPITAL STRUCTUREISSUER2681675.0000000FOR2681675.000000FORS000002088Sanofi80105N105US80105N105404/30/2025Approve Issuance of Equity or Equity-Linked Securities for Private Placements, up to Aggregate Nominal Amount of EUR 240 MillionCAPITAL STRUCTUREISSUER2681675.0000000FOR2681675.000000FORS000002088Sanofi80105N105US80105N105404/30/2025Approve Issuance of Debt Securities Giving Access to New Shares of Subsidiaries and/or Debt Securities, up to Aggregate Amount of EUR 7 BillionCAPITAL STRUCTUREOTHERDebt RelatedISSUER2681675.0000000FOR2681675.000000FORS000002088Sanofi80105N105US80105N105404/30/2025Authorize Board to Increase Capital in the Event of Additional Demand Related to Delegation Submitted to Shareholder Vote Under Items 18, 19, and 20CAPITAL STRUCTUREISSUER2681675.0000000FOR2681675.000000FORS000002088Sanofi80105N105US80105N105404/30/2025Authorize Capital Increase of up to 10 Percent of Issued Capital for Contributions in KindCAPITAL STRUCTUREISSUER2681675.0000000FOR2681675.000000FORS000002088Sanofi80105N105US80105N105404/30/2025Authorize Capitalization of Reserves of Up to EUR 500 Million for Bonus Issue or Increase in Par ValueCAPITAL STRUCTUREISSUER2681675.0000000FOR2681675.000000FORS000002088Sanofi80105N105US80105N105404/30/2025Authorize Capital Issuances for Use in Employee Stock Purchase PlansCOMPENSATIONISSUER2681675.0000000FOR2681675.000000FORS000002088Sanofi80105N105US80105N105404/30/2025Authorize Capital Issuances for Use in Employee Stock Purchase Plans Reserved for Employees and Corporate Officers of International SubsidiariesCOMPENSATIONISSUER2681675.0000000FOR2681675.000000FORS000002088Sanofi80105N105US80105N105404/30/2025Amend Articles 3 and 13 of BylawsCORPORATE GOVERNANCEISSUER2681675.0000000FOR2681675.000000FORS000002088Sanofi80105N105US80105N105404/30/2025Authorize Filing of Required Documents/Other FormalitiesCORPORATE GOVERNANCEISSUER2681675.0000000FOR2681675.000000FORS000002088Boston Scientific Corporation101137107US101137107705/01/2025Proposal to elect ten Directors: Yoshiaki FujimoriDIRECTOR ELECTIONSISSUER3939130.0000000FOR3939130.000000FORS000002088Boston Scientific Corporation101137107US101137107705/01/2025Proposal to elect ten Directors: David C. HabigerDIRECTOR ELECTIONSISSUER3939130.0000000FOR3939130.000000FORS000002088Boston Scientific Corporation101137107US101137107705/01/2025Proposal to elect ten Directors: Edward J. LudwigDIRECTOR ELECTIONSISSUER3939130.0000000FOR3939130.000000FORS000002088Boston Scientific Corporation101137107US101137107705/01/2025Proposal to elect ten Directors: Michael F. MahoneyDIRECTOR ELECTIONSISSUER3939130.0000000FOR3939130.000000FORS000002088Boston Scientific Corporation101137107US101137107705/01/2025Proposal to elect ten Directors: Jessica L. MegaDIRECTOR ELECTIONSISSUER3939130.0000000FOR3939130.000000FORS000002088Boston Scientific Corporation101137107US101137107705/01/2025Proposal to elect ten Directors: Susan E. MoranoDIRECTOR ELECTIONSISSUER3939130.0000000FOR3939130.000000FORS000002088Boston Scientific Corporation101137107US101137107705/01/2025Proposal to elect ten Directors: Cheryl PegusDIRECTOR ELECTIONSISSUER3939130.0000000FOR3939130.000000FORS000002088Boston Scientific Corporation101137107US101137107705/01/2025Proposal to elect ten Directors: John E. SununuDIRECTOR ELECTIONSISSUER3939130.0000000FOR3939130.000000FORS000002088Boston Scientific Corporation101137107US101137107705/01/2025Proposal to elect ten Directors: David S. WichmannDIRECTOR ELECTIONSISSUER3939130.0000000FOR3939130.000000FORS000002088Boston Scientific Corporation101137107US101137107705/01/2025Proposal to elect ten Directors: Ellen M. ZaneDIRECTOR ELECTIONSISSUER3939130.0000000FOR3939130.000000FORS000002088Boston Scientific Corporation101137107US101137107705/01/2025To approve, on a non-binding, advisory basis, the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER3939130.0000000FOR3939130.000000FORS000002088Boston Scientific Corporation101137107US101137107705/01/2025To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the 2025 fiscal year.AUDIT-RELATEDISSUER3939130.0000000FOR3939130.000000FORS000002088Boston Scientific Corporation101137107US101137107705/01/2025Stockholder proposal titled "Support Simple Majority Vote."CORPORATE GOVERNANCESECURITY HOLDER3939130.0000000FOR3939130.000000NONES000002088Encompass Health Corporation29261A100US29261A100705/01/2025Election of ten nominees to the Board of Directors to serve until our 2026 Annual Meeting of Stockholders: Greg D. CarmichaelDIRECTOR ELECTIONSISSUER65590.0000000FOR65590.000000FORS000002088Encompass Health Corporation29261A100US29261A100705/01/2025Election of ten nominees to the Board of Directors to serve until our 2026 Annual Meeting of Stockholders: Edward M. Christie IIIDIRECTOR ELECTIONSISSUER65590.0000000FOR65590.000000FORS000002088Encompass Health Corporation29261A100US29261A100705/01/2025Election of ten nominees to the Board of Directors to serve until our 2026 Annual Meeting of Stockholders: Joan E. HermanDIRECTOR ELECTIONSISSUER65590.0000000FOR65590.000000FORS000002088Encompass Health Corporation29261A100US29261A100705/01/2025Election of ten nominees to the Board of Directors to serve until our 2026 Annual Meeting of Stockholders: Leslye G. KatzDIRECTOR ELECTIONSISSUER65590.0000000FOR65590.000000FORS000002088Encompass Health Corporation29261A100US29261A100705/01/2025Election of ten nominees to the Board of Directors to serve until our 2026 Annual Meeting of Stockholders: Patricia A. MarylandDIRECTOR ELECTIONSISSUER65590.0000000FOR65590.000000FORS000002088Encompass Health Corporation29261A100US29261A100705/01/2025Election of ten nominees to the Board of Directors to serve until our 2026 Annual Meeting of Stockholders: Kevin J. O'ConnorDIRECTOR ELECTIONSISSUER65590.0000000FOR65590.000000FORS000002088Encompass Health Corporation29261A100US29261A100705/01/2025Election of ten nominees to the Board of Directors to serve until our 2026 Annual Meeting of Stockholders: Christopher R. ReidyDIRECTOR ELECTIONSISSUER65590.0000000FOR65590.000000FORS000002088Encompass Health Corporation29261A100US29261A100705/01/2025Election of ten nominees to the Board of Directors to serve until our 2026 Annual Meeting of Stockholders: Nancy M. SchlichtingDIRECTOR ELECTIONSISSUER65590.0000000FOR65590.000000FORS000002088Encompass Health Corporation29261A100US29261A100705/01/2025Election of ten nominees to the Board of Directors to serve until our 2026 Annual Meeting of Stockholders: Mark J. TarrDIRECTOR ELECTIONSISSUER65590.0000000FOR65590.000000FORS000002088Encompass Health Corporation29261A100US29261A100705/01/2025Election of ten nominees to the Board of Directors to serve until our 2026 Annual Meeting of Stockholders: Terrance WilliamsDIRECTOR ELECTIONSISSUER65590.0000000FOR65590.000000FORS000002088Encompass Health Corporation29261A100US29261A100705/01/2025Ratification of the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm for 2025.AUDIT-RELATEDISSUER65590.0000000FOR65590.000000FORS000002088Encompass Health Corporation29261A100US29261A100705/01/2025An advisory vote to approve executive compensation.SECTION 14A SAY-ON-PAY VOTESISSUER65590.0000000FOR65590.000000FORS000002088Encompass Health Corporation29261A100US29261A100705/01/2025A vote to approve the Company's 2025 Omnibus Performance Incentive Plan.COMPENSATIONISSUER65590.0000000FOR65590.000000FORS000002088Intuitive Surgical, Inc.46120E602US46120E602305/01/2025Election of Directors: Craig H. Barratt, Ph.D.DIRECTOR ELECTIONSISSUER1424099.0000000FOR1424099.000000FORS000002088Intuitive Surgical, Inc.46120E602US46120E602305/01/2025Election of Directors: Joseph C. BeeryDIRECTOR ELECTIONSISSUER1424099.0000000FOR1424099.000000FORS000002088Intuitive Surgical, Inc.46120E602US46120E602305/01/2025Election of Directors: Lewis ChewDIRECTOR ELECTIONSISSUER1424099.0000000FOR1424099.000000FORS000002088Intuitive Surgical, Inc.46120E602US46120E602305/01/2025Election of Directors: Gary S. Guthart, Ph.D.DIRECTOR ELECTIONSISSUER1424099.0000000FOR1424099.000000FORS000002088Intuitive Surgical, Inc.46120E602US46120E602305/01/2025Election of Directors: Amal M. JohnsonDIRECTOR ELECTIONSISSUER1424099.0000000FOR1424099.000000FORS000002088Intuitive Surgical, Inc.46120E602US46120E602305/01/2025Election of Directors: Sreelakshmi KolliDIRECTOR ELECTIONSISSUER1424099.0000000FOR1424099.000000FORS000002088Intuitive Surgical, Inc.46120E602US46120E602305/01/2025Election of Directors: Amy L. Ladd, M.D.DIRECTOR ELECTIONSISSUER1424099.0000000FOR1424099.000000FORS000002088Intuitive Surgical, Inc.46120E602US46120E602305/01/2025Election of Directors: Keith R. Leonard, Jr.DIRECTOR ELECTIONSISSUER1424099.0000000FOR1424099.000000FORS000002088Intuitive Surgical, Inc.46120E602US46120E602305/01/2025Election of Directors: Jami Dover NachtsheimDIRECTOR ELECTIONSISSUER1424099.0000000FOR1424099.000000FORS000002088Intuitive Surgical, Inc.46120E602US46120E602305/01/2025Election of Directors: Monica P. Reed, M.D.DIRECTOR ELECTIONSISSUER1424099.0000000FOR1424099.000000FORS000002088Intuitive Surgical, Inc.46120E602US46120E602305/01/2025Election of Directors: David J. RosaDIRECTOR ELECTIONSISSUER1424099.0000000FOR1424099.000000FORS000002088Intuitive Surgical, Inc.46120E602US46120E602305/01/2025To approve, by advisory vote, the compensation of the Company's Named Executive Officers.SECTION 14A SAY-ON-PAY VOTESISSUER1424099.0000000FOR1424099.000000FORS000002088Intuitive Surgical, Inc.46120E602US46120E602305/01/2025The ratification of appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025.AUDIT-RELATEDISSUER1424099.0000000FOR1424099.000000FORS000002088Intuitive Surgical, Inc.46120E602US46120E602305/01/2025The amendment and restatement of the Amended and Restated 2010 Incentive Award Plan.COMPENSATIONISSUER1424099.0000000FOR1424099.000000FORS000002088Intuitive Surgical, Inc.46120E602US46120E602305/01/2025The stockholder proposal purportedly "to improve the executive compensation program," if properly presented at the Annual Meeting.COMPENSATIONSECURITY HOLDER1424099.0000000AGAINST1424099.000000FORS000002088Intuitive Surgical, Inc.46120E602US46120E602305/01/2025The stockholder proposal that is titled "requesting a shareholder approval requirement for excessive golden parachutes," if properly presented at the Annual Meeting.COMPENSATIONSECURITY HOLDER1424099.0000000AGAINST1424099.000000FORS000002088Lantheus Holdings, Inc.516544103US516544103205/01/2025The election of four Class I directors to our Board of Directors: Ms. Mary Anne HeinoDIRECTOR ELECTIONSISSUER216294.0000000AGAINST216294.000000AGAINSTS000002088Lantheus Holdings, Inc.516544103US516544103205/01/2025The election of four Class I directors to our Board of Directors: Dr. Gerard BerDIRECTOR ELECTIONSISSUER216294.0000000AGAINST216294.000000AGAINSTS000002088Lantheus Holdings, Inc.516544103US516544103205/01/2025The election of four Class I directors to our Board of Directors: Ms. Julie EastlandDIRECTOR ELECTIONSISSUER216294.0000000AGAINST216294.000000AGAINSTS000002088Lantheus Holdings, Inc.516544103US516544103205/01/2025The election of four Class I directors to our Board of Directors: Mr. Samuel LenoDIRECTOR ELECTIONSISSUER216294.0000000AGAINST216294.000000AGAINSTS000002088Lantheus Holdings, Inc.516544103US516544103205/01/2025The approval, on an advisory basis, of the compensation paid to our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER216294.0000000FOR216294.000000FORS000002088Lantheus Holdings, Inc.516544103US516544103205/01/2025The ratification of the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025.AUDIT-RELATEDISSUER216294.0000000FOR216294.000000FORS000002088Lantheus Holdings, Inc.516544103US516544103205/01/2025The shareholder proposal regarding the declassification of our Board of Directors.SHAREHOLDER RIGHTS AND DEFENSESSECURITY HOLDER216294.0000000FOR216294.000000NONES000002088Biohaven Ltd.G1110E107VGG1110E107905/05/2025Election of Directors for a term expiring at the 2028 Annual Meeting of shareholders: Vlad Coric, M.D.DIRECTOR ELECTIONSISSUER1650053.0000000FOR1650053.000000FORS000002088Biohaven Ltd.G1110E107VGG1110E107905/05/2025Election of Directors for a term expiring at the 2028 Annual Meeting of shareholders: Kishan MehtaDIRECTOR ELECTIONSISSUER1650053.0000000FOR1650053.000000FORS000002088Biohaven Ltd.G1110E107VGG1110E107905/05/2025Ratification of appointment of Ernst & Young LLP as independent auditors for fiscal year 2025.AUDIT-RELATEDISSUER1650053.0000000FOR1650053.000000FORS000002088Biohaven Ltd.G1110E107VGG1110E107905/05/2025A non-binding advisory vote on the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER1650053.0000000FOR1650053.000000FORS000002088Eli Lilly and Company532457108US532457108305/05/2025Election of the following directors, each to serve a three-year term: Ralph AlvarezDIRECTOR ELECTIONSISSUER1593533.0000000FOR1593533.000000FORS000002088Eli Lilly and Company532457108US532457108305/05/2025Election of the following directors, each to serve a three-year term: Mary Lynne HedleyDIRECTOR ELECTIONSISSUER1593533.0000000FOR1593533.000000FORS000002088Eli Lilly and Company532457108US532457108305/05/2025Election of the following directors, each to serve a three-year term: Kimberly JohnsonDIRECTOR ELECTIONSISSUER1593533.0000000FOR1593533.000000FORS000002088Eli Lilly and Company532457108US532457108305/05/2025Election of the following directors, each to serve a three-year term: Juan LucianoDIRECTOR ELECTIONSISSUER1593533.0000000FOR1593533.000000FORS000002088Eli Lilly and Company532457108US532457108305/05/2025Approval, on an advisory basis, of the compensation paid to the company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER1593533.0000000FOR1593533.000000FORS000002088Eli Lilly and Company532457108US532457108305/05/2025Ratification of the appointment of Ernst & Young LLP as the independent auditor for 2025.AUDIT-RELATEDISSUER1593533.0000000FOR1593533.000000FORS000002088Eli Lilly and Company532457108US532457108305/05/2025Approval of amendments to the company's Articles of Incorporation to eliminate the classified board structure.SHAREHOLDER RIGHTS AND DEFENSESISSUER1593533.0000000FOR1593533.000000FORS000002088Eli Lilly and Company532457108US532457108305/05/2025Approval of amendments to the company's Articles of Incorporation to eliminate supermajority voting provisions.CORPORATE GOVERNANCEISSUER1593533.0000000FOR1593533.000000FORS000002088Danaher Corporation235851102US235851102805/06/2025To elect the thirteen directors named in the attached Proxy Statement to hold office until the 2026 Annual Meeting of Shareholders and until their successors are elected and qualified: Rainer M. BlairDIRECTOR ELECTIONSISSUER1797981.0000000FOR1797981.000000FORS000002088Danaher Corporation235851102US235851102805/06/2025To elect the thirteen directors named in the attached Proxy Statement to hold office until the 2026 Annual Meeting of Shareholders and until their successors are elected and qualified: Feroz DewanDIRECTOR ELECTIONSISSUER1797981.0000000FOR1797981.000000FORS000002088Danaher Corporation235851102US235851102805/06/2025To elect the thirteen directors named in the attached Proxy Statement to hold office until the 2026 Annual Meeting of Shareholders and until their successors are elected and qualified: Linda FillerDIRECTOR ELECTIONSISSUER1797981.0000000FOR1797981.000000FORS000002088Danaher Corporation235851102US235851102805/06/2025To elect the thirteen directors named in the attached Proxy Statement to hold office until the 2026 Annual Meeting of Shareholders and until their successors are elected and qualified: Charles W. LamannaDIRECTOR ELECTIONSISSUER1797981.0000000FOR1797981.000000FORS000002088Danaher Corporation235851102US235851102805/06/2025To elect the thirteen directors named in the attached Proxy Statement to hold office until the 2026 Annual Meeting of Shareholders and until their successors are elected and qualified: Teri ListDIRECTOR ELECTIONSISSUER1797981.0000000FOR1797981.000000FORS000002088Danaher Corporation235851102US235851102805/06/2025To elect the thirteen directors named in the attached Proxy Statement to hold office until the 2026 Annual Meeting of Shareholders and until their successors are elected and qualified: Jessica L. Mega, MD, MPHDIRECTOR ELECTIONSISSUER1797981.0000000FOR1797981.000000FORS000002088Danaher Corporation235851102US235851102805/06/2025To elect the thirteen directors named in the attached Proxy Statement to hold office until the 2026 Annual Meeting of Shareholders and until their successors are elected and qualified: Mitchell P. RalesDIRECTOR ELECTIONSISSUER1797981.0000000FOR1797981.000000FORS000002088Danaher Corporation235851102US235851102805/06/2025To elect the thirteen directors named in the attached Proxy Statement to hold office until the 2026 Annual Meeting of Shareholders and until their successors are elected and qualified: Steven M. RalesDIRECTOR ELECTIONSISSUER1797981.0000000FOR1797981.000000FORS000002088Danaher Corporation235851102US235851102805/06/2025To elect the thirteen directors named in the attached Proxy Statement to hold office until the 2026 Annual Meeting of Shareholders and until their successors are elected and qualified: A. Shane SandersDIRECTOR ELECTIONSISSUER1797981.0000000FOR1797981.000000FORS000002088Danaher Corporation235851102US235851102805/06/2025To elect the thirteen directors named in the attached Proxy Statement to hold office until the 2026 Annual Meeting of Shareholders and until their successors are elected and qualified: John T. SchwietersDIRECTOR ELECTIONSISSUER1797981.0000000FOR1797981.000000FORS000002088Danaher Corporation235851102US235851102805/06/2025To elect the thirteen directors named in the attached Proxy Statement to hold office until the 2026 Annual Meeting of Shareholders and until their successors are elected and qualified: Alan G. SpoonDIRECTOR ELECTIONSISSUER1797981.0000000FOR1797981.000000FORS000002088Danaher Corporation235851102US235851102805/06/2025To elect the thirteen directors named in the attached Proxy Statement to hold office until the 2026 Annual Meeting of Shareholders and until their successors are elected and qualified: Raymond C. Stevens, Ph.D.DIRECTOR ELECTIONSISSUER1797981.0000000FOR1797981.000000FORS000002088Danaher Corporation235851102US235851102805/06/2025To elect the thirteen directors named in the attached Proxy Statement to hold office until the 2026 Annual Meeting of Shareholders and until their successors are elected and qualified: Elias A. Zerhouni, MDDIRECTOR ELECTIONSISSUER1797981.0000000FOR1797981.000000FORS000002088Danaher Corporation235851102US235851102805/06/2025To ratify the selection of Ernst & Young LLP as Danaher's independent registered public accounting firm for the year ending December 31, 2025.AUDIT-RELATEDISSUER1797981.0000000FOR1797981.000000FORS000002088Danaher Corporation235851102US235851102805/06/2025To approve on an advisory basis the Company's named executive officer compensation.SECTION 14A SAY-ON-PAY VOTESISSUER1797981.0000000FOR1797981.000000FORS000002088Gilead Sciences, Inc.375558103US375558103605/07/2025To elect the nine director nominees to be named in the Proxy Statement to serve for the next year and until their successors are elected and qualified: Jacqueline K. Barton, Ph.D.DIRECTOR ELECTIONSISSUER1585827.0000000FOR1585827.000000FORS000002088Gilead Sciences, Inc.375558103US375558103605/07/2025To elect the nine director nominees to be named in the Proxy Statement to serve for the next year and until their successors are elected and qualified: Jeffrey A. Bluestone, Ph.D.DIRECTOR ELECTIONSISSUER1585827.0000000FOR1585827.000000FORS000002088Gilead Sciences, Inc.375558103US375558103605/07/2025To elect the nine director nominees to be named in the Proxy Statement to serve for the next year and until their successors are elected and qualified: Sandra J. Horning, M.D.DIRECTOR ELECTIONSISSUER1585827.0000000FOR1585827.000000FORS000002088Gilead Sciences, Inc.375558103US375558103605/07/2025To elect the nine director nominees to be named in the Proxy Statement to serve for the next year and until their successors are elected and qualified: Kelly A. KramerDIRECTOR ELECTIONSISSUER1585827.0000000FOR1585827.000000FORS000002088Gilead Sciences, Inc.375558103US375558103605/07/2025To elect the nine director nominees to be named in the Proxy Statement to serve for the next year and until their successors are elected and qualified: Ted W. Love, M.D.DIRECTOR ELECTIONSISSUER1585827.0000000FOR1585827.000000FORS000002088Gilead Sciences, Inc.375558103US375558103605/07/2025To elect the nine director nominees to be named in the Proxy Statement to serve for the next year and until their successors are elected and qualified: Harish ManwaniDIRECTOR ELECTIONSISSUER1585827.0000000FOR1585827.000000FORS000002088Gilead Sciences, Inc.375558103US375558103605/07/2025To elect the nine director nominees to be named in the Proxy Statement to serve for the next year and until their successors are elected and qualified: Daniel P. O'DayDIRECTOR ELECTIONSISSUER1585827.0000000FOR1585827.000000FORS000002088Gilead Sciences, Inc.375558103US375558103605/07/2025To elect the nine director nominees to be named in the Proxy Statement to serve for the next year and until their successors are elected and qualified: Javier J. RodriguezDIRECTOR ELECTIONSISSUER1585827.0000000FOR1585827.000000FORS000002088Gilead Sciences, Inc.375558103US375558103605/07/2025To elect the nine director nominees to be named in the Proxy Statement to serve for the next year and until their successors are elected and qualified: Anthony WeltersDIRECTOR ELECTIONSISSUER1585827.0000000FOR1585827.000000FORS000002088Gilead Sciences, Inc.375558103US375558103605/07/2025To ratify the selection of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025.AUDIT-RELATEDISSUER1585827.0000000FOR1585827.000000FORS000002088Gilead Sciences, Inc.375558103US375558103605/07/2025To approve, on an advisory basis, the compensation of our Named Executive Officers as presented in the Proxy Statement.SECTION 14A SAY-ON-PAY VOTESISSUER1585827.0000000FOR1585827.000000FORS000002088Gilead Sciences, Inc.375558103US375558103605/07/2025To vote on a stockholder proposal requesting the CEO pay ratio factor be included in the Company's executive compensation programs, if properly presented at the Annual Meeting.DIVERSITY, EQUITY, AND INCLUSIONSECURITY HOLDER1585827.0000000AGAINST1585827.000000FORS000002088Gilead Sciences, Inc.375558103US375558103605/07/2025To vote on a stockholder proposal requesting an independent Board Chair policy, if properly presented at the Annual Meeting.CORPORATE GOVERNANCESECURITY HOLDER1585827.0000000AGAINST1585827.000000FORS000002088Gilead Sciences, Inc.375558103US375558103605/07/2025To vote on a stockholder proposal requesting a comprehensive human rights policy and human rights due diligence process, if properly presented at the Annual Meeting.HUMAN RIGHTS OR HUMAN CAPITAL/WORKFORCESECURITY HOLDER1585827.0000000AGAINST1585827.000000FORS000002088Gilead Sciences, Inc.375558103US375558103605/07/2025To vote on a stockholder proposal requesting a report on the risks of the Company's DEI practices for contractors, if properly presented at the Annual Meeting.ENVIRONMENT OR CLIMATEDIVERSITY, EQUITY, AND INCLUSIONOTHER SOCIAL ISSUESSECURITY HOLDER1585827.0000000AGAINST1585827.000000FORS000002088IDEXX Laboratories, Inc.45168D104US45168D104605/07/2025Election of Directors (Proposal One): Stuart M. EssigDIRECTOR ELECTIONSISSUER149373.0000000AGAINST149373.000000AGAINSTS000002088IDEXX Laboratories, Inc.45168D104US45168D104605/07/2025Election of Directors (Proposal One): Jonathan J. MazelskyDIRECTOR ELECTIONSISSUER149373.0000000FOR149373.000000FORS000002088IDEXX Laboratories, Inc.45168D104US45168D104605/07/2025Election of Directors (Proposal One): M. Anne SzostakDIRECTOR ELECTIONSISSUER149373.0000000AGAINST149373.000000AGAINSTS000002088IDEXX Laboratories, Inc.45168D104US45168D104605/07/2025Ratification of Appointment of Independent Registered Public Accounting Firm. To ratify the selection of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the current fiscal year (Proposal Two).AUDIT-RELATEDISSUER149373.0000000FOR149373.000000FORS000002088IDEXX Laboratories, Inc.45168D104US45168D104605/07/2025Advisory Vote on Executive Compensation. To approve a nonbinding advisory resolution on the Company's executive compensation (Proposal Three).SECTION 14A SAY-ON-PAY VOTESISSUER149373.0000000FOR149373.000000FORS000002088IDEXX Laboratories, Inc.45168D104US45168D104605/07/2025Amend Certificate of Incorporation to Remove Supermajority Voting Provisions (Proposal Four).CORPORATE GOVERNANCEISSUER149373.0000000FOR149373.000000FORS000002088IDEXX Laboratories, Inc.45168D104US45168D104605/07/2025Amend Certificate of Incorporation to Reflect New Delaware Law Provisions Allowing for Officer Exculpation (Proposal Five).CORPORATE GOVERNANCEISSUER149373.0000000FOR149373.000000FORS000002088IDEXX Laboratories, Inc.45168D104US45168D104605/07/2025Shareholder Proposal Regarding the Annual Election of Directors (Proposal Six).SHAREHOLDER RIGHTS AND DEFENSESSECURITY HOLDER149373.0000000FOR149373.000000NONES000002088Alnylam Pharmaceuticals, Inc.02043Q107US02043Q107605/08/2025To elect the following nominees as Class III directors of Alnylam: Carolyn R. Bertozzi, Ph.D.DIRECTOR ELECTIONSISSUER1280359.0000000AGAINST1280359.000000AGAINSTS000002088Alnylam Pharmaceuticals, Inc.02043Q107US02043Q107605/08/2025To elect the following nominees as Class III directors of Alnylam: Margaret A. Hamburg, M.D.DIRECTOR ELECTIONSISSUER1280359.0000000AGAINST1280359.000000AGAINSTS000002088Alnylam Pharmaceuticals, Inc.02043Q107US02043Q107605/08/2025To elect the following nominees as Class III directors of Alnylam: Colleen F. ReitanDIRECTOR ELECTIONSISSUER1280359.0000000AGAINST1280359.000000AGAINSTS000002088Alnylam Pharmaceuticals, Inc.02043Q107US02043Q107605/08/2025To elect the following nominees as Class III directors of Alnylam: Amy W. SchulmanDIRECTOR ELECTIONSISSUER1280359.0000000AGAINST1280359.000000AGAINSTS000002088Alnylam Pharmaceuticals, Inc.02043Q107US02043Q107605/08/2025To approve an Amendment to our Restated Certificate of Incorporation allowing for officer exculpation.CORPORATE GOVERNANCEISSUER1280359.0000000FOR1280359.000000FORS000002088Alnylam Pharmaceuticals, Inc.02043Q107US02043Q107605/08/2025To approve the second amended and restated 2018 Stock Incentive Plan.COMPENSATIONISSUER1280359.0000000FOR1280359.000000FORS000002088Alnylam Pharmaceuticals, Inc.02043Q107US02043Q107605/08/2025To approve, in a non-binding advisory vote, the compensation of Alnylam's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER1280359.0000000FOR1280359.000000FORS000002088Alnylam Pharmaceuticals, Inc.02043Q107US02043Q107605/08/2025To ratify the appointment of PricewaterhouseCoopers LLP, an independent registered public accounting firm, as Alnylam's independent auditors for the fiscal year ending December 31, 2025.AUDIT-RELATEDISSUER1280359.0000000FOR1280359.000000FORS000002088DexCom, Inc.252131107US252131107405/08/2025To elect ten nominees for director, each to hold office until our 2026 annual meeting of stockholders: Kevin R. SayerDIRECTOR ELECTIONSISSUER354223.0000000FOR354223.000000FORS000002088DexCom, Inc.252131107US252131107405/08/2025To elect ten nominees for director, each to hold office until our 2026 annual meeting of stockholders: Steven R. AltmanDIRECTOR ELECTIONSISSUER354223.0000000FOR354223.000000FORS000002088DexCom, Inc.252131107US252131107405/08/2025To elect ten nominees for director, each to hold office until our 2026 annual meeting of stockholders: Nicholas AugustinosDIRECTOR ELECTIONSISSUER354223.0000000FOR354223.000000FORS000002088DexCom, Inc.252131107US252131107405/08/2025To elect ten nominees for director, each to hold office until our 2026 annual meeting of stockholders: Richard A. CollinsDIRECTOR ELECTIONSISSUER354223.0000000FOR354223.000000FORS000002088DexCom, Inc.252131107US252131107405/08/2025To elect ten nominees for director, each to hold office until our 2026 annual meeting of stockholders: Rimma DriscollDIRECTOR ELECTIONSISSUER354223.0000000FOR354223.000000FORS000002088DexCom, Inc.252131107US252131107405/08/2025To elect ten nominees for director, each to hold office until our 2026 annual meeting of stockholders: Mark G. FolettaDIRECTOR ELECTIONSISSUER354223.0000000FOR354223.000000FORS000002088DexCom, Inc.252131107US252131107405/08/2025To elect ten nominees for director, each to hold office until our 2026 annual meeting of stockholders: Renee GalaDIRECTOR ELECTIONSISSUER354223.0000000FOR354223.000000FORS000002088DexCom, Inc.252131107US252131107405/08/2025To elect ten nominees for director, each to hold office until our 2026 annual meeting of stockholders: Bridgette P. HellerDIRECTOR ELECTIONSISSUER354223.0000000FOR354223.000000FORS000002088DexCom, Inc.252131107US252131107405/08/2025To elect ten nominees for director, each to hold office until our 2026 annual meeting of stockholders: Kyle MaladyDIRECTOR ELECTIONSISSUER354223.0000000FOR354223.000000FORS000002088DexCom, Inc.252131107US252131107405/08/2025To ratify the selection by the Audit Committee of our Board of Directors of Deloitte & Touche LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025.AUDIT-RELATEDISSUER354223.0000000FOR354223.000000FORS000002088DexCom, Inc.252131107US252131107405/08/2025To provide a non-binding advisory vote on the compensation of our named executive officers for the fiscal year ended December 31, 2024.SECTION 14A SAY-ON-PAY VOTESISSUER354223.0000000FOR354223.000000FORS000002088DexCom, Inc.252131107US252131107405/08/2025To approve our Amended and Restated 2015 Equity Incentive Plan (as amended and restated) to, among other things, increase the number of shares reserved for issuance thereunder by 3,400,000 shares.COMPENSATIONISSUER354223.0000000FOR354223.000000FORS000002088DexCom, Inc.252131107US252131107405/08/2025To approve our Amended and Restated 2015 Employee Stock Purchase Plan to, among other things, increase the number of shares reserved for issuance thereunder by 8,000,000 shares.COMPENSATIONISSUER354223.0000000FOR354223.000000FORS000002088Stryker Corporation863667101US863667101305/08/2025Election of Ten Directors: Mary K. BrainerdDIRECTOR ELECTIONSISSUER1494255.0000000FOR1494255.000000FORS000002088Stryker Corporation863667101US863667101305/08/2025Election of Ten Directors: Giovanni Caforio, M.D.DIRECTOR ELECTIONSISSUER1494255.0000000FOR1494255.000000FORS000002088Stryker Corporation863667101US863667101305/08/2025Election of Ten Directors: Kevin A. LoboDIRECTOR ELECTIONSISSUER1494255.0000000FOR1494255.000000FORS000002088Stryker Corporation863667101US863667101305/08/2025Election of Ten Directors: Emmanuel P. MacedaDIRECTOR ELECTIONSISSUER1494255.0000000FOR1494255.000000FORS000002088Stryker Corporation863667101US863667101305/08/2025Election of Ten Directors: Sherilyn S. McCoyDIRECTOR ELECTIONSISSUER1494255.0000000FOR1494255.000000FORS000002088Stryker Corporation863667101US863667101305/08/2025Election of Ten Directors: Rachel M. RuggeriDIRECTOR ELECTIONSISSUER1494255.0000000FOR1494255.000000FORS000002088Stryker Corporation863667101US863667101305/08/2025Election of Ten Directors: Andrew K. SilvernailDIRECTOR ELECTIONSISSUER1494255.0000000FOR1494255.000000FORS000002088Stryker Corporation863667101US863667101305/08/2025Election of Ten Directors: Lisa M. Skeete TatumDIRECTOR ELECTIONSISSUER1494255.0000000FOR1494255.000000FORS000002088Stryker Corporation863667101US863667101305/08/2025Election of Ten Directors: Ronda E. StrykerDIRECTOR ELECTIONSISSUER1494255.0000000FOR1494255.000000FORS000002088Stryker Corporation863667101US863667101305/08/2025Election of Ten Directors: Rajeev SuriDIRECTOR ELECTIONSISSUER1494255.0000000FOR1494255.000000FORS000002088Stryker Corporation863667101US863667101305/08/2025Ratification of Appointment of Ernst & Young LLP as Our Independent Registered Public Accounting Firm for 2025.AUDIT-RELATEDISSUER1494255.0000000FOR1494255.000000FORS000002088Stryker Corporation863667101US863667101305/08/2025Approval of the 2011 Long-Term Incentive Plan, as Amended and Restated.COMPENSATIONISSUER1494255.0000000FOR1494255.000000FORS000002088Stryker Corporation863667101US863667101305/08/2025Approval of the 2011 Performance Incentive Award Plan, as Amended and Restated.COMPENSATIONISSUER1494255.0000000FOR1494255.000000FORS000002088Stryker Corporation863667101US863667101305/08/2025Approval of the 2008 Stock Purchase Plan, as Amended and Restated.COMPENSATIONISSUER1494255.0000000FOR1494255.000000FORS000002088Stryker Corporation863667101US863667101305/08/2025Advisory Vote to Approve Named Executive Officer Compensation.SECTION 14A SAY-ON-PAY VOTESISSUER1494255.0000000FOR1494255.000000FORS000002088Stryker Corporation863667101US863667101305/08/2025Shareholder Proposal to Support Transparency in Political Spending.OTHER SOCIAL ISSUESSECURITY HOLDER1494255.0000000AGAINST1494255.000000FORS000002088Sensorion SAF8312Z102FR001259646805/12/2025Approve Financial Statements and Discharge DirectorsCAPITAL STRUCTURECORPORATE GOVERNANCEISSUER10026597.0000000FOR10026597.000000FORS000002088Sensorion SAF8312Z102FR001259646805/12/2025Approve Consolidated Financial Statements and Statutory ReportsCORPORATE GOVERNANCEISSUER10026597.0000000FOR10026597.000000FORS000002088Sensorion SAF8312Z102FR001259646805/12/2025Approve Treatment of LossesCAPITAL STRUCTUREISSUER10026597.0000000FOR10026597.000000FORS000002088Sensorion SAF8312Z102FR001259646805/12/2025Approve Auditors' Special Report on Related-Party TransactionsCORPORATE GOVERNANCEISSUER10026597.0000000FOR10026597.000000FORS000002088Sensorion SAF8312Z102FR001259646805/12/2025Reelect Aniz Girach as DirectorDIRECTOR ELECTIONSISSUER10026597.0000000FOR10026597.000000FORS000002088Sensorion SAF8312Z102FR001259646805/12/2025Reelect Sofinnova Partners as DirectorDIRECTOR ELECTIONSISSUER10026597.0000000FOR10026597.000000FORS000002088Sensorion SAF8312Z102FR001259646805/12/2025Reelect Khalil Barrage as DirectorDIRECTOR ELECTIONSISSUER10026597.0000000FOR10026597.000000FORS000002088Sensorion SAF8312Z102FR001259646805/12/2025Ratify Appointment of Amit Munshi as DirectorDIRECTOR ELECTIONSISSUER10026597.0000000FOR10026597.000000FORS000002088Sensorion SAF8312Z102FR001259646805/12/2025Reelect Amit Munshi as DirectorDIRECTOR ELECTIONSISSUER10026597.0000000FOR10026597.000000FORS000002088Sensorion SAF8312Z102FR001259646805/12/2025Approve Remuneration of Directors in the Aggregate Amount of EUR 500,000COMPENSATIONISSUER10026597.0000000FOR10026597.000000FORS000002088Sensorion SAF8312Z102FR001259646805/12/2025Authorize Repurchase of Up to 10 Percent of Issued Share CapitalCAPITAL STRUCTUREISSUER10026597.0000000AGAINST10026597.000000AGAINSTS000002088Sensorion SAF8312Z102FR001259646805/12/2025Authorize Decrease in Share Capital via Cancellation of Repurchased SharesCAPITAL STRUCTUREISSUER10026597.0000000FOR10026597.000000FORS000002088Sensorion SAF8312Z102FR001259646805/12/2025Authorize Issuance of Equity or Equity-Linked Securities without Preemptive Rights up to Aggregate Nominal Amount of EUR 30 MillionCAPITAL STRUCTUREISSUER10026597.0000000AGAINST10026597.000000AGAINSTS000002088Sensorion SAF8312Z102FR001259646805/12/2025Approve Issuance of Equity or Equity-Linked Securities for Private Placements, up to Aggregate Nominal Amount of EUR 30 MillionCAPITAL STRUCTUREISSUER10026597.0000000AGAINST10026597.000000AGAINSTS000002088Sensorion SAF8312Z102FR001259646805/12/2025Approve Issuance of Equity or Equity-Linked Securities Reserved for Specific Beneficiaries, up to Aggregate Nominal Amount of EUR 30 MillionCAPITAL STRUCTUREISSUER10026597.0000000AGAINST10026597.000000AGAINSTS000002088Sensorion SAF8312Z102FR001259646805/12/2025Approve Issuance of Equity or Equity-Linked Securities Reserved for Specific Beneficiaries, up to Aggregate Nominal Amount of EUR 30 MillionCAPITAL STRUCTUREISSUER10026597.0000000AGAINST10026597.000000AGAINSTS000002088Sensorion SAF8312Z102FR001259646805/12/2025Authorize Issuance of Equity or Equity-Linked Securities with Preemptive Rights up to Aggregate Nominal Amount of EUR 30 MillionCAPITAL STRUCTUREISSUER10026597.0000000FOR10026597.000000FORS000002088Sensorion SAF8312Z102FR001259646805/12/2025Authorize Capitalization of Reserves of Up to EUR 30 Million for Bonus Issue or Increase in Par ValueCAPITAL STRUCTUREISSUER10026597.0000000FOR10026597.000000FORS000002088Sensorion SAF8312Z102FR001259646805/12/2025Authorize Board to Increase Capital in the Event of Additional Demand Related to Delegation Submitted to Shareholder Vote Under Items 13-17CAPITAL STRUCTUREISSUER10026597.0000000AGAINST10026597.000000AGAINSTS000002088Sensorion SAF8312Z102FR001259646805/12/2025Set Total Limit for Capital Increase to Result from Issuance Requests Under Items 13-17 at EUR 30 MillionCAPITAL STRUCTUREISSUER10026597.0000000FOR10026597.000000FORS000002088Sensorion SAF8312Z102FR001259646805/12/2025Approve Issuance of 11 Million Warrants (BSA 2025) without Preemptive Rights Reserved for Specific BeneficiariesCOMPENSATIONISSUER10026597.0000000AGAINST10026597.000000AGAINSTS000002088Sensorion SAF8312Z102FR001259646805/12/2025Approve Issuance of 11 Million Warrants (BSPCE 2025) without Preemptive Rights Reserved for Specific BeneficiariesCOMPENSATIONISSUER10026597.0000000AGAINST10026597.000000AGAINSTS000002088Sensorion SAF8312Z102FR001259646805/12/2025Authorize up to 11 Million Shares for Use in Stock Option PlansCOMPENSATIONISSUER10026597.0000000AGAINST10026597.000000AGAINSTS000002088Sensorion SAF8312Z102FR001259646805/12/2025Authorize up to 10 Percent of Issued Capital for Use in Restricted Stock PlansCOMPENSATIONISSUER10026597.0000000AGAINST10026597.000000AGAINSTS000002088Sensorion SAF8312Z102FR001259646805/12/2025Authorize Capital Issuances for Use in Employee Stock Purchase PlansCOMPENSATIONISSUER10026597.0000000FOR10026597.000000FORS000002088Sensorion SAF8312Z102FR001259646805/12/2025Amend Article 17 of Bylaws to Incorporate Legal ChangesCORPORATE GOVERNANCEISSUER10026597.0000000AGAINST10026597.000000AGAINSTS000002088Sensorion SAF8312Z102FR001259646805/12/2025Authorize Filing of Required Documents/Other FormalitiesCORPORATE GOVERNANCEISSUER10026597.0000000FOR10026597.000000FORS000002088Centene Corporation15135B101US15135B101705/13/2025ELECTION OF DIRECTORS: Jessica L. BlumeDIRECTOR ELECTIONSISSUER862595.0000000FOR862595.000000FORS000002088Centene Corporation15135B101US15135B101705/13/2025ELECTION OF DIRECTORS: Kenneth A. BurdickDIRECTOR ELECTIONSISSUER862595.0000000FOR862595.000000FORS000002088Centene Corporation15135B101US15135B101705/13/2025ELECTION OF DIRECTORS: Christopher J. CoughlinDIRECTOR ELECTIONSISSUER862595.0000000FOR862595.000000FORS000002088Centene Corporation15135B101US15135B101705/13/2025ELECTION OF DIRECTORS: H. James DallasDIRECTOR ELECTIONSISSUER862595.0000000FOR862595.000000FORS000002088Centene Corporation15135B101US15135B101705/13/2025ELECTION OF DIRECTORS: Wayne S. DeVeydtDIRECTOR ELECTIONSISSUER862595.0000000FOR862595.000000FORS000002088Centene Corporation15135B101US15135B101705/13/2025ELECTION OF DIRECTORS: Frederick H. EppingerDIRECTOR ELECTIONSISSUER862595.0000000FOR862595.000000FORS000002088Centene Corporation15135B101US15135B101705/13/2025ELECTION OF DIRECTORS: Monte E. FordDIRECTOR ELECTIONSISSUER862595.0000000FOR862595.000000FORS000002088Centene Corporation15135B101US15135B101705/13/2025ELECTION OF DIRECTORS: Thomas R. GrecoDIRECTOR ELECTIONSISSUER862595.0000000FOR862595.000000FORS000002088Centene Corporation15135B101US15135B101705/13/2025ELECTION OF DIRECTORS: Sarah M. LondonDIRECTOR ELECTIONSISSUER862595.0000000FOR862595.000000FORS000002088Centene Corporation15135B101US15135B101705/13/2025ELECTION OF DIRECTORS: Theodore R. SamuelsDIRECTOR ELECTIONSISSUER862595.0000000FOR862595.000000FORS000002088Centene Corporation15135B101US15135B101705/13/2025ELECTION OF DIRECTORS: Kenneth Y. TanjiDIRECTOR ELECTIONSISSUER862595.0000000FOR862595.000000FORS000002088Centene Corporation15135B101US15135B101705/13/2025ADVISORY VOTE TO APPROVE EXECUTIVE COMPENSATION.SECTION 14A SAY-ON-PAY VOTESISSUER862595.0000000FOR862595.000000FORS000002088Centene Corporation15135B101US15135B101705/13/2025RATIFICATION OF APPOINTMENT OF KPMG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE YEAR ENDING DECEMBER 31, 2025.AUDIT-RELATEDISSUER862595.0000000FOR862595.000000FORS000002088Centene Corporation15135B101US15135B101705/13/2025APPROVAL OF THE 2025 STOCK INCENTIVE PLAN.COMPENSATIONISSUER862595.0000000FOR862595.000000FORS000002088Centene Corporation15135B101US15135B101705/13/2025STOCKHOLDER PROPOSAL TO DISCLOSE PLAN TO REDUCE TOTAL CONTRIBUTION TO CLIMATE CHANGE.ENVIRONMENT OR CLIMATESECURITY HOLDER862595.0000000AGAINST862595.000000FORS000002088Centene Corporation15135B101US15135B101705/13/2025STOCKHOLDER PROPOSAL FOR REPORT ON CLIMATE RISK TO RETIREMENT INVESTMENTS.ENVIRONMENT OR CLIMATESECURITY HOLDER862595.0000000AGAINST862595.000000FORS000002088Prothena Corporation plcG72800108IE00B91XRN2005/13/2025To elect, by separate resolution, three directors to hold office until no later than the Annual General Meeting of the Company's Shareholders in 2028, unless they resign, are removed from office, or are otherwise disqualified from serving as directors of the Company: Paula K. CobbDIRECTOR ELECTIONSISSUER375290.0000000FOR375290.000000FORS000002088Prothena Corporation plcG72800108IE00B91XRN2005/13/2025To elect, by separate resolution, three directors to hold office until no later than the Annual General Meeting of the Company's Shareholders in 2028, unless they resign, are removed from office, or are otherwise disqualified from serving as directors of the Company: Lars G. EkmanDIRECTOR ELECTIONSISSUER375290.0000000FOR375290.000000FORS000002088Prothena Corporation plcG72800108IE00B91XRN2005/13/2025To elect, by separate resolution, three directors to hold office until no later than the Annual General Meeting of the Company's Shareholders in 2028, unless they resign, are removed from office, or are otherwise disqualified from serving as directors of the Company: Gene G. KinneyDIRECTOR ELECTIONSISSUER375290.0000000FOR375290.000000FORS000002088Prothena Corporation plcG72800108IE00B91XRN2005/13/2025To ratify, on a non-binding vote, the appointment of KPMG LLP as the Company's independent registered public accounting firm for its fiscal year 2025, and to authorize, in a binding vote, the Company's Board of Directors, acting through its Audit Committee, to approve remuneration of that auditor.AUDIT-RELATEDISSUER375290.0000000FOR375290.000000FORS000002088Prothena Corporation plcG72800108IE00B91XRN2005/13/2025To approve, in a non-binding advisory vote, the compensation of the executive officers named in the Company's Proxy Statement for the Annual General Meeting.SECTION 14A SAY-ON-PAY VOTESISSUER375290.0000000FOR375290.000000FORS000002088Prothena Corporation plcG72800108IE00B91XRN2005/13/2025To approve an amendment to the Company's 2018 Long Term Incentive Plan to increase the number of ordinary shares available for issuance under that Plan by 2,000,000 ordinary shares.COMPENSATIONISSUER375290.0000000FOR375290.000000FORS000002088Cytokinetics, Incorporated23282W605US23282W605705/14/2025To elect the three nominees listed below as Class III Directors, each to serve for a three-year term and until their successors are duly elected and qualified: John T. HendersonDIRECTOR ELECTIONSISSUER360285.0000000FOR360285.000000FORS000002088Cytokinetics, Incorporated23282W605US23282W605705/14/2025To elect the three nominees listed below as Class III Directors, each to serve for a three-year term and until their successors are duly elected and qualified: B. Lynne ParshallDIRECTOR ELECTIONSISSUER360285.0000000FOR360285.000000FORS000002088Cytokinetics, Incorporated23282W605US23282W605705/14/2025To elect the three nominees listed below as Class III Directors, each to serve for a three-year term and until their successors are duly elected and qualified: Muna BhanjiDIRECTOR ELECTIONSISSUER360285.0000000FOR360285.000000FORS000002088Cytokinetics, Incorporated23282W605US23282W605705/14/2025To approve the amendment and restatement of the Cytokinetics Amended and Restated 2004 Equity Incentive Plan to: (i) increase the number of authorized shares reserved for issuance under such plan by 5,000,000 shares of common stock and (ii) provide for limitations on the maximum grant value that non-executive directors may receive under such plan of $1,000,000 for annual grants to continuing directors and $1,250,000 for the initial grant to new directors.COMPENSATIONISSUER360285.0000000FOR360285.000000FORS000002088Cytokinetics, Incorporated23282W605US23282W605705/14/2025To approve an amendment to Cytokinetics, Incorporated's Amended and Restated Certificate of Incorporation to increase the number of authorized shares of common available for issuance by Cytokinetics, Incorporated from 163,000,000 to 326,000,000 shares of common stock.CAPITAL STRUCTUREISSUER360285.0000000FOR360285.000000FORS000002088Cytokinetics, Incorporated23282W605US23282W605705/14/2025To ratify the appointment by the Audit Committee of the Board of Directors of Ernst & Young LLP as the Cytokinetics, Incorporated's independent registered public accounting firm for the fiscal year ending December 31, 2025.AUDIT-RELATEDISSUER360285.0000000FOR360285.000000FORS000002088Cytokinetics, Incorporated23282W605US23282W605705/14/2025To approve, on an advisory basis, the compensation of Cytokinetics, Incorporated's named executive officers, as disclosed in the Proxy Statement.SECTION 14A SAY-ON-PAY VOTESISSUER360285.0000000FOR360285.000000FORS000002088Elevance Health, Inc.036752103US036752103805/14/2025Election of Directors: Susan D. DeVoreDIRECTOR ELECTIONSISSUER618592.0000000FOR618592.000000FORS000002088Elevance Health, Inc.036752103US036752103805/14/2025Election of Directors: Bahija JallalDIRECTOR ELECTIONSISSUER618592.0000000FOR618592.000000FORS000002088Elevance Health, Inc.036752103US036752103805/14/2025Election of Directors: Ryan M. SchneiderDIRECTOR ELECTIONSISSUER618592.0000000FOR618592.000000FORS000002088Elevance Health, Inc.036752103US036752103805/14/2025Advisory vote to approve the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER618592.0000000FOR618592.000000FORS000002088Elevance Health, Inc.036752103US036752103805/14/2025To ratify the appointment of Ernst & Young LLP as the independent registered public accounting firm for 2025.AUDIT-RELATEDISSUER618592.0000000FOR618592.000000FORS000002088Elevance Health, Inc.036752103US036752103805/14/2025Shareholder proposal requesting report on the effectiveness of Diversity, Equity and Inclusion efforts.DIVERSITY, EQUITY, AND INCLUSIONSECURITY HOLDER618592.0000000AGAINST618592.000000FORS000002088SpringWorks Therapeutics, Inc.85205L107US85205L107005/14/2025Election of Class III Directors: Alan FuhrmanDIRECTOR ELECTIONSISSUER689071.0000000FOR689071.000000FORS000002088SpringWorks Therapeutics, Inc.85205L107US85205L107005/14/2025Election of Class III Directors: Julie Hambleton, M.D.DIRECTOR ELECTIONSISSUER689071.0000000FOR689071.000000FORS000002088SpringWorks Therapeutics, Inc.85205L107US85205L107005/14/2025Election of Class III Directors: Daniel S. Lynch, M.B.A.DIRECTOR ELECTIONSISSUER689071.0000000FOR689071.000000FORS000002088SpringWorks Therapeutics, Inc.85205L107US85205L107005/14/2025Ratification of the appointment of Ernst & Young LLP as SpringWorks Therapeutics' independent registered public accounting firm for the fiscal year ending December 31, 2025AUDIT-RELATEDISSUER689071.0000000FOR689071.000000FORS000002088SpringWorks Therapeutics, Inc.85205L107US85205L107005/14/2025Non-binding advisory vote on executive compensationSECTION 14A SAY-ON-PAY VOTESISSUER689071.0000000FOR689071.000000FORS000002088Vera Therapeutics, Inc.92337R101US92337R101405/14/2025To elect the three Class I directors named below to hold office until the Company's 2028 annual meeting of stockholders: Marshall Fordyce, M.D.DIRECTOR ELECTIONSISSUER1281101.0000000FOR1281101.000000FORS000002088Vera Therapeutics, Inc.92337R101US92337R101405/14/2025To elect the three Class I directors named below to hold office until the Company's 2028 annual meeting of stockholders: Beth Seidenberg, M.D.DIRECTOR ELECTIONSISSUER1281101.0000000FOR1281101.000000FORS000002088Vera Therapeutics, Inc.92337R101US92337R101405/14/2025To elect the three Class I directors named below to hold office until the Company's 2028 annual meeting of stockholders: Kimball HallDIRECTOR ELECTIONSISSUER1281101.0000000FOR1281101.000000FORS000002088Vera Therapeutics, Inc.92337R101US92337R101405/14/2025To ratify the selection by the Audit Committee of the Board of Directors of KPMG LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2025.AUDIT-RELATEDISSUER1281101.0000000FOR1281101.000000FORS000002088Vera Therapeutics, Inc.92337R101US92337R101405/14/2025To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the Proxy Statement.SECTION 14A SAY-ON-PAY VOTESISSUER1281101.0000000FOR1281101.000000FORS000002088Vera Therapeutics, Inc.92337R101US92337R101405/14/2025To indicate, on an advisory basis, the preferred frequency of stockholder advisory votes on the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER1281101.0000000ONE YEAR1281101.000000FORS000002088Vertex Pharmaceuticals Incorporated92532F100US92532F100305/14/2025Election of Directors: Sangeeta BhatiaDIRECTOR ELECTIONSISSUER856858.0000000FOR856858.000000FORS000002088Vertex Pharmaceuticals Incorporated92532F100US92532F100305/14/2025Election of Directors: Lloyd CarneyDIRECTOR ELECTIONSISSUER856858.0000000FOR856858.000000FORS000002088Vertex Pharmaceuticals Incorporated92532F100US92532F100305/14/2025Election of Directors: Alan GarberDIRECTOR ELECTIONSISSUER856858.0000000FOR856858.000000FORS000002088Vertex Pharmaceuticals Incorporated92532F100US92532F100305/14/2025Election of Directors: Reshma KewalramaniDIRECTOR ELECTIONSISSUER856858.0000000FOR856858.000000FORS000002088Vertex Pharmaceuticals Incorporated92532F100US92532F100305/14/2025Election of Directors: Michel LagardeDIRECTOR ELECTIONSISSUER856858.0000000FOR856858.000000FORS000002088Vertex Pharmaceuticals Incorporated92532F100US92532F100305/14/2025Election of Directors: Jeffrey LeidenDIRECTOR ELECTIONSISSUER856858.0000000FOR856858.000000FORS000002088Vertex Pharmaceuticals Incorporated92532F100US92532F100305/14/2025Election of Directors: Diana McKenzieDIRECTOR ELECTIONSISSUER856858.0000000FOR856858.000000FORS000002088Vertex Pharmaceuticals Incorporated92532F100US92532F100305/14/2025Election of Directors: Bruce SachsDIRECTOR ELECTIONSISSUER856858.0000000FOR856858.000000FORS000002088Vertex Pharmaceuticals Incorporated92532F100US92532F100305/14/2025Election of Directors: Jennifer SchneiderDIRECTOR ELECTIONSISSUER856858.0000000FOR856858.000000FORS000002088Vertex Pharmaceuticals Incorporated92532F100US92532F100305/14/2025Election of Directors: Nancy ThornberryDIRECTOR ELECTIONSISSUER856858.0000000FOR856858.000000FORS000002088Vertex Pharmaceuticals Incorporated92532F100US92532F100305/14/2025Election of Directors: Suketu UpadhyayDIRECTOR ELECTIONSISSUER856858.0000000FOR856858.000000FORS000002088Vertex Pharmaceuticals Incorporated92532F100US92532F100305/14/2025Ratification of Ernst & Young LLP as independent Registered Public Accounting firm for the year ending December 31, 2025.AUDIT-RELATEDISSUER856858.0000000FOR856858.000000FORS000002088Vertex Pharmaceuticals Incorporated92532F100US92532F100305/14/2025Advisory vote to approve named executive officer compensation.SECTION 14A SAY-ON-PAY VOTESISSUER856858.0000000FOR856858.000000FORS000002088Vertex Pharmaceuticals Incorporated92532F100US92532F100305/14/2025Shareholder proposal, if properly presented at the meeting, regarding excessive golden parachutes.COMPENSATIONSECURITY HOLDER856858.0000000AGAINST856858.000000FORS000002088CVS Health Corporation126650100US126650100605/15/2025Election of Directors: Fernando AguirreDIRECTOR ELECTIONSISSUER694816.0000000FOR694816.000000FORS000002088CVS Health Corporation126650100US126650100605/15/2025Election of Directors: Jeffrey R. Balser, M.D., Ph.D.DIRECTOR ELECTIONSISSUER694816.0000000FOR694816.000000FORS000002088CVS Health Corporation126650100US126650100605/15/2025Election of Directors: C. David Brown IIDIRECTOR ELECTIONSISSUER694816.0000000FOR694816.000000FORS000002088CVS Health Corporation126650100US126650100605/15/2025Election of Directors: Alecia A. DeCoudreauxDIRECTOR ELECTIONSISSUER694816.0000000FOR694816.000000FORS000002088CVS Health Corporation126650100US126650100605/15/2025Election of Directors: Roger N. FarahDIRECTOR ELECTIONSISSUER694816.0000000FOR694816.000000FORS000002088CVS Health Corporation126650100US126650100605/15/2025Election of Directors: Anne M. FinucaneDIRECTOR ELECTIONSISSUER694816.0000000FOR694816.000000FORS000002088CVS Health Corporation126650100US126650100605/15/2025Election of Directors: J. David JoynerDIRECTOR ELECTIONSISSUER694816.0000000FOR694816.000000FORS000002088CVS Health Corporation126650100US126650100605/15/2025Election of Directors: J. Scott KirbyDIRECTOR ELECTIONSISSUER694816.0000000FOR694816.000000FORS000002088CVS Health Corporation126650100US126650100605/15/2025Election of Directors: Michael F. MahoneyDIRECTOR ELECTIONSISSUER694816.0000000FOR694816.000000FORS000002088CVS Health Corporation126650100US126650100605/15/2025Election of Directors: Leslie V. NorwalkDIRECTOR ELECTIONSISSUER694816.0000000FOR694816.000000FORS000002088CVS Health Corporation126650100US126650100605/15/2025Election of Directors: Larry M. RobbinsDIRECTOR ELECTIONSISSUER694816.0000000FOR694816.000000FORS000002088CVS Health Corporation126650100US126650100605/15/2025Election of Directors: Guy P. SansoneDIRECTOR ELECTIONSISSUER694816.0000000FOR694816.000000FORS000002088CVS Health Corporation126650100US126650100605/15/2025Election of Directors: Douglas H. ShulmanDIRECTOR ELECTIONSISSUER694816.0000000FOR694816.000000FORS000002088CVS Health Corporation126650100US126650100605/15/2025Ratification of the Appointment of Our Independent Registered Public Accounting Firm for 2025.AUDIT-RELATEDISSUER694816.0000000FOR694816.000000FORS000002088CVS Health Corporation126650100US126650100605/15/2025Say on Pay, a Proposal to Approve, on an Advisory Basis, the Company's Executive Compensation.SECTION 14A SAY-ON-PAY VOTESISSUER694816.0000000FOR694816.000000FORS000002088CVS Health Corporation126650100US126650100605/15/2025Stockholder Proposal for Reducing the Threshold for Our Stockholder Right to Act By Written Consent.CORPORATE GOVERNANCESECURITY HOLDER694816.0000000AGAINST694816.000000FORS000002088Immunocore Holdings Plc45258D105US45258D105405/15/2025To re-appoint as a director Roy S. Herbst, M.D., Ph.D., who retires in accordance with the articles of association.DIRECTOR ELECTIONSISSUER916568.0000000AGAINST916568.000000AGAINSTS000002088Immunocore Holdings Plc45258D105US45258D105405/15/2025To re-appoint as a director Ranjeev Krishana, who retires in accordance with the articles of association.DIRECTOR ELECTIONSISSUER916568.0000000FOR916568.000000FORS000002088Immunocore Holdings Plc45258D105US45258D105405/15/2025To re-appoint as a director Professor Sir Peter Ratcliffe, who retires in accordance with the articles of association.DIRECTOR ELECTIONSISSUER916568.0000000FOR916568.000000FORS000002088Immunocore Holdings Plc45258D105US45258D105405/15/2025To approve, on advisory basis, the compensation of the Company's named executive officers, as disclosed in the proxy statement.SECTION 14A SAY-ON-PAY VOTESISSUER916568.0000000AGAINST916568.000000AGAINSTS000002088Immunocore Holdings Plc45258D105US45258D105405/15/2025To ratify the appointment of Deloitte LLP, a limited liability partnership organized under the laws of England, as our U.S. independent registered public accounting firm for the year ending 31 December 2025.AUDIT-RELATEDISSUER916568.0000000FOR916568.000000FORS000002088Immunocore Holdings Plc45258D105US45258D105405/15/2025To re-appoint Deloitte LLP, a limited liability partnership organized under the laws of England, as our U.K. statutory auditors, to hold office until the conclusion of our next annual general meeting of shareholders.AUDIT-RELATEDISSUER916568.0000000FOR916568.000000FORS000002088Immunocore Holdings Plc45258D105US45258D105405/15/2025To authorize the audit committee to determine the U.K. statutory auditors' remuneration for the year ending 31 December 2025.AUDIT-RELATEDISSUER916568.0000000FOR916568.000000FORS000002088Immunocore Holdings Plc45258D105US45258D105405/15/2025To receive and adopt the U.K. statutory annual accounts and reports for the year ended 31 December 2024.CORPORATE GOVERNANCEISSUER916568.0000000FOR916568.000000FORS000002088Immunocore Holdings Plc45258D105US45258D105405/15/2025To approve the directors' remuneration report for the year ended 31 December 2024, which is set forth as Annex A to the proxy statement (excluding the directors' remuneration policy set out on pages A-5 to A-15 of Annex A to the proxy statement).COMPENSATIONISSUER916568.0000000AGAINST916568.000000AGAINSTS000002088Immunocore Holdings Plc45258D105US45258D105405/15/2025To approve the directors' remuneration policy, which is set forth on pages A-5 to A-15 of Annex A to the proxy statement, which will take effect immediately after the end of the AGM.COMPENSATIONISSUER916568.0000000AGAINST916568.000000AGAINSTS000002088Immunocore Holdings Plc45258D105US45258D105405/15/2025To authorize the Company to make political donations/incur political expenditure.OTHER SOCIAL ISSUESISSUER916568.0000000FOR916568.000000FORS000002088Immunocore Holdings Plc45258D105US45258D105405/15/2025To authorize the directors to allot shares or to grant rights to subscribe for or convert any security into shares up to an aggregate nominal amount of pounds150,000.CAPITAL STRUCTUREISSUER916568.0000000AGAINST916568.000000AGAINSTS000002088Immunocore Holdings Plc45258D105US45258D105405/15/2025To empower the directors to allot equity securities for cash pursuant to the authorization in resolution 12 as if U.K. statutory pre-emption rights did not apply.CAPITAL STRUCTUREISSUER916568.0000000AGAINST916568.000000AGAINSTS000002088Insmed Incorporated457669307US457669307505/15/2025Election of two Class I directors, Leo Lee and William H. Lewis, to serve until the 2028 Annual Meeting of Shareholders: Leo LeeDIRECTOR ELECTIONSISSUER2632302.0000000WITHHOLD2632302.000000AGAINSTS000002088Insmed Incorporated457669307US457669307505/15/2025Election of two Class I directors, Leo Lee and William H. Lewis, to serve until the 2028 Annual Meeting of Shareholders: William H. LewisDIRECTOR ELECTIONSISSUER2632302.0000000FOR2632302.000000FORS000002088Insmed Incorporated457669307US457669307505/15/2025An advisory vote on the 2024 compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER2632302.0000000FOR2632302.000000FORS000002088Insmed Incorporated457669307US457669307505/15/2025Ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for the year ending December 31, 2025.AUDIT-RELATEDISSUER2632302.0000000FOR2632302.000000FORS000002088Insmed Incorporated457669307US457669307505/15/2025Approval of Amendment No. 2 to the Insmed Incorporated Amended and Restated 2019 Incentive Plan.COMPENSATIONISSUER2632302.0000000FOR2632302.000000FORS000002088Labcorp Holdings Inc.504922105US504922105505/15/2025Election of the members of the Company's Board of Directors: Kerrii B. AndersonDIRECTOR ELECTIONSISSUER53200.0000000FOR53200.000000FORS000002088Labcorp Holdings Inc.504922105US504922105505/15/2025Election of the members of the Company's Board of Directors: Jeffrey A. DavisDIRECTOR ELECTIONSISSUER53200.0000000FOR53200.000000FORS000002088Labcorp Holdings Inc.504922105US504922105505/15/2025Election of the members of the Company's Board of Directors: D. Gary Gilliland, M.D., Ph.D.DIRECTOR ELECTIONSISSUER53200.0000000FOR53200.000000FORS000002088Labcorp Holdings Inc.504922105US504922105505/15/2025Election of the members of the Company's Board of Directors: Kirsten M. KliphouseDIRECTOR ELECTIONSISSUER53200.0000000FOR53200.000000FORS000002088Labcorp Holdings Inc.504922105US504922105505/15/2025Election of the members of the Company's Board of Directors: Garheng Kong, M.D., Ph.D.DIRECTOR ELECTIONSISSUER53200.0000000FOR53200.000000FORS000002088Labcorp Holdings Inc.504922105US504922105505/15/2025Election of the members of the Company's Board of Directors: Peter M. NeupertDIRECTOR ELECTIONSISSUER53200.0000000FOR53200.000000FORS000002088Labcorp Holdings Inc.504922105US504922105505/15/2025Election of the members of the Company's Board of Directors: Richelle P. ParhamDIRECTOR ELECTIONSISSUER53200.0000000FOR53200.000000FORS000002088Labcorp Holdings Inc.504922105US504922105505/15/2025Election of the members of the Company's Board of Directors: Paul B. Rothman, M.D.DIRECTOR ELECTIONSISSUER53200.0000000FOR53200.000000FORS000002088Labcorp Holdings Inc.504922105US504922105505/15/2025Election of the members of the Company's Board of Directors: Adam H. SchechterDIRECTOR ELECTIONSISSUER53200.0000000FOR53200.000000FORS000002088Labcorp Holdings Inc.504922105US504922105505/15/2025Election of the members of the Company's Board of Directors: Kathryn E. WengelDIRECTOR ELECTIONSISSUER53200.0000000FOR53200.000000FORS000002088Labcorp Holdings Inc.504922105US504922105505/15/2025To approve, by non-binding vote, the compensation of Company's Named Executive Officers.SECTION 14A SAY-ON-PAY VOTESISSUER53200.0000000FOR53200.000000FORS000002088Labcorp Holdings Inc.504922105US504922105505/15/2025To approve the Company's 2025 Omnibus Incentive Plan.COMPENSATIONISSUER53200.0000000FOR53200.000000FORS000002088Labcorp Holdings Inc.504922105US504922105505/15/2025To approve the Company's 2025 Employee Stock Purchase Plan.COMPENSATIONISSUER53200.0000000FOR53200.000000FORS000002088Labcorp Holdings Inc.504922105US504922105505/15/2025To ratify the appointment of Deloitte & Touche LLP as Labcorp Holdings Inc.'s independent registered public accounting firm for the year ending December 31, 2025.AUDIT-RELATEDISSUER53200.0000000FOR53200.000000FORS000002088Lyell Immunopharma, Inc.55083R203US55083R203105/15/2025Election of Class I Director: Catherine FriedmanDIRECTOR ELECTIONSISSUER4579227.0000000FOR4579227.000000FORS000002088Lyell Immunopharma, Inc.55083R203US55083R203105/15/2025Ratification of the appointment of Ernst & Young LLP as the company's independent registered public accounting firm for its fiscal year ending December 31, 2025.AUDIT-RELATEDISSUER4579227.0000000FOR4579227.000000FORS000002088Lyell Immunopharma, Inc.55083R203US55083R203105/15/2025Approval, on a non-binding advisory basis, of the compensation of the company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER4579227.0000000FOR4579227.000000FORS000002088Lyell Immunopharma, Inc.55083R203US55083R203105/15/2025Approval of a series of alternate amendments to the company's Amended and Restated Certificate of Incorporation to effect a reverse stock split of its common stock at a ratio in the range of 1-for-10 to 1-for-25, with such ratio to be determined in the discretion of the company's board of directors and with such reverse stock split to be effected at such time and date, if at all, as determined by the company's board of directors in its sole discretion.CAPITAL STRUCTUREISSUER4579227.0000000FOR4579227.000000FORS000002088MediWound Ltd.M68830112IL001131630905/15/2025Reelect Nachum (Homi) Shamir as DirectorDIRECTOR ELECTIONSISSUER122173.0000000FOR122173.000000FORS000002088MediWound Ltd.M68830112IL001131630905/15/2025Reelect Stephen T. Wills as DirectorDIRECTOR ELECTIONSISSUER122173.0000000AGAINST122173.000000AGAINSTS000002088MediWound Ltd.M68830112IL001131630905/15/2025Reelect Vickie R. Driver as DirectorDIRECTOR ELECTIONSISSUER122173.0000000FOR122173.000000FORS000002088MediWound Ltd.M68830112IL001131630905/15/2025Reelect David Fox as DirectorDIRECTOR ELECTIONSISSUER122173.0000000FOR122173.000000FORS000002088MediWound Ltd.M68830112IL001131630905/15/2025Reelect Shmuel (Milky) Rubinstein as DirectorDIRECTOR ELECTIONSISSUER122173.0000000FOR122173.000000FORS000002088MediWound Ltd.M68830112IL001131630905/15/2025Reappoint Somekh Chaikin, a member firm of KPMG as Auditors and Authorize Board to Fix Their RemunerationAUDIT-RELATEDISSUER122173.0000000FOR122173.000000FORS000002088MediWound Ltd.M68830112IL001131630905/15/2025Approve Renewal of Updated Compensation Policy for the Directors and Officers of the CompanyCOMPENSATIONISSUER122173.0000000AGAINST122173.000000AGAINSTS000002088MediWound Ltd.M68830112IL001131630905/15/2025Approve 2024 Annual Cash Bonus to Ofer Gonen, CEOCOMPENSATIONISSUER122173.0000000FOR122173.000000FORS000002088Quest Diagnostics Incorporated74834L100US74834L100805/15/2025Election of Directors: Robert B. CarterDIRECTOR ELECTIONSISSUER340550.0000000FOR340550.000000FORS000002088Quest Diagnostics Incorporated74834L100US74834L100805/15/2025Election of Directors: James E. DavisDIRECTOR ELECTIONSISSUER340550.0000000FOR340550.000000FORS000002088Quest Diagnostics Incorporated74834L100US74834L100805/15/2025Election of Directors: Luis A. Diaz, Jr., M.D.DIRECTOR ELECTIONSISSUER340550.0000000FOR340550.000000FORS000002088Quest Diagnostics Incorporated74834L100US74834L100805/15/2025Election of Directors: Tracey C. DoiDIRECTOR ELECTIONSISSUER340550.0000000FOR340550.000000FORS000002088Quest Diagnostics Incorporated74834L100US74834L100805/15/2025Election of Directors: Vicky B. GreggDIRECTOR ELECTIONSISSUER340550.0000000AGAINST340550.000000AGAINSTS000002088Quest Diagnostics Incorporated74834L100US74834L100805/15/2025Election of Directors: Wright L. Lassiter, IIIDIRECTOR ELECTIONSISSUER340550.0000000FOR340550.000000FORS000002088Quest Diagnostics Incorporated74834L100US74834L100805/15/2025Election of Directors: Timothy L. MainDIRECTOR ELECTIONSISSUER340550.0000000FOR340550.000000FORS000002088Quest Diagnostics Incorporated74834L100US74834L100805/15/2025Election of Directors: Denise M. MorrisonDIRECTOR ELECTIONSISSUER340550.0000000FOR340550.000000FORS000002088Quest Diagnostics Incorporated74834L100US74834L100805/15/2025Election of Directors: Gary M. PfeifferDIRECTOR ELECTIONSISSUER340550.0000000FOR340550.000000FORS000002088Quest Diagnostics Incorporated74834L100US74834L100805/15/2025Election of Directors: Timothy M. RingDIRECTOR ELECTIONSISSUER340550.0000000FOR340550.000000FORS000002088Quest Diagnostics Incorporated74834L100US74834L100805/15/2025An advisory resolution to approve the executive officer compensation disclosed in the Company's 2025 proxy statementSECTION 14A SAY-ON-PAY VOTESISSUER340550.0000000FOR340550.000000FORS000002088Quest Diagnostics Incorporated74834L100US74834L100805/15/2025Ratification of the appointment of our independent registered public accounting firm for 2025AUDIT-RELATEDISSUER340550.0000000FOR340550.000000FORS000002088Quest Diagnostics Incorporated74834L100US74834L100805/15/2025Stockholder proposal, as described in the accompanying proxy statement, if properly presented at the Annual MeetingCORPORATE GOVERNANCESECURITY HOLDER340550.0000000AGAINST340550.000000FORS000002088Repligen Corporation759916109US759916109505/15/2025Election of Directors: Olivier LoeillotDIRECTOR ELECTIONSISSUER235695.0000000FOR235695.000000FORS000002088Repligen Corporation759916109US759916109505/15/2025Election of Directors: Tony J. HuntDIRECTOR ELECTIONSISSUER235695.0000000FOR235695.000000FORS000002088Repligen Corporation759916109US759916109505/15/2025Election of Directors: Karen A. DawesDIRECTOR ELECTIONSISSUER235695.0000000FOR235695.000000FORS000002088Repligen Corporation759916109US759916109505/15/2025Election of Directors: Nicolas M. BarthelemyDIRECTOR ELECTIONSISSUER235695.0000000FOR235695.000000FORS000002088Repligen Corporation759916109US759916109505/15/2025Election of Directors: Carrie Eglinton MannerDIRECTOR ELECTIONSISSUER235695.0000000FOR235695.000000FORS000002088Repligen Corporation759916109US759916109505/15/2025Election of Directors: Konstantin Konstantinov, Ph.D.DIRECTOR ELECTIONSISSUER235695.0000000FOR235695.000000FORS000002088Repligen Corporation759916109US759916109505/15/2025Election of Directors: Martin D. Madaus, D.V.M., Ph.D.DIRECTOR ELECTIONSISSUER235695.0000000FOR235695.000000FORS000002088Repligen Corporation759916109US759916109505/15/2025Election of Directors: Rohin Mhatre, Ph.D.DIRECTOR ELECTIONSISSUER235695.0000000FOR235695.000000FORS000002088Repligen Corporation759916109US759916109505/15/2025Election of Directors: Glenn P. MuirDIRECTOR ELECTIONSISSUER235695.0000000FOR235695.000000FORS000002088Repligen Corporation759916109US759916109505/15/2025Election of Directors: Margaret A. PaxDIRECTOR ELECTIONSISSUER235695.0000000FOR235695.000000FORS000002088Repligen Corporation759916109US759916109505/15/2025Ratification of the selection of Ernst & Young LLP as Repligen Corporation's independent registered public accounting firm for the fiscal year ending December 31, 2025.AUDIT-RELATEDISSUER235695.0000000FOR235695.000000FORS000002088Repligen Corporation759916109US759916109505/15/2025Advisory vote to approve the compensation paid to Repligen Corporation's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER235695.0000000FOR235695.000000FORS000002088Repligen Corporation759916109US759916109505/15/2025Approval of an amendment to the Corporation's certificate of incorporation to limit the liability of certain officers of the company as permitted by Delaware law.CORPORATE GOVERNANCEISSUER235695.0000000FOR235695.000000FORS000002088Ultragenyx Pharmaceutical Inc.90400D108US90400D108105/15/2025Nominees: Matthew K. FustDIRECTOR ELECTIONSISSUER892486.0000000FOR892486.000000FORS000002088Ultragenyx Pharmaceutical Inc.90400D108US90400D108105/15/2025Nominees: Amrit Ray, M.D.DIRECTOR ELECTIONSISSUER892486.0000000FOR892486.000000FORS000002088Ultragenyx Pharmaceutical Inc.90400D108US90400D108105/15/2025Approval of the Second Amended and Restated 2023 Incentive Plan.COMPENSATIONISSUER892486.0000000FOR892486.000000FORS000002088Ultragenyx Pharmaceutical Inc.90400D108US90400D108105/15/2025Ratification of the selection of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025.AUDIT-RELATEDISSUER892486.0000000FOR892486.000000FORS000002088Ultragenyx Pharmaceutical Inc.90400D108US90400D108105/15/2025Advisory (non-binding) vote to approve the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER892486.0000000FOR892486.000000FORS000002088Krystal Biotech, Inc.501147102US501147102705/16/2025Election of Class II Directors: Daniel S. JanneyDIRECTOR ELECTIONSISSUER250489.0000000FOR250489.000000FORS000002088Krystal Biotech, Inc.501147102US501147102705/16/2025Election of Class II Directors: Dino A. RossiDIRECTOR ELECTIONSISSUER250489.0000000FOR250489.000000FORS000002088Krystal Biotech, Inc.501147102US501147102705/16/2025Election of Class II Directors: E. Rand SutherlandDIRECTOR ELECTIONSISSUER250489.0000000FOR250489.000000FORS000002088Krystal Biotech, Inc.501147102US501147102705/16/2025To ratify the appointment of KPMG LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2025.AUDIT-RELATEDISSUER250489.0000000FOR250489.000000FORS000002088Krystal Biotech, Inc.501147102US501147102705/16/2025Approval of the compensation of the Company's named executive officers, on a non-binding, advisory basis.SECTION 14A SAY-ON-PAY VOTESISSUER250489.0000000FOR250489.000000FORS000002088Alkermes plcG01767105IE00B56GVS1505/21/2025To elect as directors to serve a one-year term until the Company's 2026 annual general meeting of shareholders: Shane M. CookeDIRECTOR ELECTIONSISSUER1279380.0000000FOR1279380.000000FORS000002088Alkermes plcG01767105IE00B56GVS1505/21/2025To elect as directors to serve a one-year term until the Company's 2026 annual general meeting of shareholders: Richard B. Gaynor, M.D.DIRECTOR ELECTIONSISSUER1279380.0000000FOR1279380.000000FORS000002088Alkermes plcG01767105IE00B56GVS1505/21/2025To elect as directors to serve a one-year term until the Company's 2026 annual general meeting of shareholders: Cato T. Laurencin, M.D., Ph.D.DIRECTOR ELECTIONSISSUER1279380.0000000FOR1279380.000000FORS000002088Alkermes plcG01767105IE00B56GVS1505/21/2025To elect as directors to serve a one-year term until the Company's 2026 annual general meeting of shareholders: Nancy S. LurkerDIRECTOR ELECTIONSISSUER1279380.0000000FOR1279380.000000FORS000002088Alkermes plcG01767105IE00B56GVS1505/21/2025To elect as directors to serve a one-year term until the Company's 2026 annual general meeting of shareholders: Brian P. McKeonDIRECTOR ELECTIONSISSUER1279380.0000000FOR1279380.000000FORS000002088Alkermes plcG01767105IE00B56GVS1505/21/2025To elect as directors to serve a one-year term until the Company's 2026 annual general meeting of shareholders: Richard F. PopsDIRECTOR ELECTIONSISSUER1279380.0000000FOR1279380.000000FORS000002088Alkermes plcG01767105IE00B56GVS1505/21/2025To elect as directors to serve a one-year term until the Company's 2026 annual general meeting of shareholders: Nancy L. Snyderman, M.D.DIRECTOR ELECTIONSISSUER1279380.0000000FOR1279380.000000FORS000002088Alkermes plcG01767105IE00B56GVS1505/21/2025To elect as directors to serve a one-year term until the Company's 2026 annual general meeting of shareholders: Frank Anders WilsonDIRECTOR ELECTIONSISSUER1279380.0000000FOR1279380.000000FORS000002088Alkermes plcG01767105IE00B56GVS1505/21/2025To elect as directors to serve a one-year term until the Company's 2026 annual general meeting of shareholders: Christopher I. Wright, M.D., Ph.D.DIRECTOR ELECTIONSISSUER1279380.0000000FOR1279380.000000FORS000002088Alkermes plcG01767105IE00B56GVS1505/21/2025To approve, in a non-binding, advisory vote, the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER1279380.0000000FOR1279380.000000FORS000002088Alkermes plcG01767105IE00B56GVS1505/21/2025To ratify, in a non-binding vote, the appointment of PricewaterhouseCoopers LLP as the independent auditor and accounting firm of the Company and to authorize, in a binding vote, the Audit and Risk Committee of the Board to set the independent auditor and accounting firm's remuneration.AUDIT-RELATEDISSUER1279380.0000000FOR1279380.000000FORS000002088Alkermes plcG01767105IE00B56GVS1505/21/2025To approve the Alkermes plc 2018 Stock Option and Incentive Plan, as amended.COMPENSATIONISSUER1279380.0000000FOR1279380.000000FORS000002088Alkermes plcG01767105IE00B56GVS1505/21/2025To renew Board authority to allot and issue shares under Irish law.CAPITAL STRUCTUREISSUER1279380.0000000FOR1279380.000000FORS000002088Alkermes plcG01767105IE00B56GVS1505/21/2025To renew Board authority to disapply the statutory pre-emption rights that would otherwise apply under Irish law.CAPITAL STRUCTUREISSUER1279380.0000000FOR1279380.000000FORS000002088BeiGene Ltd.07725L102US07725L102605/21/2025THAT Mr. Anthony C. Hooper be and is hereby re-elected to serve as a Class III director of the Company until the 2028 annual general meeting of shareholders and until his successor is duly elected and qualified, subject to his earlier resignation or removal.DIRECTOR ELECTIONSISSUER683344.0000000FOR683344.000000FORS000002088BeiGene Ltd.07725L102US07725L102605/21/2025THAT Mr. Ranjeev Krishana be and is hereby re-elected to serve as a Class III director of the Company until the 2028 annual general meeting of shareholders and until his successor is duly elected and qualified, subject to his earlier resignation or removal.DIRECTOR ELECTIONSISSUER683344.0000000FOR683344.000000FORS000002088BeiGene Ltd.07725L102US07725L102605/21/2025THAT Dr. Xiaodong Wang be and is hereby re-elected to serve as a Class III director of the Company until the 2028 annual general meeting of shareholders and until his successor is duly elected and qualified, subject to his earlier resignation or removal.DIRECTOR ELECTIONSISSUER683344.0000000FOR683344.000000FORS000002088BeiGene Ltd.07725L102US07725L102605/21/2025THAT Mr. Qingqing Yi be and is hereby re-elected to serve as a Class III director of the Company until the 2028 annual general meeting of shareholders and until his successor is duly elected and qualified, subject to his earlier resignation or removal.DIRECTOR ELECTIONSISSUER683344.0000000FOR683344.000000FORS000002088BeiGene Ltd.07725L102US07725L102605/21/2025THAT Ms. Shalini Sharp be and is hereby re-elected to serve as a Class II director of the Company until the 2027 annual general meeting of shareholders and until her successor is duly elected and qualified, subject to her earlier resignation or removal.DIRECTOR ELECTIONSISSUER683344.0000000AGAINST683344.000000AGAINSTS000002088BeiGene Ltd.07725L102US07725L102605/21/2025THAT the appointment of Ernst & Young LLP, Ernst & Young and Ernst & Young Hua Ming LLP as the Company's independent auditors for the fiscal year ending December 31, 2025 be and is hereby ratified and confirmed.AUDIT-RELATEDISSUER683344.0000000FOR683344.000000FORS000002088BeiGene Ltd.07725L102US07725L102605/21/2025THAT the Board of Directors is hereby authorized to fix the auditors' compensation for the fiscal year ending December 31, 2025.AUDIT-RELATEDISSUER683344.0000000FOR683344.000000FORS000002088BeiGene Ltd.07725L102US07725L102605/21/2025THAT the granting of a share issue mandate to the Board of Directors to issue, allot or deal with unissued ordinary shares and/or American Depositary Shares ("ADSs") (including any sale or transfer of treasury shares out of treasury) not exceeding 20% of the total number of issued shares of the Company (excluding treasury shares) as of the date of passing of this ordinary resolution up to the next annual general meeting of shareholders of the Company be and is hereby approved.CAPITAL STRUCTUREISSUER683344.0000000AGAINST683344.000000AGAINSTS000002088BeiGene Ltd.07725L102US07725L102605/21/2025THAT the granting of a share repurchase mandate to the Board of Directors to repurchase an amount of ordinary shares (excluding the Company's ordinary shares listed on the Science and Technology Innovation Board of Shanghai Stock Exchange and traded in RMB ("RMB shares")) and/or ADSs, not exceeding 10% of the total number of issued ordinary shares (excluding RMB shares and treasury shares) of the Company as of the date of passing of this ordinary resolution up to the next annual general meeting of shareholders of the Company be and is hereby approved.CAPITAL STRUCTUREISSUER683344.0000000FOR683344.000000FORS000002088BeiGene Ltd.07725L102US07725L102605/21/2025THAT the Company and its underwriters be and are hereby authorized, in their sole discretion, to allocate to Amgen Inc. ("Amgen"), up to a maximum amount of shares in order to maintain the same shareholding percentage of Amgen (based on the then-outstanding share capital of the Company) before and after the allocation of the corresponding securities issued pursuant to an offering conducted pursuant to the general mandate set forth in Resolution 8 for a period of five years, which period will be subject to an extension on a rolling basis each year.CAPITAL STRUCTUREISSUER683344.0000000AGAINST683344.000000AGAINSTS000002088BeiGene Ltd.07725L102US07725L102605/21/2025THAT, on a non-binding, advisory basis, the compensation of the Company's named executive officers, as disclosed in the Proxy Statement, be and is hereby approved.SECTION 14A SAY-ON-PAY VOTESISSUER683344.0000000AGAINST683344.000000AGAINSTS000002088BeiGene Ltd.07725L102US07725L102605/21/2025THAT the adjournment of the Annual Meeting by the chairman, if necessary, to solicit additional proxies if there are insufficient votes at the time of the Annual Meeting to approve any of the proposals described above, be and is hereby approved.CORPORATE GOVERNANCEISSUER683344.0000000AGAINST683344.000000AGAINSTS000002088Merus N.V.N5749R100NL001160626405/21/2025Adoption of Merus N.V.'s Dutch statutory annual accounts for the financial year 2024.CORPORATE GOVERNANCEISSUER347940.0000000FOR347940.000000FORS000002088Merus N.V.N5749R100NL001160626405/21/2025Appointment of KPMG Accountants N.V. as Merus N.V.'s external auditor for the financial year 2025 for purposes of Dutch law.AUDIT-RELATEDISSUER347940.0000000FOR347940.000000FORS000002088Merus N.V.N5749R100NL001160626405/21/2025Release of each member of Merus N.V.'s board of directors from liability for the exercise of their duties during the financial year 2024.CORPORATE GOVERNANCEISSUER347940.0000000FOR347940.000000FORS000002088Merus N.V.N5749R100NL001160626405/21/2025Opportunity to make recommendations for nomination by Merus N.V.'s group of non-executive directors.CORPORATE GOVERNANCEISSUER347940.0000000FOR347940.000000FORS000002088Merus N.V.N5749R100NL001160626405/21/2025Re-appointment of Anand Mehra, M.D. as non-executive director.DIRECTOR ELECTIONSISSUER347940.0000000FOR347940.000000FORS000002088Merus N.V.N5749R100NL001160626405/21/2025Opportunity to make recommendations for nomination by Merus N.V.'s group of non-executive directors.CORPORATE GOVERNANCEISSUER347940.0000000FOR347940.000000FORS000002088Merus N.V.N5749R100NL001160626405/21/2025Re-appointment of Maxine Gowen, Ph.D. as non-executive director.DIRECTOR ELECTIONSISSUER347940.0000000FOR347940.000000FORS000002088Merus N.V.N5749R100NL001160626405/21/2025Granting authorization to Merus N.V.'s board of directors to acquire shares (or depository receipts for such shares) in Merus N.V.'s capital.CAPITAL STRUCTUREISSUER347940.0000000FOR347940.000000FORS000002088Merus N.V.N5749R100NL001160626405/21/2025Approval, on an advisory (non-binding) basis, of the compensation of Merus N.V.'s named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER347940.0000000FOR347940.000000FORS000002088Neurocrine Biosciences, Inc.64125C109US64125C109905/21/2025The election of the four nominees for Class II directors named below to the Board of Directors to serve for a term of three years: Kyle W. Gano, Ph.D.DIRECTOR ELECTIONSISSUER588501.0000000FOR588501.000000FORS000002088Neurocrine Biosciences, Inc.64125C109US64125C109905/21/2025The election of the four nominees for Class II directors named below to the Board of Directors to serve for a term of three years: Richard F. PopsDIRECTOR ELECTIONSISSUER588501.0000000WITHHOLD588501.000000AGAINSTS000002088Neurocrine Biosciences, Inc.64125C109US64125C109905/21/2025The election of the four nominees for Class II directors named below to the Board of Directors to serve for a term of three years: Shalini SharpDIRECTOR ELECTIONSISSUER588501.0000000WITHHOLD588501.000000AGAINSTS000002088Neurocrine Biosciences, Inc.64125C109US64125C109905/21/2025The election of the four nominees for Class II directors named below to the Board of Directors to serve for a term of three years: Stephen A. Sherwin, M.D.DIRECTOR ELECTIONSISSUER588501.0000000WITHHOLD588501.000000AGAINSTS000002088Neurocrine Biosciences, Inc.64125C109US64125C109905/21/2025Advisory vote on the compensation paid to the Company's named executive officers;SECTION 14A SAY-ON-PAY VOTESISSUER588501.0000000FOR588501.000000FORS000002088Neurocrine Biosciences, Inc.64125C109US64125C109905/21/2025To approve the Company's 2025 Equity Incentive Plan;COMPENSATIONISSUER588501.0000000FOR588501.000000FORS000002088Neurocrine Biosciences, Inc.64125C109US64125C109905/21/2025To approve an amendment and restatement of the Company's 2018 Employee Stock Purchase Plan; andCOMPENSATIONISSUER588501.0000000FOR588501.000000FORS000002088Neurocrine Biosciences, Inc.64125C109US64125C109905/21/2025To ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025.AUDIT-RELATEDISSUER588501.0000000FOR588501.000000FORS000002088Thermo Fisher Scientific Inc.883556102US883556102305/21/2025Election of Directors: Marc N. CasperDIRECTOR ELECTIONSISSUER995064.0000000FOR995064.000000FORS000002088Thermo Fisher Scientific Inc.883556102US883556102305/21/2025Election of Directors: Nelson J. ChaiDIRECTOR ELECTIONSISSUER995064.0000000FOR995064.000000FORS000002088Thermo Fisher Scientific Inc.883556102US883556102305/21/2025Election of Directors: Ruby R. ChandyDIRECTOR ELECTIONSISSUER995064.0000000FOR995064.000000FORS000002088Thermo Fisher Scientific Inc.883556102US883556102305/21/2025Election of Directors: C. Martin HarrisDIRECTOR ELECTIONSISSUER995064.0000000FOR995064.000000FORS000002088Thermo Fisher Scientific Inc.883556102US883556102305/21/2025Election of Directors: Tyler JacksDIRECTOR ELECTIONSISSUER995064.0000000FOR995064.000000FORS000002088Thermo Fisher Scientific Inc.883556102US883556102305/21/2025Election of Directors: Jennifer M. JohnsonDIRECTOR ELECTIONSISSUER995064.0000000FOR995064.000000FORS000002088Thermo Fisher Scientific Inc.883556102US883556102305/21/2025Election of Directors: R. Alexandra KeithDIRECTOR ELECTIONSISSUER995064.0000000FOR995064.000000FORS000002088Thermo Fisher Scientific Inc.883556102US883556102305/21/2025Election of Directors: Karen S. LynchDIRECTOR ELECTIONSISSUER995064.0000000FOR995064.000000FORS000002088Thermo Fisher Scientific Inc.883556102US883556102305/21/2025Election of Directors: James C. MullenDIRECTOR ELECTIONSISSUER995064.0000000FOR995064.000000FORS000002088Thermo Fisher Scientific Inc.883556102US883556102305/21/2025Election of Directors: Debora L. SparDIRECTOR ELECTIONSISSUER995064.0000000FOR995064.000000FORS000002088Thermo Fisher Scientific Inc.883556102US883556102305/21/2025Election of Directors: Scott M. SperlingDIRECTOR ELECTIONSISSUER995064.0000000FOR995064.000000FORS000002088Thermo Fisher Scientific Inc.883556102US883556102305/21/2025Election of Directors: Dion J. WeislerDIRECTOR ELECTIONSISSUER995064.0000000FOR995064.000000FORS000002088Thermo Fisher Scientific Inc.883556102US883556102305/21/2025An advisory vote to approve named executive officer compensation.SECTION 14A SAY-ON-PAY VOTESISSUER995064.0000000FOR995064.000000FORS000002088Thermo Fisher Scientific Inc.883556102US883556102305/21/2025Ratification of the Audit Committee's selection of PricewaterhouseCoopers LLP as the Company's independent auditors for 2025.AUDIT-RELATEDISSUER995064.0000000FOR995064.000000FORS000002088Thermo Fisher Scientific Inc.883556102US883556102305/21/2025Shareholder proposal.CORPORATE GOVERNANCESECURITY HOLDER995064.0000000AGAINST995064.000000FORS000002088SCHOLAR ROCK HOLDING CORPORATION80706P103US80706P103005/22/2025To elect three Class I directors to our Board of Directors, each to serve until the 2028 Annual Meeting of stockholders and until his successor has been duly elected and qualified, or until his earlier death, resignation, or removal: Srinivas Akkaraju, M.D., Ph.D.DIRECTOR ELECTIONSISSUER2025440.0000000FOR2025440.000000FORS000002088SCHOLAR ROCK HOLDING CORPORATION80706P103US80706P103005/22/2025To elect three Class I directors to our Board of Directors, each to serve until the 2028 Annual Meeting of stockholders and until his successor has been duly elected and qualified, or until his earlier death, resignation, or removal: Joshua ReedDIRECTOR ELECTIONSISSUER2025440.0000000FOR2025440.000000FORS000002088SCHOLAR ROCK HOLDING CORPORATION80706P103US80706P103005/22/2025To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER2025440.0000000FOR2025440.000000FORS000002088Tenet Healthcare Corporation88033G407US88033G407305/22/2025Election of Directors: Saumya SutariaDIRECTOR ELECTIONSISSUER631564.0000000FOR631564.000000FORS000002088Tenet Healthcare Corporation88033G407US88033G407305/22/2025Election of Directors: J. Robert KerreyDIRECTOR ELECTIONSISSUER631564.0000000FOR631564.000000FORS000002088Tenet Healthcare Corporation88033G407US88033G407305/22/2025Election of Directors: Vineeta AgarwalaDIRECTOR ELECTIONSISSUER631564.0000000FOR631564.000000FORS000002088Tenet Healthcare Corporation88033G407US88033G407305/22/2025Election of Directors: James L. BiermanDIRECTOR ELECTIONSISSUER631564.0000000FOR631564.000000FORS000002088Tenet Healthcare Corporation88033G407US88033G407305/22/2025Election of Directors: Roy BluntDIRECTOR ELECTIONSISSUER631564.0000000FOR631564.000000FORS000002088Tenet Healthcare Corporation88033G407US88033G407305/22/2025Election of Directors: Richard W. FisherDIRECTOR ELECTIONSISSUER631564.0000000FOR631564.000000FORS000002088Tenet Healthcare Corporation88033G407US88033G407305/22/2025Election of Directors: Meghan M. FitzGeraldDIRECTOR ELECTIONSISSUER631564.0000000FOR631564.000000FORS000002088Tenet Healthcare Corporation88033G407US88033G407305/22/2025Election of Directors: Cecil D. HaneyDIRECTOR ELECTIONSISSUER631564.0000000FOR631564.000000FORS000002088Tenet Healthcare Corporation88033G407US88033G407305/22/2025Election of Directors: Christopher S. LynchDIRECTOR ELECTIONSISSUER631564.0000000FOR631564.000000FORS000002088Tenet Healthcare Corporation88033G407US88033G407305/22/2025Election of Directors: Richard J. MarkDIRECTOR ELECTIONSISSUER631564.0000000FOR631564.000000FORS000002088Tenet Healthcare Corporation88033G407US88033G407305/22/2025Election of Directors: Tammy RomoDIRECTOR ELECTIONSISSUER631564.0000000FOR631564.000000FORS000002088Tenet Healthcare Corporation88033G407US88033G407305/22/2025Election of Directors: Stephen H. RusckowskiDIRECTOR ELECTIONSISSUER631564.0000000FOR631564.000000FORS000002088Tenet Healthcare Corporation88033G407US88033G407305/22/2025Election of Directors: Nadja Y. WestDIRECTOR ELECTIONSISSUER631564.0000000FOR631564.000000FORS000002088Tenet Healthcare Corporation88033G407US88033G407305/22/2025To approve, on an advisory basis, the Company's executive compensation.SECTION 14A SAY-ON-PAY VOTESISSUER631564.0000000FOR631564.000000FORS000002088Tenet Healthcare Corporation88033G407US88033G407305/22/2025To ratify the selection of Deloitte & Touche LLP as the Company's independent registered public accountants for the year ending December 31, 2025.AUDIT-RELATEDISSUER631564.0000000FOR631564.000000FORS000002088Tenet Healthcare Corporation88033G407US88033G407305/22/2025To report on strategies and programs for improving maternal health outcomes.OTHER SOCIAL ISSUESSECURITY HOLDER631564.0000000AGAINST631564.000000FORS000002088Amgen Inc.031162100US031162100905/23/2025To elect twelve directors to the Board of Directors of Amgen Inc. for a term of office expiring at the 2026 annual meeting of stockholders. The nominees for election to the Board of Directors are: Dr. Wanda M. AustinDIRECTOR ELECTIONSISSUER599300.0000000FOR599300.000000FORS000002088Amgen Inc.031162100US031162100905/23/2025To elect twelve directors to the Board of Directors of Amgen Inc. for a term of office expiring at the 2026 annual meeting of stockholders. The nominees for election to the Board of Directors are: Mr. Robert A. BradwayDIRECTOR ELECTIONSISSUER599300.0000000FOR599300.000000FORS000002088Amgen Inc.031162100US031162100905/23/2025To elect twelve directors to the Board of Directors of Amgen Inc. for a term of office expiring at the 2026 annual meeting of stockholders. The nominees for election to the Board of Directors are: Dr. Michael V. DrakeDIRECTOR ELECTIONSISSUER599300.0000000FOR599300.000000FORS000002088Amgen Inc.031162100US031162100905/23/2025To elect twelve directors to the Board of Directors of Amgen Inc. for a term of office expiring at the 2026 annual meeting of stockholders. The nominees for election to the Board of Directors are: Dr. Brian J. DrukerDIRECTOR ELECTIONSISSUER599300.0000000FOR599300.000000FORS000002088Amgen Inc.031162100US031162100905/23/2025To elect twelve directors to the Board of Directors of Amgen Inc. for a term of office expiring at the 2026 annual meeting of stockholders. The nominees for election to the Board of Directors are: Mr. Robert A. EckertDIRECTOR ELECTIONSISSUER599300.0000000FOR599300.000000FORS000002088Amgen Inc.031162100US031162100905/23/2025To elect twelve directors to the Board of Directors of Amgen Inc. for a term of office expiring at the 2026 annual meeting of stockholders. The nominees for election to the Board of Directors are: Mr. Greg C. GarlandDIRECTOR ELECTIONSISSUER599300.0000000FOR599300.000000FORS000002088Amgen Inc.031162100US031162100905/23/2025To elect twelve directors to the Board of Directors of Amgen Inc. for a term of office expiring at the 2026 annual meeting of stockholders. The nominees for election to the Board of Directors are: Mr. Charles M. Holley, Jr.DIRECTOR ELECTIONSISSUER599300.0000000FOR599300.000000FORS000002088Amgen Inc.031162100US031162100905/23/2025To elect twelve directors to the Board of Directors of Amgen Inc. for a term of office expiring at the 2026 annual meeting of stockholders. The nominees for election to the Board of Directors are: Dr. S. Omar IshrakDIRECTOR ELECTIONSISSUER599300.0000000FOR599300.000000FORS000002088Amgen Inc.031162100US031162100905/23/2025To elect twelve directors to the Board of Directors of Amgen Inc. for a term of office expiring at the 2026 annual meeting of stockholders. The nominees for election to the Board of Directors are: Dr. Tyler JacksDIRECTOR ELECTIONSISSUER599300.0000000FOR599300.000000FORS000002088Amgen Inc.031162100US031162100905/23/2025To elect twelve directors to the Board of Directors of Amgen Inc. for a term of office expiring at the 2026 annual meeting of stockholders. The nominees for election to the Board of Directors are: Dr. Mary E. KlotmanDIRECTOR ELECTIONSISSUER599300.0000000FOR599300.000000FORS000002088Amgen Inc.031162100US031162100905/23/2025To elect twelve directors to the Board of Directors of Amgen Inc. for a term of office expiring at the 2026 annual meeting of stockholders. The nominees for election to the Board of Directors are: Ms. Ellen J. KullmanDIRECTOR ELECTIONSISSUER599300.0000000FOR599300.000000FORS000002088Amgen Inc.031162100US031162100905/23/2025To elect twelve directors to the Board of Directors of Amgen Inc. for a term of office expiring at the 2026 annual meeting of stockholders. The nominees for election to the Board of Directors are: Ms. Amy E. MilesDIRECTOR ELECTIONSISSUER599300.0000000FOR599300.000000FORS000002088Amgen Inc.031162100US031162100905/23/2025Advisory vote to approve our executive compensation.SECTION 14A SAY-ON-PAY VOTESISSUER599300.0000000FOR599300.000000FORS000002088Amgen Inc.031162100US031162100905/23/2025To ratify the selection of Ernst & Young LLP as our independent registered public accountants for the fiscal year ending December 31, 2025.AUDIT-RELATEDISSUER599300.0000000FOR599300.000000FORS000002088argenx SE04016X101US04016X101905/27/2025Approve Remuneration ReportCOMPENSATIONISSUER724581.0000000FOR724581.000000FORS000002088argenx SE04016X101US04016X101905/27/2025Adopt Financial Statements and Statutory ReportsCORPORATE GOVERNANCEISSUER724581.0000000FOR724581.000000FORS000002088argenx SE04016X101US04016X101905/27/2025Approve Allocation of Income to the Retained Earnings of the CompanyCAPITAL STRUCTUREISSUER724581.0000000FOR724581.000000FORS000002088argenx SE04016X101US04016X101905/27/2025Approve Discharge of DirectorsCORPORATE GOVERNANCEISSUER724581.0000000FOR724581.000000FORS000002088argenx SE04016X101US04016X101905/27/2025Approve Remuneration PolicyCOMPENSATIONISSUER724581.0000000FOR724581.000000FORS000002088argenx SE04016X101US04016X101905/27/2025Reelect Anthony Rosenberg as Non-Executive DirectorDIRECTOR ELECTIONSISSUER724581.0000000FOR724581.000000FORS000002088argenx SE04016X101US04016X101905/27/2025Grant Board Authority to Issue Shares and Exclude Pre-emptive RightsCAPITAL STRUCTUREISSUER724581.0000000FOR724581.000000FORS000002088Ascendis Pharma A/S04351P101US04351P101205/27/2025Elect Lars Luthjohan as Chair of MeetingCORPORATE GOVERNANCEISSUER910511.0000000FOR910511.000000FORS000002088Ascendis Pharma A/S04351P101US04351P101205/27/2025Accept Financial Statements and Statutory Reports; Approve Discharge of Management and BoardCAPITAL STRUCTURECORPORATE GOVERNANCEISSUER910511.0000000FOR910511.000000FORS000002088Ascendis Pharma A/S04351P101US04351P101205/27/2025Approve Treatment of Net LossCAPITAL STRUCTUREISSUER910511.0000000FOR910511.000000FORS000002088Ascendis Pharma A/S04351P101US04351P101205/27/2025Reelect Albert Cha as DirectorDIRECTOR ELECTIONSISSUER910511.0000000FOR910511.000000FORS000002088Ascendis Pharma A/S04351P101US04351P101205/27/2025Reelect Lars Holtug as DirectorDIRECTOR ELECTIONSISSUER910511.0000000FOR910511.000000FORS000002088Ascendis Pharma A/S04351P101US04351P101205/27/2025Reelect Jan Moller Mikkelsen as DirectorDIRECTOR ELECTIONSISSUER910511.0000000FOR910511.000000FORS000002088Ascendis Pharma A/S04351P101US04351P101205/27/2025Reelect Lisa Jane Morrison as DirectorDIRECTOR ELECTIONSISSUER910511.0000000FOR910511.000000FORS000002088Ascendis Pharma A/S04351P101US04351P101205/27/2025Reelect William Carl Fairey Jr as DirectorDIRECTOR ELECTIONSISSUER910511.0000000FOR910511.000000FORS000002088Ascendis Pharma A/S04351P101US04351P101205/27/2025Reelect Siham Imani as DirectorDIRECTOR ELECTIONSISSUER910511.0000000FOR910511.000000FORS000002088Ascendis Pharma A/S04351P101US04351P101205/27/2025Ratify Deloitte as AuditorAUDIT-RELATEDISSUER910511.0000000FOR910511.000000FORS000002088Ascendis Pharma A/S04351P101US04351P101205/27/2025Approve Creation of DKK 3.8 Million Pool of Capital without Preemptive RightsCAPITAL STRUCTUREISSUER910511.0000000FOR910511.000000FORS000002088Ascendis Pharma A/S04351P101US04351P101205/27/2025Approve Issuance of Warrants to Board MembersCOMPENSATIONISSUER910511.0000000AGAINST910511.000000AGAINSTS000002088Ascendis Pharma A/S04351P101US04351P101205/27/2025Amend Articles Re: Board-RelatedCORPORATE GOVERNANCEISSUER910511.0000000FOR910511.000000FORS000002088Merck & Co., Inc.58933Y105US58933Y105505/27/2025Election of Directors: Douglas M. Baker, Jr.DIRECTOR ELECTIONSISSUER2203146.0000000FOR2203146.000000FORS000002088Merck & Co., Inc.58933Y105US58933Y105505/27/2025Election of Directors: Mary Ellen CoeDIRECTOR ELECTIONSISSUER2203146.0000000FOR2203146.000000FORS000002088Merck & Co., Inc.58933Y105US58933Y105505/27/2025Election of Directors: Pamela J. CraigDIRECTOR ELECTIONSISSUER2203146.0000000FOR2203146.000000FORS000002088Merck & Co., Inc.58933Y105US58933Y105505/27/2025Election of Directors: Robert M. DavisDIRECTOR ELECTIONSISSUER2203146.0000000FOR2203146.000000FORS000002088Merck & Co., Inc.58933Y105US58933Y105505/27/2025Election of Directors: Thomas H. GlocerDIRECTOR ELECTIONSISSUER2203146.0000000FOR2203146.000000FORS000002088Merck & Co., Inc.58933Y105US58933Y105505/27/2025Election of Directors: Surendralal L. KarsanbhaiDIRECTOR ELECTIONSISSUER2203146.0000000FOR2203146.000000FORS000002088Merck & Co., Inc.58933Y105US58933Y105505/27/2025Election of Directors: Risa J. Lavizzo-Mourey, M.D.DIRECTOR ELECTIONSISSUER2203146.0000000FOR2203146.000000FORS000002088Merck & Co., Inc.58933Y105US58933Y105505/27/2025Election of Directors: Stephen L. Mayo, Ph.D.DIRECTOR ELECTIONSISSUER2203146.0000000FOR2203146.000000FORS000002088Merck & Co., Inc.58933Y105US58933Y105505/27/2025Election of Directors: Paul B. Rothman, M.D.DIRECTOR ELECTIONSISSUER2203146.0000000FOR2203146.000000FORS000002088Merck & Co., Inc.58933Y105US58933Y105505/27/2025Election of Directors: Patricia F. RussoDIRECTOR ELECTIONSISSUER2203146.0000000FOR2203146.000000FORS000002088Merck & Co., Inc.58933Y105US58933Y105505/27/2025Election of Directors: Christine E. Seidman, M.D.DIRECTOR ELECTIONSISSUER2203146.0000000FOR2203146.000000FORS000002088Merck & Co., Inc.58933Y105US58933Y105505/27/2025Election of Directors: Inge G. ThulinDIRECTOR ELECTIONSISSUER2203146.0000000FOR2203146.000000FORS000002088Merck & Co., Inc.58933Y105US58933Y105505/27/2025Election of Directors: Kathy J. WardenDIRECTOR ELECTIONSISSUER2203146.0000000FOR2203146.000000FORS000002088Merck & Co., Inc.58933Y105US58933Y105505/27/2025Non-binding advisory vote to approve the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER2203146.0000000FOR2203146.000000FORS000002088Merck & Co., Inc.58933Y105US58933Y105505/27/2025Ratification of the appointment of the Company's independent registered public accounting firm for 2025.AUDIT-RELATEDISSUER2203146.0000000FOR2203146.000000FORS000002088Merck & Co., Inc.58933Y105US58933Y105505/27/2025Shareholder proposal regarding a human rights impact assessment.HUMAN RIGHTS OR HUMAN CAPITAL/WORKFORCESECURITY HOLDER2203146.0000000AGAINST2203146.000000FORS000002088Merck & Co., Inc.58933Y105US58933Y105505/27/2025Shareholder proposal regarding a tax transparency report.OTHER SOCIAL ISSUESSECURITY HOLDER2203146.0000000AGAINST2203146.000000FORS000002088Merck & Co., Inc.58933Y105US58933Y105505/27/2025Shareholder proposal to revisit DEl goals in executive pay incentives.ENVIRONMENT OR CLIMATEDIVERSITY, EQUITY, AND INCLUSIONOTHER SOCIAL ISSUESSECURITY HOLDER2203146.0000000AGAINST2203146.000000FORS000002088Merck & Co., Inc.58933Y105US58933Y105505/27/2025Shareholder proposal regarding a report on civil liberties in advertising services.ENVIRONMENT OR CLIMATEDIVERSITY, EQUITY, AND INCLUSIONOTHER SOCIAL ISSUESSECURITY HOLDER2203146.0000000AGAINST2203146.000000FORS000002088Arcellx, Inc.03940C100US03940C100905/28/2025To elect three Class III directors to hold office until our 2028 annual meeting of stockholders and until their respective successors are elected and qualified: Rami ElghandourDIRECTOR ELECTIONSISSUER722836.0000000FOR722836.000000FORS000002088Arcellx, Inc.03940C100US03940C100905/28/2025To elect three Class III directors to hold office until our 2028 annual meeting of stockholders and until their respective successors are elected and qualified: David LubnerDIRECTOR ELECTIONSISSUER722836.0000000FOR722836.000000FORS000002088Arcellx, Inc.03940C100US03940C100905/28/2025To elect three Class III directors to hold office until our 2028 annual meeting of stockholders and until their respective successors are elected and qualified: Kristin MyersDIRECTOR ELECTIONSISSUER722836.0000000FOR722836.000000FORS000002088Arcellx, Inc.03940C100US03940C100905/28/2025To approve, on an advisory basis, the compensation of the named executive officers identified in the 2024 Summary Compensation Table in the "Executive Compensation" section of the proxy statement.SECTION 14A SAY-ON-PAY VOTESISSUER722836.0000000FOR722836.000000FORS000002088Arcellx, Inc.03940C100US03940C100905/28/2025To ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2025.AUDIT-RELATEDISSUER722836.0000000FOR722836.000000FORS000002088BrightSpring Health Services, Inc.10950A106US10950A106005/28/2025Election of Class I directors: Johnny KimDIRECTOR ELECTIONSISSUER1897226.0000000FOR1897226.000000FORS000002088BrightSpring Health Services, Inc.10950A106US10950A106005/28/2025Election of Class I directors: Timothy A. WicksDIRECTOR ELECTIONSISSUER1897226.0000000FOR1897226.000000FORS000002088BrightSpring Health Services, Inc.10950A106US10950A106005/28/2025Ratification of the appointment of KPMG LLP as the independent accounting firm for the year ending December 31, 2025AUDIT-RELATEDISSUER1897226.0000000FOR1897226.000000FORS000002088BrightSpring Health Services, Inc.10950A106US10950A106005/28/2025Advisory vote on executive compensationSECTION 14A SAY-ON-PAY VOTESISSUER1897226.0000000FOR1897226.000000FORS000002088BrightSpring Health Services, Inc.10950A106US10950A106005/28/2025Advisory vote on the frequency of holding an advisory vote on executive compensationSECTION 14A SAY-ON-PAY VOTESISSUER1897226.0000000ONE YEAR1897226.000000FORS000002088Penumbra, Inc.70975L107US70975L107005/28/2025To elect the nominees for Class I director to serve until the 2028 Annual Meeting of Stockholders and until their successors are duly elected and qualified: Janet LeedsDIRECTOR ELECTIONSISSUER553988.0000000FOR553988.000000FORS000002088Penumbra, Inc.70975L107US70975L107005/28/2025To elect the nominees for Class I director to serve until the 2028 Annual Meeting of Stockholders and until their successors are duly elected and qualified: Thomas WilderDIRECTOR ELECTIONSISSUER553988.0000000FOR553988.000000FORS000002088Penumbra, Inc.70975L107US70975L107005/28/2025To ratify the selection of PricewaterhouseCoopers LLP as the independent registered public accounting firm for Penumbra, Inc. for the fiscal year ending December 31, 2025;AUDIT-RELATEDISSUER553988.0000000FOR553988.000000FORS000002088Penumbra, Inc.70975L107US70975L107005/28/2025To approve, on an advisory basis, the compensation of Penumbra, Inc.'s named executive officers as disclosed in the proxy statement;SECTION 14A SAY-ON-PAY VOTESISSUER553988.0000000FOR553988.000000FORS000002088Penumbra, Inc.70975L107US70975L107005/28/2025To approve an amendment to Penumbra, Inc.'s Restated Certificate of Incorporation to phase in the declassification of Penumbra, Inc.'s Board of Directors, andSHAREHOLDER RIGHTS AND DEFENSESISSUER553988.0000000FOR553988.000000FORS000002088Penumbra, Inc.70975L107US70975L107005/28/2025To approve an amendment to Penumbra, Inc.'s Restated Certificate of Incorporation to eliminate the supermajority voting requirements.CORPORATE GOVERNANCEISSUER553988.0000000FOR553988.000000FORS000002088Kyverna Therapeutics, Inc.501976104US501976104905/29/2025The election of two Class I directors to hold office until the Company's 2028 annual meeting of stockholders: Beth Seidenberg, M.D.DIRECTOR ELECTIONSISSUER396569.0000000WITHHOLD396569.000000AGAINSTS000002088Kyverna Therapeutics, Inc.501976104US501976104905/29/2025The election of two Class I directors to hold office until the Company's 2028 annual meeting of stockholders: Fred E. Cohen, M.D., D.Phil.DIRECTOR ELECTIONSISSUER396569.0000000WITHHOLD396569.000000AGAINSTS000002088Kyverna Therapeutics, Inc.501976104US501976104905/29/2025The ratification of the appointment by the Audit Committee of the Company's Board of Directors of BDO USA, P.C. as the Company's independent registered public accounting firm and independent auditor for the year ending December 31, 2025.AUDIT-RELATEDISSUER396569.0000000FOR396569.000000FORS000002088Spyre Therapeutics, Inc.00773J202US00773J202405/29/2025Election of Class III Directors for terms expiring in 2028: Peter HarwinDIRECTOR ELECTIONSISSUER124302.0000000FOR124302.000000FORS000002088Spyre Therapeutics, Inc.00773J202US00773J202405/29/2025Election of Class III Directors for terms expiring in 2028: Michael Henderson, M.D.DIRECTOR ELECTIONSISSUER124302.0000000FOR124302.000000FORS000002088Spyre Therapeutics, Inc.00773J202US00773J202405/29/2025Election of Class III Directors for terms expiring in 2028: Sandra Milligan, M.D., J.D.DIRECTOR ELECTIONSISSUER124302.0000000FOR124302.000000FORS000002088Spyre Therapeutics, Inc.00773J202US00773J202405/29/2025To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER124302.0000000FOR124302.000000FORS000002088Spyre Therapeutics, Inc.00773J202US00773J202405/29/2025To ratify the appointment of KPMG LLP as the Company's independent registered public accounting firm for the year ending December 31, 2025.AUDIT-RELATEDISSUER124302.0000000FOR124302.000000FORS000002088Oruka Therapeutics, Inc.687604108US687604108706/02/2025Election of Class I Directors for terms expiring in 2028: Carl Dambkowski, M.D.DIRECTOR ELECTIONSISSUER274279.0000000FOR274279.000000FORS000002088Oruka Therapeutics, Inc.687604108US687604108706/02/2025Election of Class I Directors for terms expiring in 2028: Peter HarwinDIRECTOR ELECTIONSISSUER274279.0000000FOR274279.000000FORS000002088Oruka Therapeutics, Inc.687604108US687604108706/02/2025To ratify the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm of Oruka Therapeutics, Inc. for its fiscal year ending December 31, 2025.AUDIT-RELATEDISSUER274279.0000000FOR274279.000000FORS000002088Oruka Therapeutics, Inc.687604108US687604108706/02/2025To approve, on a non-binding, advisory basis, the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER274279.0000000FOR274279.000000FORS000002088Oruka Therapeutics, Inc.687604108US687604108706/02/2025To vote, on a non-binding, advisory basis, on the frequency of future advisory votes to approve compensation for our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER274279.0000000ONE YEAR274279.000000FORS000002088UnitedHealth Group Incorporated91324P102US91324P102106/02/2025Election of Directors: Charles BakerDIRECTOR ELECTIONSISSUER1731838.0000000FOR1731838.000000FORS000002088UnitedHealth Group Incorporated91324P102US91324P102106/02/2025Election of Directors: Timothy FlynnDIRECTOR ELECTIONSISSUER1731838.0000000FOR1731838.000000FORS000002088UnitedHealth Group Incorporated91324P102US91324P102106/02/2025Election of Directors: Paul GarciaDIRECTOR ELECTIONSISSUER1731838.0000000FOR1731838.000000FORS000002088UnitedHealth Group Incorporated91324P102US91324P102106/02/2025Election of Directors: Kristen GilDIRECTOR ELECTIONSISSUER1731838.0000000FOR1731838.000000FORS000002088UnitedHealth Group Incorporated91324P102US91324P102106/02/2025Election of Directors: Stephen HemsleyDIRECTOR ELECTIONSISSUER1731838.0000000FOR1731838.000000FORS000002088UnitedHealth Group Incorporated91324P102US91324P102106/02/2025Election of Directors: Michele HooperDIRECTOR ELECTIONSISSUER1731838.0000000FOR1731838.000000FORS000002088UnitedHealth Group Incorporated91324P102US91324P102106/02/2025Election of Directors: F. William McNabb IIIDIRECTOR ELECTIONSISSUER1731838.0000000FOR1731838.000000FORS000002088UnitedHealth Group Incorporated91324P102US91324P102106/02/2025Election of Directors: Valerie Montgomery Rice, M.D.DIRECTOR ELECTIONSISSUER1731838.0000000FOR1731838.000000FORS000002088UnitedHealth Group Incorporated91324P102US91324P102106/02/2025Election of Directors: John Noseworthy, M.D.DIRECTOR ELECTIONSISSUER1731838.0000000FOR1731838.000000FORS000002088UnitedHealth Group Incorporated91324P102US91324P102106/02/2025Advisory approval of the Company's executive compensation.SECTION 14A SAY-ON-PAY VOTESISSUER1731838.0000000FOR1731838.000000FORS000002088UnitedHealth Group Incorporated91324P102US91324P102106/02/2025Ratification of the appointment of Deloitte & Touche LLP as the independent registered public accounting firm for the Company for the year ending December 31, 2025.AUDIT-RELATEDISSUER1731838.0000000FOR1731838.000000FORS000002088UnitedHealth Group Incorporated91324P102US91324P102106/02/2025If properly presented at the 2025 Annual Meeting of Shareholders, the shareholder proposal requesting a shareholder vote regarding excessive golden parachutes.COMPENSATIONSECURITY HOLDER1731838.0000000AGAINST1731838.000000FORS000002088Akero Therapeutics, Inc.00973Y108US00973Y108206/03/2025To elect two class III directors, Judy Chou, Ph.D. and Tomas Heyman, to our board of directors, to serve until the 2028 Annual Meeting of stockholders and until her or his successor has been duly elected and qualified, or until her or his earlier death, resignation or removal: Judy Chou, Ph.D.DIRECTOR ELECTIONSISSUER1183681.0000000WITHHOLD1183681.000000AGAINSTS000002088Akero Therapeutics, Inc.00973Y108US00973Y108206/03/2025To elect two class III directors, Judy Chou, Ph.D. and Tomas Heyman, to our board of directors, to serve until the 2028 Annual Meeting of stockholders and until her or his successor has been duly elected and qualified, or until her or his earlier death, resignation or removal: Tomas HeymanDIRECTOR ELECTIONSISSUER1183681.0000000WITHHOLD1183681.000000AGAINSTS000002088Akero Therapeutics, Inc.00973Y108US00973Y108206/03/2025To ratify the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025.AUDIT-RELATEDISSUER1183681.0000000FOR1183681.000000FORS000002088Akero Therapeutics, Inc.00973Y108US00973Y108206/03/2025To consider and act upon a non-binding, advisory vote to approve the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER1183681.0000000FOR1183681.000000FORS000002088Denali Therapeutics Inc.24823R105US24823R105906/03/2025ELECTION OF DIRECTORS: Julian BakerDIRECTOR ELECTIONSISSUER1983741.0000000FOR1983741.000000FORS000002088Denali Therapeutics Inc.24823R105US24823R105906/03/2025ELECTION OF DIRECTORS: Peter KleinDIRECTOR ELECTIONSISSUER1983741.0000000FOR1983741.000000FORS000002088Denali Therapeutics Inc.24823R105US24823R105906/03/2025ELECTION OF DIRECTORS: Steve KrognesDIRECTOR ELECTIONSISSUER1983741.0000000WITHHOLD1983741.000000AGAINSTS000002088Denali Therapeutics Inc.24823R105US24823R105906/03/2025Ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2025AUDIT-RELATEDISSUER1983741.0000000FOR1983741.000000FORS000002088Denali Therapeutics Inc.24823R105US24823R105906/03/2025Advisory vote on executive compensationSECTION 14A SAY-ON-PAY VOTESISSUER1983741.0000000FOR1983741.000000FORS000002088Voyager Therapeutics, Inc.92915B106US92915B106106/03/2025To elect each of the following nominees to serve as a Class I director until the 2028 Annual Meeting of Stockholders and until his or her successor is duly elected and qualified: Grace E. Colon, Ph.D.DIRECTOR ELECTIONSISSUER373964.0000000FOR373964.000000FORS000002088Voyager Therapeutics, Inc.92915B106US92915B106106/03/2025To elect each of the following nominees to serve as a Class I director until the 2028 Annual Meeting of Stockholders and until his or her successor is duly elected and qualified: Catherine J. Mackey, Ph.D.DIRECTOR ELECTIONSISSUER373964.0000000FOR373964.000000FORS000002088Voyager Therapeutics, Inc.92915B106US92915B106106/03/2025To elect each of the following nominees to serve as a Class I director until the 2028 Annual Meeting of Stockholders and until his or her successor is duly elected and qualified: Glenn Pierce, M.D., Ph.D.DIRECTOR ELECTIONSISSUER373964.0000000FOR373964.000000FORS000002088Voyager Therapeutics, Inc.92915B106US92915B106106/03/2025To elect each of the following nominees to serve as a Class I director until the 2028 Annual Meeting of Stockholders and until his or her successor is duly elected and qualified: George Scangos, Ph.D.DIRECTOR ELECTIONSISSUER373964.0000000FOR373964.000000FORS000002088Voyager Therapeutics, Inc.92915B106US92915B106106/03/2025To approve, on a non-binding advisory basis, the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER373964.0000000FOR373964.000000FORS000002088Voyager Therapeutics, Inc.92915B106US92915B106106/03/2025To ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025.AUDIT-RELATEDISSUER373964.0000000FOR373964.000000FORS000002088Voyager Therapeutics, Inc.92915B106US92915B106106/03/2025To approve the Voyager Therapeutics, Inc. 2025 Stock Incentive Plan.COMPENSATIONISSUER373964.0000000AGAINST373964.000000AGAINSTS000002088Voyager Therapeutics, Inc.92915B106US92915B106106/03/2025To approve the Voyager Therapeutics, Inc. Amended and Restated 2015 Employee Stock Purchase Plan.COMPENSATIONISSUER373964.0000000FOR373964.000000FORS000002088Beam Therapeutics Inc.07373V105US07373V105206/04/2025Election of the following nominees as Class II directors for three-year terms ending at our Annual Meeting of Stockholders to be held in 2028: Mark Fishman, M.D.DIRECTOR ELECTIONSISSUER1206099.0000000FOR1206099.000000FORS000002088Beam Therapeutics Inc.07373V105US07373V105206/04/2025Election of the following nominees as Class II directors for three-year terms ending at our Annual Meeting of Stockholders to be held in 2028: Carole Ho, M.D.DIRECTOR ELECTIONSISSUER1206099.0000000FOR1206099.000000FORS000002088Beam Therapeutics Inc.07373V105US07373V105206/04/2025Election of the following nominees as Class II directors for three-year terms ending at our Annual Meeting of Stockholders to be held in 2028: Kathleen WalshDIRECTOR ELECTIONSISSUER1206099.0000000FOR1206099.000000FORS000002088Beam Therapeutics Inc.07373V105US07373V105206/04/2025Ratify the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2025.AUDIT-RELATEDISSUER1206099.0000000FOR1206099.000000FORS000002088Beam Therapeutics Inc.07373V105US07373V105206/04/2025Approve, on an advisory basis, the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER1206099.0000000FOR1206099.000000FORS000002088Climb Bio, Inc.28658R106US28658R106806/04/2025The election of two directors, each to serve for a three-year term expiring at the 2028 annual meeting of stockholders and until his or her respective successor has been duly elected and qualified: Judith Dunn, Ph.D.DIRECTOR ELECTIONSISSUER440991.0000000WITHHOLD440991.000000AGAINSTS000002088Climb Bio, Inc.28658R106US28658R106806/04/2025The election of two directors, each to serve for a three-year term expiring at the 2028 annual meeting of stockholders and until his or her respective successor has been duly elected and qualified: Stephen Thomas, Ph.D.DIRECTOR ELECTIONSISSUER440991.0000000FOR440991.000000FORS000002088Climb Bio, Inc.28658R106US28658R106806/04/2025The ratification of the selection of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025.AUDIT-RELATEDISSUER440991.0000000FOR440991.000000FORS000002088Generation Bio Co.37148K209US37148K209606/04/2025Election of three Class II directors to our board of directors, each to serve until the 2028 Annual Meeting of Stockholders: Ron CooperDIRECTOR ELECTIONSISSUER1524394.0000000FOR1524394.000000FORS000002088Generation Bio Co.37148K209US37148K209606/04/2025Election of three Class II directors to our board of directors, each to serve until the 2028 Annual Meeting of Stockholders: Anthony Quinn, M.B. Ch. N., Ph.D.DIRECTOR ELECTIONSISSUER1524394.0000000FOR1524394.000000FORS000002088Generation Bio Co.37148K209US37148K209606/04/2025Election of three Class II directors to our board of directors, each to serve until the 2028 Annual Meeting of Stockholders: Jason RhodesDIRECTOR ELECTIONSISSUER1524394.0000000FOR1524394.000000FORS000002088Generation Bio Co.37148K209US37148K209606/04/2025Ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025.AUDIT-RELATEDISSUER1524394.0000000FOR1524394.000000FORS000002088Generation Bio Co.37148K209US37148K209606/04/2025Approval, on an advisory (non-binding) basis, of the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER1524394.0000000FOR1524394.000000FORS000002088Generation Bio Co.37148K209US37148K209606/04/2025Adoption and approval of an amendment to our restated certificate of incorporation to effect a reverse stock split of our issued shares of common stock at a ratio within the range of not less than 1-for-10 and not greater than 1-for-30, without reducing the authorized number of shares of our common stock, with the exact ratio within such range and the implementation and timing of such reverse stock split to be determined at the sole discretion of our board of directors, without further approval or authorization of our stockholders.CAPITAL STRUCTUREISSUER1524394.0000000FOR1524394.000000FORS000002088NovoCure LimitedG6674U108JE00BYSS4X4806/04/2025Election of Directors: Ashley CordovaDIRECTOR ELECTIONSISSUER266277.0000000FOR266277.000000FORS000002088NovoCure LimitedG6674U108JE00BYSS4X4806/04/2025Election of Directors: Asaf DanzigerDIRECTOR ELECTIONSISSUER266277.0000000FOR266277.000000FORS000002088NovoCure LimitedG6674U108JE00BYSS4X4806/04/2025Election of Directors: William DoyleDIRECTOR ELECTIONSISSUER266277.0000000FOR266277.000000FORS000002088NovoCure LimitedG6674U108JE00BYSS4X4806/04/2025Election of Directors: Jeryl HillemanDIRECTOR ELECTIONSISSUER266277.0000000FOR266277.000000FORS000002088NovoCure LimitedG6674U108JE00BYSS4X4806/04/2025Election of Directors: David HungDIRECTOR ELECTIONSISSUER266277.0000000FOR266277.000000FORS000002088NovoCure LimitedG6674U108JE00BYSS4X4806/04/2025Election of Directors: Kinyip Gabriel LeungDIRECTOR ELECTIONSISSUER266277.0000000FOR266277.000000FORS000002088NovoCure LimitedG6674U108JE00BYSS4X4806/04/2025Election of Directors: Martin MaddenDIRECTOR ELECTIONSISSUER266277.0000000FOR266277.000000FORS000002088NovoCure LimitedG6674U108JE00BYSS4X4806/04/2025Election of Directors: Allyson OceanDIRECTOR ELECTIONSISSUER266277.0000000FOR266277.000000FORS000002088NovoCure LimitedG6674U108JE00BYSS4X4806/04/2025Election of Directors: Timothy ScannellDIRECTOR ELECTIONSISSUER266277.0000000FOR266277.000000FORS000002088NovoCure LimitedG6674U108JE00BYSS4X4806/04/2025Election of Directors: Kristin StaffordDIRECTOR ELECTIONSISSUER266277.0000000FOR266277.000000FORS000002088NovoCure LimitedG6674U108JE00BYSS4X4806/04/2025Election of Directors: William VernonDIRECTOR ELECTIONSISSUER266277.0000000FOR266277.000000FORS000002088NovoCure LimitedG6674U108JE00BYSS4X4806/04/2025The approval and ratification of the appointment, by the Audit Committee of our Board of Directors, of Kost Forer Gabbay & Kasierer, a member of Ernst & Young Global, as the auditor and independent registered public accounting firm of the Company for the Company's fiscal year ending December 31, 2025.AUDIT-RELATEDISSUER266277.0000000FOR266277.000000FORS000002088NovoCure LimitedG6674U108JE00BYSS4X4806/04/2025A non-binding advisory vote to approve executive compensation.SECTION 14A SAY-ON-PAY VOTESISSUER266277.0000000FOR266277.000000FORS000002088NovoCure LimitedG6674U108JE00BYSS4X4806/04/2025The approval of our 2025 Employee Share Purchase Plan.COMPENSATIONISSUER266277.0000000FOR266277.000000FORS000002088Oscar Health, Inc.687793109US687793109606/04/2025Election of Directors: Mark T. BertoliniDIRECTOR ELECTIONSISSUER1988874.0000000FOR1988874.000000FORS000002088Oscar Health, Inc.687793109US687793109606/04/2025Election of Directors: Jeffery H. BoydDIRECTOR ELECTIONSISSUER1988874.0000000FOR1988874.000000FORS000002088Oscar Health, Inc.687793109US687793109606/04/2025Election of Directors: William Gassen IIIDIRECTOR ELECTIONSISSUER1988874.0000000FOR1988874.000000FORS000002088Oscar Health, Inc.687793109US687793109606/04/2025Election of Directors: Joshua KushnerDIRECTOR ELECTIONSISSUER1988874.0000000FOR1988874.000000FORS000002088Oscar Health, Inc.687793109US687793109606/04/2025Election of Directors: Laura LangDIRECTOR ELECTIONSISSUER1988874.0000000FOR1988874.000000FORS000002088Oscar Health, Inc.687793109US687793109606/04/2025Election of Directors: David PlouffeDIRECTOR ELECTIONSISSUER1988874.0000000FOR1988874.000000FORS000002088Oscar Health, Inc.687793109US687793109606/04/2025Election of Directors: Siddhartha SankaranDIRECTOR ELECTIONSISSUER1988874.0000000FOR1988874.000000FORS000002088Oscar Health, Inc.687793109US687793109606/04/2025Election of Directors: Mario SchlosserDIRECTOR ELECTIONSISSUER1988874.0000000FOR1988874.000000FORS000002088Oscar Health, Inc.687793109US687793109606/04/2025Election of Directors: Vanessa A. WittmanDIRECTOR ELECTIONSISSUER1988874.0000000FOR1988874.000000FORS000002088Oscar Health, Inc.687793109US687793109606/04/2025Ratification of the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025.AUDIT-RELATEDISSUER1988874.0000000FOR1988874.000000FORS000002088Oscar Health, Inc.687793109US687793109606/04/2025Approval, on an advisory (non-binding) basis, of the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER1988874.0000000FOR1988874.000000FORS000002088Alignment Healthcare, Inc.01625V104US01625V104406/05/2025Election of Directors: Margaret McCarthyDIRECTOR ELECTIONSISSUER1618965.0000000FOR1618965.000000FORS000002088Alignment Healthcare, Inc.01625V104US01625V104406/05/2025Election of Directors: Mark McClellanDIRECTOR ELECTIONSISSUER1618965.0000000WITHHOLD1618965.000000AGAINSTS000002088Alignment Healthcare, Inc.01625V104US01625V104406/05/2025Election of Directors: Robbert VorhoffDIRECTOR ELECTIONSISSUER1618965.0000000FOR1618965.000000FORS000002088Alignment Healthcare, Inc.01625V104US01625V104406/05/2025Ratify the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for the year ending December 31, 2025AUDIT-RELATEDISSUER1618965.0000000FOR1618965.000000FORS000002088Alignment Healthcare, Inc.01625V104US01625V104406/05/2025Approve, on an advisory basis, the compensation of our Named Executive OfficersSECTION 14A SAY-ON-PAY VOTESISSUER1618965.0000000FOR1618965.000000FORS000002088Annexon, Inc.03589W102US03589W102706/05/2025To elect the two nominees for director to serve as Class II directors to hold office until the 2028 annual meeting of stockholders: Jung E. ChoiDIRECTOR ELECTIONSISSUER276205.0000000FOR276205.000000FORS000002088Annexon, Inc.03589W102US03589W102706/05/2025To elect the two nominees for director to serve as Class II directors to hold office until the 2028 annual meeting of stockholders: William D. WaddillDIRECTOR ELECTIONSISSUER276205.0000000FOR276205.000000FORS000002088Annexon, Inc.03589W102US03589W102706/05/2025To ratify the selection of KPMG LLP as the Company's independent registered public accounting firm for the Company's fiscal year ending December 31, 2025.AUDIT-RELATEDISSUER276205.0000000FOR276205.000000FORS000002088Annexon, Inc.03589W102US03589W102706/05/2025To approve, on a non-binding advisory basis, the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER276205.0000000FOR276205.000000FORS000002088Celldex Therapeutics, Inc.15117B202US15117B202506/05/2025Election of Directors: Anthony S. MarucciDIRECTOR ELECTIONSISSUER470986.0000000FOR470986.000000FORS000002088Celldex Therapeutics, Inc.15117B202US15117B202506/05/2025Election of Directors: Keith L. BrownlieDIRECTOR ELECTIONSISSUER470986.0000000FOR470986.000000FORS000002088Celldex Therapeutics, Inc.15117B202US15117B202506/05/2025Election of Directors: Cheryl L. CohenDIRECTOR ELECTIONSISSUER470986.0000000FOR470986.000000FORS000002088Celldex Therapeutics, Inc.15117B202US15117B202506/05/2025Election of Directors: Herbert J. ConradDIRECTOR ELECTIONSISSUER470986.0000000FOR470986.000000FORS000002088Celldex Therapeutics, Inc.15117B202US15117B202506/05/2025Election of Directors: Rita I. Jain, M.D.DIRECTOR ELECTIONSISSUER470986.0000000FOR470986.000000FORS000002088Celldex Therapeutics, Inc.15117B202US15117B202506/05/2025Election of Directors: James J. MarinoDIRECTOR ELECTIONSISSUER470986.0000000FOR470986.000000FORS000002088Celldex Therapeutics, Inc.15117B202US15117B202506/05/2025Election of Directors: Garry Neil, M.D.DIRECTOR ELECTIONSISSUER470986.0000000FOR470986.000000FORS000002088Celldex Therapeutics, Inc.15117B202US15117B202506/05/2025Election of Directors: Harry H. Penner, Jr.DIRECTOR ELECTIONSISSUER470986.0000000FOR470986.000000FORS000002088Celldex Therapeutics, Inc.15117B202US15117B202506/05/2025Election of Directors: Denice TorresDIRECTOR ELECTIONSISSUER470986.0000000FOR470986.000000FORS000002088Celldex Therapeutics, Inc.15117B202US15117B202506/05/2025To ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the year ending December 31, 2025.AUDIT-RELATEDISSUER470986.0000000FOR470986.000000FORS000002088Celldex Therapeutics, Inc.15117B202US15117B202506/05/2025To approve an amendment to our 2021 Omnibus Equity Incentive Plan, including an increase in the number of shares reserved for issuance thereunder by 2,000,000 shares to 9,500,000 shares.COMPENSATIONISSUER470986.0000000FOR470986.000000FORS000002088Celldex Therapeutics, Inc.15117B202US15117B202506/05/2025To approve, on an advisory basis, the compensation of the Company's Named Executive Officers as disclosed in this Proxy Statement.SECTION 14A SAY-ON-PAY VOTESISSUER470986.0000000FOR470986.000000FORS000002088CG Oncology, Inc.156944100US156944100906/05/2025To elect the Board's three nominees for Class I director named as nominees to hold office until the 2028 Annual Meeting of Stockholders and their successors are duly elected and qualified, or until their earlier death, resignation or removal: Arthur KuanDIRECTOR ELECTIONSISSUER460237.0000000FOR460237.000000FORS000002088CG Oncology, Inc.156944100US156944100906/05/2025To elect the Board's three nominees for Class I director named as nominees to hold office until the 2028 Annual Meeting of Stockholders and their successors are duly elected and qualified, or until their earlier death, resignation or removal: James J. MuleDIRECTOR ELECTIONSISSUER460237.0000000WITHHOLD460237.000000AGAINSTS000002088CG Oncology, Inc.156944100US156944100906/05/2025To elect the Board's three nominees for Class I director named as nominees to hold office until the 2028 Annual Meeting of Stockholders and their successors are duly elected and qualified, or until their earlier death, resignation or removal: Leonard PostDIRECTOR ELECTIONSISSUER460237.0000000FOR460237.000000FORS000002088CG Oncology, Inc.156944100US156944100906/05/2025To ratify the appointment by the Audit Committee of the Board of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025.AUDIT-RELATEDISSUER460237.0000000FOR460237.000000FORS000002088Ionis Pharmaceuticals, Inc.462222100US462222100406/05/2025Election of Directors: Allene M. DiazDIRECTOR ELECTIONSISSUER494678.0000000AGAINST494678.000000AGAINSTS000002088Ionis Pharmaceuticals, Inc.462222100US462222100406/05/2025Election of Directors: Michael HaydenDIRECTOR ELECTIONSISSUER494678.0000000AGAINST494678.000000AGAINSTS000002088Ionis Pharmaceuticals, Inc.462222100US462222100406/05/2025Election of Directors: Joseph Klein, IIIDIRECTOR ELECTIONSISSUER494678.0000000AGAINST494678.000000AGAINSTS000002088Ionis Pharmaceuticals, Inc.462222100US462222100406/05/2025Election of Directors: Joseph LoscalzoDIRECTOR ELECTIONSISSUER494678.0000000AGAINST494678.000000AGAINSTS000002088Ionis Pharmaceuticals, Inc.462222100US462222100406/05/2025To make an advisory vote on executive compensation.SECTION 14A SAY-ON-PAY VOTESISSUER494678.0000000FOR494678.000000FORS000002088Ionis Pharmaceuticals, Inc.462222100US462222100406/05/2025To approve an amendment of the Ionis Pharmaceuticals, Inc. 2011 Equity Incentive Plan to increase the aggregate number of shares of common stock authorized for issuance under such plan by 4,000,000 shares to an aggregate of 42,500,000 shares.COMPENSATIONISSUER494678.0000000FOR494678.000000FORS000002088Ionis Pharmaceuticals, Inc.462222100US462222100406/05/2025To ratify the Audit Committee's selection of Ernst & Young LLP as independent auditors for the 2025 fiscal year.AUDIT-RELATEDISSUER494678.0000000FOR494678.000000FORS000002088MBX Biosciences, Inc.55287L101US55287L101706/05/2025Election of two Class I Directors, each to serve until the Company's 2028 Annual Meeting of Stockholders or until such person's successor is duly elected and qualified, or until their earlier death, resignation or removal: Tiba Aynechi, Ph.D.DIRECTOR ELECTIONSISSUER905262.0000000FOR905262.000000FORS000002088MBX Biosciences, Inc.55287L101US55287L101706/05/2025Election of two Class I Directors, each to serve until the Company's 2028 Annual Meeting of Stockholders or until such person's successor is duly elected and qualified, or until their earlier death, resignation or removal: P. Kent HawrylukDIRECTOR ELECTIONSISSUER905262.0000000FOR905262.000000FORS000002088MBX Biosciences, Inc.55287L101US55287L101706/05/2025Ratification of the appointment of Ernst & Young LLP as the Company's Independent Registered Public Accounting Firm for the Fiscal Year ending December 31, 2025.AUDIT-RELATEDISSUER905262.0000000FOR905262.000000FORS000002088MoonLake Immunotherapeutics61559X104KY61559X104506/05/2025Election of the three Class III director nominees to serve until the 2028 Annual General Meeting of Shareholders and until their successors are duly elected and qualified: Dr. Jorge Santos da SilvaDIRECTOR ELECTIONSISSUER1283609.0000000FOR1283609.000000FORS000002088MoonLake Immunotherapeutics61559X104KY61559X104506/05/2025Election of the three Class III director nominees to serve until the 2028 Annual General Meeting of Shareholders and until their successors are duly elected and qualified: Simon SturgeDIRECTOR ELECTIONSISSUER1283609.0000000FOR1283609.000000FORS000002088MoonLake Immunotherapeutics61559X104KY61559X104506/05/2025Election of the three Class III director nominees to serve until the 2028 Annual General Meeting of Shareholders and until their successors are duly elected and qualified: Dr. Andrew PhillipsDIRECTOR ELECTIONSISSUER1283609.0000000FOR1283609.000000FORS000002088MoonLake Immunotherapeutics61559X104KY61559X104506/05/2025Ratification, by ordinary resolution, of the selection of Baker Tilly US, LLP as the Company's independent registered public accounting firm for the year ending December 31, 2025.AUDIT-RELATEDISSUER1283609.0000000FOR1283609.000000FORS000002088MoonLake Immunotherapeutics61559X104KY61559X104506/05/2025Approval of, on a non-binding, advisory basis, the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER1283609.0000000FOR1283609.000000FORS000002088Sana Biotechnology, Inc.799566104US799566104506/05/2025To elect three Class I directors to our Board of Directors, each to serve for a three-year term expiring at the 2028 annual meeting of stockholders or until his or her respective successor is duly elected and qualified. The nominees for election are: Steven D. Harr, M.D.DIRECTOR ELECTIONSISSUER1860705.0000000FOR1860705.000000FORS000002088Sana Biotechnology, Inc.799566104US799566104506/05/2025To elect three Class I directors to our Board of Directors, each to serve for a three-year term expiring at the 2028 annual meeting of stockholders or until his or her respective successor is duly elected and qualified. The nominees for election are: Robert L. RosielloDIRECTOR ELECTIONSISSUER1860705.0000000FOR1860705.000000FORS000002088Sana Biotechnology, Inc.799566104US799566104506/05/2025To elect three Class I directors to our Board of Directors, each to serve for a three-year term expiring at the 2028 annual meeting of stockholders or until his or her respective successor is duly elected and qualified. The nominees for election are: Michelle Seitz, CFADIRECTOR ELECTIONSISSUER1860705.0000000FOR1860705.000000FORS000002088Sana Biotechnology, Inc.799566104US799566104506/05/2025To elect three Class I directors to our Board of Directors, each to serve for a three-year term expiring at the 2028 annual meeting of stockholders or until his or her respective successor is duly elected and qualified. The nominees for election are: Patrick Y. Yang, Ph.D.DIRECTOR ELECTIONSISSUER1860705.0000000FOR1860705.000000FORS000002088Sana Biotechnology, Inc.799566104US799566104506/05/2025To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025.AUDIT-RELATEDISSUER1860705.0000000FOR1860705.000000FORS000002088Soleno Therapeutics, Inc.834203309US834203309406/05/2025To elect two Class II directors to each serve until the 2028 Annual Meeting of stockholders or until his successor is duly elected and qualified: Anish Bhatnagar, M.D.DIRECTOR ELECTIONSISSUER559052.0000000FOR559052.000000FORS000002088Soleno Therapeutics, Inc.834203309US834203309406/05/2025To elect two Class II directors to each serve until the 2028 Annual Meeting of stockholders or until his successor is duly elected and qualified: William G. HarrisDIRECTOR ELECTIONSISSUER559052.0000000WITHHOLD559052.000000AGAINSTS000002088Soleno Therapeutics, Inc.834203309US834203309406/05/2025To ratify the appointment of CBIZ CPAs P.C. as our independent registered public accounting firm for the fiscal year ending December 31, 2025.AUDIT-RELATEDISSUER559052.0000000FOR559052.000000FORS000002088Relay Therapeutics, Inc.75943R102US75943R102306/06/2025To elect the two class II directors to our board of directors, to serve until the 2028 annual meeting of stockholders and until their successor has been duly elected and qualified, or until such director's earlier death, resignation or removal: Alexis BorisyDIRECTOR ELECTIONSISSUER790429.0000000FOR790429.000000FORS000002088Relay Therapeutics, Inc.75943R102US75943R102306/06/2025To elect the two class II directors to our board of directors, to serve until the 2028 annual meeting of stockholders and until their successor has been duly elected and qualified, or until such director's earlier death, resignation or removal: Mark Murcko, Ph.D.DIRECTOR ELECTIONSISSUER790429.0000000FOR790429.000000FORS000002088Relay Therapeutics, Inc.75943R102US75943R102306/06/2025To consider and act upon an advisory vote on the compensation of our named executive officers;SECTION 14A SAY-ON-PAY VOTESISSUER790429.0000000FOR790429.000000FORS000002088Relay Therapeutics, Inc.75943R102US75943R102306/06/2025To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025; andAUDIT-RELATEDISSUER790429.0000000FOR790429.000000FORS000002088Bicara Therapeutics Inc.055477103US055477103206/09/2025To elect three class I directors to our board of directors, to serve until the 2028 annual meeting of stockholders and until his or her successor has been duly elected and qualified, or until his or her earlier death, resignation or removal: Kiran Mazumdar-ShawDIRECTOR ELECTIONSISSUER837694.0000000WITHHOLD837694.000000AGAINSTS000002088Bicara Therapeutics Inc.055477103US055477103206/09/2025To elect three class I directors to our board of directors, to serve until the 2028 annual meeting of stockholders and until his or her successor has been duly elected and qualified, or until his or her earlier death, resignation or removal: Jake Simson, Ph.D.DIRECTOR ELECTIONSISSUER837694.0000000FOR837694.000000FORS000002088Bicara Therapeutics Inc.055477103US055477103206/09/2025To elect three class I directors to our board of directors, to serve until the 2028 annual meeting of stockholders and until his or her successor has been duly elected and qualified, or until his or her earlier death, resignation or removal: Ryan Cohlhepp, Pharm D.DIRECTOR ELECTIONSISSUER837694.0000000FOR837694.000000FORS000002088Bicara Therapeutics Inc.055477103US055477103206/09/2025To ratify the appointment of KPMG LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025; andAUDIT-RELATEDISSUER837694.0000000FOR837694.000000FORS000002088Cabaletta Bio, Inc.12674W109US12674W109906/09/2025To elect two class III directors to our board of directors, to serve until the 2028 annual meeting of stockholders and until their successor has been duly elected and qualified, or until their earlier death, resignation or removal: Steven Nichtberger, M.D.DIRECTOR ELECTIONSISSUER315501.0000000FOR315501.000000FORS000002088Cabaletta Bio, Inc.12674W109US12674W109906/09/2025To elect two class III directors to our board of directors, to serve until the 2028 annual meeting of stockholders and until their successor has been duly elected and qualified, or until their earlier death, resignation or removal: Mark Simon, MBADIRECTOR ELECTIONSISSUER315501.0000000WITHHOLD315501.000000AGAINSTS000002088Cabaletta Bio, Inc.12674W109US12674W109906/09/2025To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025.AUDIT-RELATEDISSUER315501.0000000FOR315501.000000FORS000002088Cabaletta Bio, Inc.12674W109US12674W109906/09/2025To approve an amendment to our Third Amended and Restated Certificate of Incorporation to increase the number of authorized shares of Common Stock from 150,000,000 to 300,000,000.CAPITAL STRUCTUREISSUER315501.0000000FOR315501.000000FORS000002088Cabaletta Bio, Inc.12674W109US12674W109906/09/2025To approve, on a non-binding, advisory basis, the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER315501.0000000AGAINST315501.000000AGAINSTS000002088Cabaletta Bio, Inc.12674W109US12674W109906/09/2025Non-binding, advisory vote on the frequency of future non-binding, advisory votes on the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER315501.0000000ONE YEAR315501.000000FORS000002088Cabaletta Bio, Inc.12674W109US12674W109906/09/2025To approve a proposal to adjourn the Annual Meeting to a later date or dates, if necessary or appropriate, to permit further solicitation and vote of proxies in the event that there are insufficient votes for, or otherwise in connection with, the approval of Proposal 3.CORPORATE GOVERNANCEISSUER315501.0000000AGAINST315501.000000AGAINSTS000002088Avidity Biosciences, Inc.05370A108US05370A108806/10/2025To elect Class II directors for a three-year term that expires at the 2028 Annual Meeting of Stockholders and until their respective successors shall have been duly elected and qualified: Arthur Levin, Ph.D.DIRECTOR ELECTIONSISSUER2415692.0000000FOR2415692.000000FORS000002088Avidity Biosciences, Inc.05370A108US05370A108806/10/2025To elect Class II directors for a three-year term that expires at the 2028 Annual Meeting of Stockholders and until their respective successors shall have been duly elected and qualified: Simona SkerjanecDIRECTOR ELECTIONSISSUER2415692.0000000FOR2415692.000000FORS000002088Avidity Biosciences, Inc.05370A108US05370A108806/10/2025To elect Class II directors for a three-year term that expires at the 2028 Annual Meeting of Stockholders and until their respective successors shall have been duly elected and qualified: Tamar ThompsonDIRECTOR ELECTIONSISSUER2415692.0000000FOR2415692.000000FORS000002088Avidity Biosciences, Inc.05370A108US05370A108806/10/2025To ratify the appointment of Deloitte & Touche LLP as our independent public accounting firm for the fiscal year ending December 31, 2025;AUDIT-RELATEDISSUER2415692.0000000FOR2415692.000000FORS000002088Avidity Biosciences, Inc.05370A108US05370A108806/10/2025To consider and vote upon, on an advisory basis, the compensation of our named executive officers as disclosed in this proxy statement pursuant to the compensation disclosure rules of the Securities and Exchange Commission; andSECTION 14A SAY-ON-PAY VOTESISSUER2415692.0000000FOR2415692.000000FORS000002088Immunome, Inc.45257U108US45257U108806/10/2025To elect the two nominees named in this Proxy Statement to serve as Class II directors, to hold office until the 2028 Annual Meeting of Stockholders and such time as their successors are duly elected and qualified, or until their earlier death, resignation or removal: Isaac BarchasDIRECTOR ELECTIONSISSUER2278596.0000000FOR2278596.000000FORS000002088Immunome, Inc.45257U108US45257U108806/10/2025To elect the two nominees named in this Proxy Statement to serve as Class II directors, to hold office until the 2028 Annual Meeting of Stockholders and such time as their successors are duly elected and qualified, or until their earlier death, resignation or removal: Jean-Jacques BienaimeDIRECTOR ELECTIONSISSUER2278596.0000000FOR2278596.000000FORS000002088Immunome, Inc.45257U108US45257U108806/10/2025To ratify the appointment by the Audit Committee of the Board of Directors of Ernst & Young LLP as Immunome, Inc.'s independent registered public accounting firm for the fiscal year ending December 31, 2025.AUDIT-RELATEDISSUER2278596.0000000FOR2278596.000000FORS000002088Incyte Corporation45337C102US45337C102706/10/2025Election of Directors: Julian C. BakerDIRECTOR ELECTIONSISSUER97498.0000000FOR97498.000000FORS000002088Incyte Corporation45337C102US45337C102706/10/2025Election of Directors: Jean-Jacques BienaimeDIRECTOR ELECTIONSISSUER97498.0000000FOR97498.000000FORS000002088Incyte Corporation45337C102US45337C102706/10/2025Election of Directors: Otis W. BrawleyDIRECTOR ELECTIONSISSUER97498.0000000FOR97498.000000FORS000002088Incyte Corporation45337C102US45337C102706/10/2025Election of Directors: Paul J. ClancyDIRECTOR ELECTIONSISSUER97498.0000000FOR97498.000000FORS000002088Incyte Corporation45337C102US45337C102706/10/2025Election of Directors: Jacqualyn A. FouseDIRECTOR ELECTIONSISSUER97498.0000000FOR97498.000000FORS000002088Incyte Corporation45337C102US45337C102706/10/2025Election of Directors: Edmund P. HarriganDIRECTOR ELECTIONSISSUER97498.0000000FOR97498.000000FORS000002088Incyte Corporation45337C102US45337C102706/10/2025Election of Directors: Katherine A. HighDIRECTOR ELECTIONSISSUER97498.0000000FOR97498.000000FORS000002088Incyte Corporation45337C102US45337C102706/10/2025Election of Directors: Herve HoppenotDIRECTOR ELECTIONSISSUER97498.0000000FOR97498.000000FORS000002088Incyte Corporation45337C102US45337C102706/10/2025Election of Directors: Susanne SchaffertDIRECTOR ELECTIONSISSUER97498.0000000FOR97498.000000FORS000002088Incyte Corporation45337C102US45337C102706/10/2025Approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER97498.0000000FOR97498.000000FORS000002088Incyte Corporation45337C102US45337C102706/10/2025Approve amendments of the Company's Amended and Restated 2010 Stock Incentive Plan.COMPENSATIONISSUER97498.0000000AGAINST97498.000000AGAINSTS000002088Incyte Corporation45337C102US45337C102706/10/2025Approve an amendment of the Company's 1997 Employee Stock Purchase Plan.COMPENSATIONISSUER97498.0000000FOR97498.000000FORS000002088Incyte Corporation45337C102US45337C102706/10/2025Ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for 2025.AUDIT-RELATEDISSUER97498.0000000FOR97498.000000FORS000002088Iovance Biotherapeutics, Inc.462260100US462260100706/10/2025To elect seven directors to serve until the 2026 Annual Meeting of Stockholders: lain Dukes, D. Phil.DIRECTOR ELECTIONSISSUER786860.0000000FOR786860.000000FORS000002088Iovance Biotherapeutics, Inc.462260100US462260100706/10/2025To elect seven directors to serve until the 2026 Annual Meeting of Stockholders: Athena Countouriotis, M.D.DIRECTOR ELECTIONSISSUER786860.0000000AGAINST786860.000000AGAINSTS000002088Iovance Biotherapeutics, Inc.462260100US462260100706/10/2025To elect seven directors to serve until the 2026 Annual Meeting of Stockholders: Ryan MaynardDIRECTOR ELECTIONSISSUER786860.0000000FOR786860.000000FORS000002088Iovance Biotherapeutics, Inc.462260100US462260100706/10/2025To elect seven directors to serve until the 2026 Annual Meeting of Stockholders: Wayne P. RothbaumDIRECTOR ELECTIONSISSUER786860.0000000FOR786860.000000FORS000002088Iovance Biotherapeutics, Inc.462260100US462260100706/10/2025To elect seven directors to serve until the 2026 Annual Meeting of Stockholders: Frederick G. Vogt, Ph.D., J.D.DIRECTOR ELECTIONSISSUER786860.0000000FOR786860.000000FORS000002088Iovance Biotherapeutics, Inc.462260100US462260100706/10/2025To elect seven directors to serve until the 2026 Annual Meeting of Stockholders: Michael Weiser, M.D., Ph.D.DIRECTOR ELECTIONSISSUER786860.0000000FOR786860.000000FORS000002088Iovance Biotherapeutics, Inc.462260100US462260100706/10/2025To elect seven directors to serve until the 2026 Annual Meeting of Stockholders: Wendy YarnoDIRECTOR ELECTIONSISSUER786860.0000000FOR786860.000000FORS000002088Iovance Biotherapeutics, Inc.462260100US462260100706/10/2025To approve, by non-binding advisory vote, the compensation of our named executive officers;SECTION 14A SAY-ON-PAY VOTESISSUER786860.0000000FOR786860.000000FORS000002088Iovance Biotherapeutics, Inc.462260100US462260100706/10/2025To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2025;AUDIT-RELATEDISSUER786860.0000000FOR786860.000000FORS000002088Iovance Biotherapeutics, Inc.462260100US462260100706/10/2025To approve an amendment to our 2018 Equity Incentive Plan to increase the number of shares of the Company's common stock authorized for issuance thereunder by 12,500,000 shares; andCOMPENSATIONISSUER786860.0000000FOR786860.000000FORS000002088Iovance Biotherapeutics, Inc.462260100US462260100706/10/2025To approve an amendment to our 2020 Employee Stock Purchase Plan to increase the number of shares of the Company's common stock authorized for issuance thereunder by 1,000,000 shares.COMPENSATIONISSUER786860.0000000FOR786860.000000FORS000002088PROCEPT BioRobotics Corporation74276L105US74276L105206/10/2025Election of Class I directors to serve until 2028 annual meeting of shareholders and until their successors are duly elected and qualified: Elisabeth LittleDIRECTOR ELECTIONSISSUER640030.0000000FOR640030.000000FORS000002088PROCEPT BioRobotics Corporation74276L105US74276L105206/10/2025Election of Class I directors to serve until 2028 annual meeting of shareholders and until their successors are duly elected and qualified: Thomas M. PrescottDIRECTOR ELECTIONSISSUER640030.0000000FOR640030.000000FORS000002088PROCEPT BioRobotics Corporation74276L105US74276L105206/10/2025Election of Class I directors to serve until 2028 annual meeting of shareholders and until their successors are duly elected and qualified: Larry WoodDIRECTOR ELECTIONSISSUER640030.0000000FOR640030.000000FORS000002088PROCEPT BioRobotics Corporation74276L105US74276L105206/10/2025Ratification of the selection of PricewaterhouseCoopers LLP as the independent registered public accounting firm for PROCEPT for the fiscal year ending December 31, 2025.AUDIT-RELATEDISSUER640030.0000000FOR640030.000000FORS000002088PROCEPT BioRobotics Corporation74276L105US74276L105206/10/2025Approval, on a non-binding advisory basis, of the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER640030.0000000FOR640030.000000FORS000002088Sonova Holding AGH8024W106CH001254978506/10/2025Accept Financial Statements and Statutory ReportsCORPORATE GOVERNANCEISSUER183771.0000000FOR183771.000000FORS000002088Sonova Holding AGH8024W106CH001254978506/10/2025Approve Non-Financial ReportCORPORATE GOVERNANCEENVIRONMENT OR CLIMATEHUMAN RIGHTS OR HUMAN CAPITAL/WORKFORCEDIVERSITY, EQUITY, AND INCLUSIONOTHER SOCIAL ISSUESISSUER183771.0000000FOR183771.000000FORS000002088Sonova Holding AGH8024W106CH001254978506/10/2025Approve Remuneration Report (Non-Binding)COMPENSATIONISSUER183771.0000000FOR183771.000000FORS000002088Sonova Holding AGH8024W106CH001254978506/10/2025Approve Allocation of Income and Dividends of CHF 4.40 per ShareCAPITAL STRUCTUREISSUER183771.0000000FOR183771.000000FORS000002088Sonova Holding AGH8024W106CH001254978506/10/2025Approve Discharge of Board and Senior ManagementCORPORATE GOVERNANCEISSUER183771.0000000FOR183771.000000FORS000002088Sonova Holding AGH8024W106CH001254978506/10/2025Reelect Gilbert Achermann as Director and Board ChairDIRECTOR ELECTIONSISSUER183771.0000000FOR183771.000000FORS000002088Sonova Holding AGH8024W106CH001254978506/10/2025Reelect Gregory Behar as DirectorDIRECTOR ELECTIONSISSUER183771.0000000FOR183771.000000FORS000002088Sonova Holding AGH8024W106CH001254978506/10/2025Reelect Lynn Bleil as DirectorDIRECTOR ELECTIONSISSUER183771.0000000FOR183771.000000FORS000002088Sonova Holding AGH8024W106CH001254978506/10/2025Reelect Roland Diggelmann as DirectorDIRECTOR ELECTIONSISSUER183771.0000000FOR183771.000000FORS000002088Sonova Holding AGH8024W106CH001254978506/10/2025Reelect Julie Tay as DirectorDIRECTOR ELECTIONSISSUER183771.0000000FOR183771.000000FORS000002088Sonova Holding AGH8024W106CH001254978506/10/2025Reelect Ronald van der Vis as DirectorDIRECTOR ELECTIONSISSUER183771.0000000FOR183771.000000FORS000002088Sonova Holding AGH8024W106CH001254978506/10/2025Reelect Adrian Widmer as DirectorDIRECTOR ELECTIONSISSUER183771.0000000FOR183771.000000FORS000002088Sonova Holding AGH8024W106CH001254978506/10/2025Elect Laura Stoltenberg as DirectorDIRECTOR ELECTIONSISSUER183771.0000000FOR183771.000000FORS000002088Sonova Holding AGH8024W106CH001254978506/10/2025Reappoint Roland Diggelmann as Member of the Nomination and Compensation CommitteeDIRECTOR ELECTIONSCORPORATE GOVERNANCEISSUER183771.0000000FOR183771.000000FORS000002088Sonova Holding AGH8024W106CH001254978506/10/2025Reappoint Julie Tay as Member of the Nomination and Compensation CommitteeDIRECTOR ELECTIONSCORPORATE GOVERNANCEISSUER183771.0000000FOR183771.000000FORS000002088Sonova Holding AGH8024W106CH001254978506/10/2025Appoint Gregory Behar as Member of the Nomination and Compensation CommitteeDIRECTOR ELECTIONSCORPORATE GOVERNANCEISSUER183771.0000000FOR183771.000000FORS000002088Sonova Holding AGH8024W106CH001254978506/10/2025Ratify Ernst & Young AG as AuditorsAUDIT-RELATEDISSUER183771.0000000FOR183771.000000FORS000002088Sonova Holding AGH8024W106CH001254978506/10/2025Designate Keller AG as Independent ProxyCORPORATE GOVERNANCEISSUER183771.0000000FOR183771.000000FORS000002088Sonova Holding AGH8024W106CH001254978506/10/2025Approve Remuneration of Directors in the Amount of CHF 3.1 MillionCOMPENSATIONISSUER183771.0000000FOR183771.000000FORS000002088Sonova Holding AGH8024W106CH001254978506/10/2025Approve Remuneration of Executive Committee in the Amount of CHF 16.3 MillionCOMPENSATIONISSUER183771.0000000FOR183771.000000FORS000002088Sonova Holding AGH8024W106CH001254978506/10/2025Transact Other Business (Voting)CORPORATE GOVERNANCEISSUER183771.0000000AGAINST183771.000000AGAINSTS000002088Alector, Inc.014442107US014442107206/11/2025ELECTION OF DIRECTORS: Arnon Rosenthal, Ph.D.DIRECTOR ELECTIONSISSUER428128.0000000FOR428128.000000FORS000002088Alector, Inc.014442107US014442107206/11/2025ELECTION OF DIRECTORS: Paula Hammond, Ph.D.DIRECTOR ELECTIONSISSUER428128.0000000FOR428128.000000FORS000002088Alector, Inc.014442107US014442107206/11/2025Ratification of the appointment of Ernst & Young, LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2025.AUDIT-RELATEDISSUER428128.0000000FOR428128.000000FORS000002088Alector, Inc.014442107US014442107206/11/2025Advisory vote on executive compensation.SECTION 14A SAY-ON-PAY VOTESISSUER428128.0000000FOR428128.000000FORS000002088Crinetics Pharmaceuticals, Inc.22663K107US22663K107906/11/2025To elect three directors to serve as Class I directors for a three-year term to expire at the 2028 annual meeting of stockholders: Matthew K. FustDIRECTOR ELECTIONSISSUER922476.0000000FOR922476.000000FORS000002088Crinetics Pharmaceuticals, Inc.22663K107US22663K107906/11/2025To elect three directors to serve as Class I directors for a three-year term to expire at the 2028 annual meeting of stockholders: R. Scott Struthers, Ph.D.DIRECTOR ELECTIONSISSUER922476.0000000FOR922476.000000FORS000002088Crinetics Pharmaceuticals, Inc.22663K107US22663K107906/11/2025To elect three directors to serve as Class I directors for a three-year term to expire at the 2028 annual meeting of stockholders: Rogerio Vivaldi Coelho, M.D.DIRECTOR ELECTIONSISSUER922476.0000000FOR922476.000000FORS000002088Crinetics Pharmaceuticals, Inc.22663K107US22663K107906/11/2025To consider and vote upon the ratification of the selection of BDO USA, P.C. as our independent registered public accounting firm for the fiscal year ending December 31, 2025;AUDIT-RELATEDISSUER922476.0000000FOR922476.000000FORS000002088Crinetics Pharmaceuticals, Inc.22663K107US22663K107906/11/2025To consider and vote upon, on an advisory basis, the compensation of the Company's named executive officers as disclosed in the proxy statement pursuant to the compensation disclosure rules of the Securities and Exchange Commission;SECTION 14A SAY-ON-PAY VOTESISSUER922476.0000000FOR922476.000000FORS000002088Disc Medicine, Inc.254604101US254604101106/11/2025To elect each of the following Class II nominees to the Board of Directors as set forth below: Georges Gemayel, Ph.D.DIRECTOR ELECTIONSISSUER270549.0000000FOR270549.000000FORS000002088Disc Medicine, Inc.254604101US254604101106/11/2025To elect each of the following Class II nominees to the Board of Directors as set forth below: Mark Chin, M.S., M.B.A.DIRECTOR ELECTIONSISSUER270549.0000000FOR270549.000000FORS000002088Disc Medicine, Inc.254604101US254604101106/11/2025To elect each of the following Class II nominees to the Board of Directors as set forth below: Liam Ratcliffe, M.D., Ph.D.DIRECTOR ELECTIONSISSUER270549.0000000FOR270549.000000FORS000002088Disc Medicine, Inc.254604101US254604101106/11/2025To approve, on a non-binding, advisory basis, the compensation paid to the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER270549.0000000FOR270549.000000FORS000002088Disc Medicine, Inc.254604101US254604101106/11/2025To recommend, by a non-binding advisory vote, the frequency of future advisory votes on the compensation paid to the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER270549.0000000ONE YEAR270549.000000FORS000002088Disc Medicine, Inc.254604101US254604101106/11/2025To ratify the appointment of Emst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025.AUDIT-RELATEDISSUER270549.0000000FOR270549.000000FORS000002088Entrada Therapeutics, Inc.29384C108US29384C108006/11/2025Election of Directors: Dipal DoshiDIRECTOR ELECTIONSISSUER234304.0000000FOR234304.000000FORS000002088Entrada Therapeutics, Inc.29384C108US29384C108006/11/2025Election of Directors: Kush M. Parmar, M.D., Ph.D.DIRECTOR ELECTIONSISSUER234304.0000000FOR234304.000000FORS000002088Entrada Therapeutics, Inc.29384C108US29384C108006/11/2025Election of Directors: Mary ThistleDIRECTOR ELECTIONSISSUER234304.0000000FOR234304.000000FORS000002088Entrada Therapeutics, Inc.29384C108US29384C108006/11/2025Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025.AUDIT-RELATEDISSUER234304.0000000FOR234304.000000FORS000002088Janux Therapeutics, Inc.47103J105US47103J105106/11/2025To elect the three nominees for Class I director named in the accompanying proxy statement to serve for three-year terms until the 2028 Annual Meeting of Stockholders: Ronald Barrett, Ph.D.DIRECTOR ELECTIONSISSUER392552.0000000FOR392552.000000FORS000002088Janux Therapeutics, Inc.47103J105US47103J105106/11/2025To elect the three nominees for Class I director named in the accompanying proxy statement to serve for three-year terms until the 2028 Annual Meeting of Stockholders: David Campbell, Ph.D.DIRECTOR ELECTIONSISSUER392552.0000000FOR392552.000000FORS000002088Janux Therapeutics, Inc.47103J105US47103J105106/11/2025To elect the three nominees for Class I director named in the accompanying proxy statement to serve for three-year terms until the 2028 Annual Meeting of Stockholders: Winston KungDIRECTOR ELECTIONSISSUER392552.0000000FOR392552.000000FORS000002088Janux Therapeutics, Inc.47103J105US47103J105106/11/2025To ratify the selection by the Audit Committee of the Board of Directors of Ernst & Young LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2025.AUDIT-RELATEDISSUER392552.0000000FOR392552.000000FORS000002088Janux Therapeutics, Inc.47103J105US47103J105106/11/2025Approval, on an advisory basis, of the compensation of our named executive officers ("Say-On-Pay"), as disclosed in the accompanying Proxy Statement.SECTION 14A SAY-ON-PAY VOTESISSUER392552.0000000FOR392552.000000FORS000002088Janux Therapeutics, Inc.47103J105US47103J105106/11/2025Indication, on an advisory basis, of the preferred frequency of holding future Say-On-Pay votes on the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER392552.0000000ONE YEAR392552.000000FORS000002088ORIC Pharmaceuticals, Inc.68622P109US68622P109306/11/2025Election of Directors: Steven L. HoerterDIRECTOR ELECTIONSISSUER958713.0000000FOR958713.000000FORS000002088ORIC Pharmaceuticals, Inc.68622P109US68622P109306/11/2025Election of Directors: Angie You, Ph.D.DIRECTOR ELECTIONSISSUER958713.0000000FOR958713.000000FORS000002088ORIC Pharmaceuticals, Inc.68622P109US68622P109306/11/2025To ratify the appointment of KPMG LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2025.AUDIT-RELATEDISSUER958713.0000000FOR958713.000000FORS000002088Exact Sciences Corporation30063P105US30063P105706/12/2025To elect seven members of the Board of Directors to serve for one-year terms (each to serve until his or her successor is elected and qualified or until his or her earlier death, resignation or removal): Michael BarberDIRECTOR ELECTIONSISSUER909216.0000000FOR909216.000000FORS000002088Exact Sciences Corporation30063P105US30063P105706/12/2025To elect seven members of the Board of Directors to serve for one-year terms (each to serve until his or her successor is elected and qualified or until his or her earlier death, resignation or removal): Paul ClancyDIRECTOR ELECTIONSISSUER909216.0000000FOR909216.000000FORS000002088Exact Sciences Corporation30063P105US30063P105706/12/2025To elect seven members of the Board of Directors to serve for one-year terms (each to serve until his or her successor is elected and qualified or until his or her earlier death, resignation or removal): Daniel LevangieDIRECTOR ELECTIONSISSUER909216.0000000FOR909216.000000FORS000002088Exact Sciences Corporation30063P105US30063P105706/12/2025To elect seven members of the Board of Directors to serve for one-year terms (each to serve until his or her successor is elected and qualified or until his or her earlier death, resignation or removal): Kevin ConroyDIRECTOR ELECTIONSISSUER909216.0000000FOR909216.000000FORS000002088Exact Sciences Corporation30063P105US30063P105706/12/2025To elect seven members of the Board of Directors to serve for one-year terms (each to serve until his or her successor is elected and qualified or until his or her earlier death, resignation or removal): Shacey PetrovicDIRECTOR ELECTIONSISSUER909216.0000000FOR909216.000000FORS000002088Exact Sciences Corporation30063P105US30063P105706/12/2025To elect seven members of the Board of Directors to serve for one-year terms (each to serve until his or her successor is elected and qualified or until his or her earlier death, resignation or removal): Kimberly PopovitsDIRECTOR ELECTIONSISSUER909216.0000000FOR909216.000000FORS000002088Exact Sciences Corporation30063P105US30063P105706/12/2025To elect seven members of the Board of Directors to serve for one-year terms (each to serve until his or her successor is elected and qualified or until his or her earlier death, resignation or removal): Katherine ZanottiDIRECTOR ELECTIONSISSUER909216.0000000FOR909216.000000FORS000002088Exact Sciences Corporation30063P105US30063P105706/12/2025To ratify the selection of PricewaterhouseCoopers LLP as our independent registered public accounting firm for 2025.AUDIT-RELATEDISSUER909216.0000000FOR909216.000000FORS000002088Exact Sciences Corporation30063P105US30063P105706/12/2025To approve, on an advisory basis, the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER909216.0000000FOR909216.000000FORS000002088Exact Sciences Corporation30063P105US30063P105706/12/2025To approve the 2025 Omnibus Long-Term Incentive Plan.COMPENSATIONISSUER909216.0000000FOR909216.000000FORS000002088Exact Sciences Corporation30063P105US30063P105706/12/2025To approve an Amendment to the 2010 Employee Stock Purchase Plan to add 4,000,000 shares of stock to the pool of shares available for purchase by employees.COMPENSATIONISSUER909216.0000000FOR909216.000000FORS000002088Exact Sciences Corporation30063P105US30063P105706/12/2025To vote on a shareholder proposal concerning the adoption of a director election resignation governance policy, if properly presented.CORPORATE GOVERNANCESECURITY HOLDER909216.0000000AGAINST909216.000000FORS000002088Ginkgo Bioworks Holdings, Inc.37611X209US37611X209906/12/2025Election of Directors: Ross FubiniDIRECTOR ELECTIONSISSUER29541.0000000FOR29541.000000FORS000002088Ginkgo Bioworks Holdings, Inc.37611X209US37611X209906/12/2025Election of Directors: Christian HenryDIRECTOR ELECTIONSISSUER29541.0000000FOR29541.000000FORS000002088Ginkgo Bioworks Holdings, Inc.37611X209US37611X209906/12/2025Election of Directors: Sri KosuriDIRECTOR ELECTIONSISSUER29541.0000000FOR29541.000000FORS000002088Ginkgo Bioworks Holdings, Inc.37611X209US37611X209906/12/2025Election of Directors: Shyam SankarDIRECTOR ELECTIONSISSUER29541.0000000FOR29541.000000FORS000002088Ginkgo Bioworks Holdings, Inc.37611X209US37611X209906/12/2025Election of Directors: Harry E. SloanDIRECTOR ELECTIONSISSUER29541.0000000FOR29541.000000FORS000002088Ginkgo Bioworks Holdings, Inc.37611X209US37611X209906/12/2025Ratification of the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025.AUDIT-RELATEDISSUER29541.0000000FOR29541.000000FORS000002088Ginkgo Bioworks Holdings, Inc.37611X209US37611X209906/12/2025Advisory vote to approve executive compensation.SECTION 14A SAY-ON-PAY VOTESISSUER29541.0000000FOR29541.000000FORS000002088Heron Therapeutics, Inc.427746102US427746102006/12/2025To elect six director nominees to serve until the 2026 Annual Meeting of Stockholders and until their successors are duly elected and qualified or until their earlier death, resignation or removal: Craig CollardDIRECTOR ELECTIONSISSUER2326841.0000000FOR2326841.000000FORS000002088Heron Therapeutics, Inc.427746102US427746102006/12/2025To elect six director nominees to serve until the 2026 Annual Meeting of Stockholders and until their successors are duly elected and qualified or until their earlier death, resignation or removal: Sharmila Dissanaike, M.D., FACS, FCCMDIRECTOR ELECTIONSISSUER2326841.0000000FOR2326841.000000FORS000002088Heron Therapeutics, Inc.427746102US427746102006/12/2025To elect six director nominees to serve until the 2026 Annual Meeting of Stockholders and until their successors are duly elected and qualified or until their earlier death, resignation or removal: Craig JohnsonDIRECTOR ELECTIONSISSUER2326841.0000000FOR2326841.000000FORS000002088Heron Therapeutics, Inc.427746102US427746102006/12/2025To elect six director nominees to serve until the 2026 Annual Meeting of Stockholders and until their successors are duly elected and qualified or until their earlier death, resignation or removal: Michael KasetaDIRECTOR ELECTIONSISSUER2326841.0000000FOR2326841.000000FORS000002088Heron Therapeutics, Inc.427746102US427746102006/12/2025To elect six director nominees to serve until the 2026 Annual Meeting of Stockholders and until their successors are duly elected and qualified or until their earlier death, resignation or removal: Adam MorganDIRECTOR ELECTIONSISSUER2326841.0000000FOR2326841.000000FORS000002088Heron Therapeutics, Inc.427746102US427746102006/12/2025To elect six director nominees to serve until the 2026 Annual Meeting of Stockholders and until their successors are duly elected and qualified or until their earlier death, resignation or removal: Christian WaageDIRECTOR ELECTIONSISSUER2326841.0000000FOR2326841.000000FORS000002088Heron Therapeutics, Inc.427746102US427746102006/12/2025To ratify the appointment of Withum as our independent registered public accounting firm for the fiscal year ending December 31, 2025.AUDIT-RELATEDISSUER2326841.0000000FOR2326841.000000FORS000002088Heron Therapeutics, Inc.427746102US427746102006/12/2025To approve, on a nonbinding advisory basis, compensation paid to our Named Executive Officers for the fiscal year ended December 31, 2024.SECTION 14A SAY-ON-PAY VOTESISSUER2326841.0000000FOR2326841.000000FORS000002088Heron Therapeutics, Inc.427746102US427746102006/12/2025To approve, on a nonbinding advisory basis, the frequency of future advisory votes on the compensation paid to our Named Executive Officers.SECTION 14A SAY-ON-PAY VOTESISSUER2326841.0000000ONE YEAR2326841.000000FORS000002088Legend Biotech Corporation52490G102US52490G102206/12/2025Accept Financial Statements and Statutory ReportsCORPORATE GOVERNANCEISSUER545609.0000000FOR545609.000000FORS000002088Legend Biotech Corporation52490G102US52490G102206/12/2025Ratify Ernst & Young LLP as AuditorsAUDIT-RELATEDISSUER545609.0000000FOR545609.000000FORS000002088Legend Biotech Corporation52490G102US52490G102206/12/2025Elect Director Patrick CaseyDIRECTOR ELECTIONSISSUER545609.0000000FOR545609.000000FORS000002088Legend Biotech Corporation52490G102US52490G102206/12/2025Elect Director Yau Wai Man PhilipDIRECTOR ELECTIONSISSUER545609.0000000FOR545609.000000FORS000002088Legend Biotech Corporation52490G102US52490G102206/12/2025Elect Director Fangliang ZhangDIRECTOR ELECTIONSISSUER545609.0000000FOR545609.000000FORS000002088Legend Biotech Corporation52490G102US52490G102206/12/2025Authorize Board to Ratify and Execute Approved ResolutionsCORPORATE GOVERNANCEISSUER545609.0000000FOR545609.000000FORS000002088Natera, Inc.632307104US632307104206/12/2025To elect the three directors named below and in the proxy statement to serve as Class I directors until the annual meeting of stockholders to be held in 2028 and until their successors are duly elected and qualified: Roy BaynesDIRECTOR ELECTIONSISSUER558431.0000000FOR558431.000000FORS000002088Natera, Inc.632307104US632307104206/12/2025To elect the three directors named below and in the proxy statement to serve as Class I directors until the annual meeting of stockholders to be held in 2028 and until their successors are duly elected and qualified: Gail MarcusDIRECTOR ELECTIONSISSUER558431.0000000FOR558431.000000FORS000002088Natera, Inc.632307104US632307104206/12/2025To elect the three directors named below and in the proxy statement to serve as Class I directors until the annual meeting of stockholders to be held in 2028 and until their successors are duly elected and qualified: Ruth Williams-BrinkleyDIRECTOR ELECTIONSISSUER558431.0000000FOR558431.000000FORS000002088Natera, Inc.632307104US632307104206/12/2025To ratify the appointment of Ernst & Young LLP as Natera, Inc.'s independent registered public accounting firm for the fiscal year ending December 31, 2025.AUDIT-RELATEDISSUER558431.0000000FOR558431.000000FORS000002088Natera, Inc.632307104US632307104206/12/2025To approve, on an advisory (non-binding) basis, the compensation of Natera, Inc.'s named executive officers as disclosed in the proxy statement.SECTION 14A SAY-ON-PAY VOTESISSUER558431.0000000FOR558431.000000FORS000002088Natera, Inc.632307104US632307104206/12/2025To approve an amendment to Natera's Amended and Restated 2015 Equity Incentive Plan.COMPENSATIONISSUER558431.0000000FOR558431.000000FORS000002088Prelude Therapeutics Incorporated74065P101US74065P101206/12/2025Election of Class II Directors: Martin BablerDIRECTOR ELECTIONSISSUER705585.0000000FOR705585.000000FORS000002088Prelude Therapeutics Incorporated74065P101US74065P101206/12/2025Election of Class II Directors: Victor Sandor, M.D.C.M.DIRECTOR ELECTIONSISSUER705585.0000000FOR705585.000000FORS000002088Prelude Therapeutics Incorporated74065P101US74065P101206/12/2025Ratification of the appointment of Ernst & Young LLP as the Independent registered public accounting firm of the company for its fiscal year ending December 31, 2025.AUDIT-RELATEDISSUER705585.0000000FOR705585.000000FORS000002088Prelude Therapeutics Incorporated74065P101US74065P101206/12/2025To approve an amendment to our restated certificate of Incorporation, as amended, to Increase the number of authorized shares of our non-voting common stock from 12,850,259 to 112,850,259, with a corresponding Increase to the total number of authorized shares of our common stock, par value $0.0001 per share.CAPITAL STRUCTUREISSUER705585.0000000FOR705585.000000FORS000002088Sionna Therapeutics, Inc.829401108US829401108006/12/2025To elect three class I directors to serve until our 2028 annual meeting of stockholders and until his or her successor has been duly elected and qualified, or until his or her earlier death, resignation or removal: Joshua Resnick, M.D., M.B.A.DIRECTOR ELECTIONSISSUER205112.0000000FOR205112.000000FORS000002088Sionna Therapeutics, Inc.829401108US829401108006/12/2025To elect three class I directors to serve until our 2028 annual meeting of stockholders and until his or her successor has been duly elected and qualified, or until his or her earlier death, resignation or removal: Bruce Booth, D.Phil.DIRECTOR ELECTIONSISSUER205112.0000000FOR205112.000000FORS000002088Sionna Therapeutics, Inc.829401108US829401108006/12/2025To elect three class I directors to serve until our 2028 annual meeting of stockholders and until his or her successor has been duly elected and qualified, or until his or her earlier death, resignation or removal: Lucian Iancovici, M.D.DIRECTOR ELECTIONSISSUER205112.0000000FOR205112.000000FORS000002088Sionna Therapeutics, Inc.829401108US829401108006/12/2025To ratify the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025.AUDIT-RELATEDISSUER205112.0000000FOR205112.000000FORS000002088Summit Therapeutics Inc.86627T108US86627T108806/12/2025ELECTION OF DIRECTORS: Robert W. DugganDIRECTOR ELECTIONSISSUER4122796.0000000AGAINST4122796.000000AGAINSTS000002088Summit Therapeutics Inc.86627T108US86627T108806/12/2025ELECTION OF DIRECTORS: Mahkam ZanganehDIRECTOR ELECTIONSISSUER4122796.0000000AGAINST4122796.000000AGAINSTS000002088Summit Therapeutics Inc.86627T108US86627T108806/12/2025ELECTION OF DIRECTORS: Manmeet S. SoniDIRECTOR ELECTIONSISSUER4122796.0000000AGAINST4122796.000000AGAINSTS000002088Summit Therapeutics Inc.86627T108US86627T108806/12/2025ELECTION OF DIRECTORS: Kenneth A. ClarkDIRECTOR ELECTIONSISSUER4122796.0000000AGAINST4122796.000000AGAINSTS000002088Summit Therapeutics Inc.86627T108US86627T108806/12/2025ELECTION OF DIRECTORS: Robert BoothDIRECTOR ELECTIONSISSUER4122796.0000000FOR4122796.000000FORS000002088Summit Therapeutics Inc.86627T108US86627T108806/12/2025ELECTION OF DIRECTORS: Alessandra CesanoDIRECTOR ELECTIONSISSUER4122796.0000000FOR4122796.000000FORS000002088Summit Therapeutics Inc.86627T108US86627T108806/12/2025ELECTION OF DIRECTORS: Yu (Michelle) XiaDIRECTOR ELECTIONSISSUER4122796.0000000AGAINST4122796.000000AGAINSTS000002088Summit Therapeutics Inc.86627T108US86627T108806/12/2025ELECTION OF DIRECTORS: Mostafa RonaghiDIRECTOR ELECTIONSISSUER4122796.0000000FOR4122796.000000FORS000002088Summit Therapeutics Inc.86627T108US86627T108806/12/2025ELECTION OF DIRECTORS: Jeff HuberDIRECTOR ELECTIONSISSUER4122796.0000000FOR4122796.000000FORS000002088Summit Therapeutics Inc.86627T108US86627T108806/12/2025Ratification of the appointment of PricewaterhouseCoopers LLP as Independent Registered Public Accounting Firm for the fiscal year ending December 31, 2025.AUDIT-RELATEDISSUER4122796.0000000FOR4122796.000000FORS000002088Summit Therapeutics Inc.86627T108US86627T108806/12/2025Approval, by a non-binding advisory vote, of the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER4122796.0000000AGAINST4122796.000000AGAINSTS000002088Tarsus Pharmaceuticals, Inc.87650L103US87650L103506/12/2025To elect Class II directors, to serve until the 2028 annual meeting of stockholders or until their respective successor have been elected or appointed: Bobak AzamianDIRECTOR ELECTIONSISSUER301995.0000000FOR301995.000000FORS000002088Tarsus Pharmaceuticals, Inc.87650L103US87650L103506/12/2025To elect Class II directors, to serve until the 2028 annual meeting of stockholders or until their respective successor have been elected or appointed: Katherine GoodrichDIRECTOR ELECTIONSISSUER301995.0000000FOR301995.000000FORS000002088Tarsus Pharmaceuticals, Inc.87650L103US87650L103506/12/2025To hold an advisory vote to approve, on a non-binding basis, named executive officer compensation.SECTION 14A SAY-ON-PAY VOTESISSUER301995.0000000FOR301995.000000FORS000002088Tarsus Pharmaceuticals, Inc.87650L103US87650L103506/12/2025To hold an advisory vote to approve, on a non-binding basis, the frequency with which future stockholder votes on the compensation of our named executive officers will be conducted of one, two or three years.SECTION 14A SAY-ON-PAY VOTESISSUER301995.0000000ONE YEAR301995.000000FORS000002088Tarsus Pharmaceuticals, Inc.87650L103US87650L103506/12/2025To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025.AUDIT-RELATEDISSUER301995.0000000FOR301995.000000FORS000002088Vaxcyte, Inc.92243G108US92243G108506/12/2025Election of Class II Directors Nominees would serve until the 2028 Annual Meeting of Stockholders and until their successors have been duly elected and qualified, or, if sooner, until the director's death, resignation or removal: John FureyDIRECTOR ELECTIONSISSUER1062036.0000000FOR1062036.000000FORS000002088Vaxcyte, Inc.92243G108US92243G108506/12/2025Election of Class II Directors Nominees would serve until the 2028 Annual Meeting of Stockholders and until their successors have been duly elected and qualified, or, if sooner, until the director's death, resignation or removal: Jacks LeeDIRECTOR ELECTIONSISSUER1062036.0000000FOR1062036.000000FORS000002088Vaxcyte, Inc.92243G108US92243G108506/12/2025Election of Class II Directors Nominees would serve until the 2028 Annual Meeting of Stockholders and until their successors have been duly elected and qualified, or, if sooner, until the director's death, resignation or removal: Heath Lukatch, Ph.D.DIRECTOR ELECTIONSISSUER1062036.0000000FOR1062036.000000FORS000002088Vaxcyte, Inc.92243G108US92243G108506/12/2025Ratification of the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025.AUDIT-RELATEDISSUER1062036.0000000FOR1062036.000000FORS000002088Vaxcyte, Inc.92243G108US92243G108506/12/2025Approval, on a non-binding, advisory basis, of the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER1062036.0000000AGAINST1062036.000000AGAINSTS000002088Vaxcyte, Inc.92243G108US92243G108506/12/2025Approval of the amendment and restatement of the Company's Amended and Restated Certificate of Incorporation to provide for officer exculpation as permitted by recent amendments to the Delaware General Corporation Law.CORPORATE GOVERNANCEISSUER1062036.0000000FOR1062036.000000FORS000002088Xencor, Inc.98401F105US98401F105706/12/2025To elect the eight nominees to the Board of Directors named in the accompanying Proxy Statement to serve until the next annual meeting and until their successors are duly elected and qualified: Dr. Bassil I. DahiyatDIRECTOR ELECTIONSISSUER598436.0000000FOR598436.000000FORS000002088Xencor, Inc.98401F105US98401F105706/12/2025To elect the eight nominees to the Board of Directors named in the accompanying Proxy Statement to serve until the next annual meeting and until their successors are duly elected and qualified: Dr. Ellen G. FeigalDIRECTOR ELECTIONSISSUER598436.0000000FOR598436.000000FORS000002088Xencor, Inc.98401F105US98401F105706/12/2025To elect the eight nominees to the Board of Directors named in the accompanying Proxy Statement to serve until the next annual meeting and until their successors are duly elected and qualified: Dr. Kevin C. GormanDIRECTOR ELECTIONSISSUER598436.0000000FOR598436.000000FORS000002088Xencor, Inc.98401F105US98401F105706/12/2025To elect the eight nominees to the Board of Directors named in the accompanying Proxy Statement to serve until the next annual meeting and until their successors are duly elected and qualified: Mr. Kurt A. GustafsonDIRECTOR ELECTIONSISSUER598436.0000000FOR598436.000000FORS000002088Xencor, Inc.98401F105US98401F105706/12/2025To elect the eight nominees to the Board of Directors named in the accompanying Proxy Statement to serve until the next annual meeting and until their successors are duly elected and qualified: Dr. Barbara KlenckeDIRECTOR ELECTIONSISSUER598436.0000000FOR598436.000000FORS000002088Xencor, Inc.98401F105US98401F105706/12/2025To elect the eight nominees to the Board of Directors named in the accompanying Proxy Statement to serve until the next annual meeting and until their successors are duly elected and qualified: Dr. A. Bruce MontgomeryDIRECTOR ELECTIONSISSUER598436.0000000FOR598436.000000FORS000002088Xencor, Inc.98401F105US98401F105706/12/2025To elect the eight nominees to the Board of Directors named in the accompanying Proxy Statement to serve until the next annual meeting and until their successors are duly elected and qualified: Mr. Richard J. RanieriDIRECTOR ELECTIONSISSUER598436.0000000FOR598436.000000FORS000002088Xencor, Inc.98401F105US98401F105706/12/2025To elect the eight nominees to the Board of Directors named in the accompanying Proxy Statement to serve until the next annual meeting and until their successors are duly elected and qualified: Mr. Todd E. SimpsonDIRECTOR ELECTIONSISSUER598436.0000000FOR598436.000000FORS000002088Xencor, Inc.98401F105US98401F105706/12/2025To ratify the selection by the Audit Committee of the Board of Directors of KPMG LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2025;AUDIT-RELATEDISSUER598436.0000000FOR598436.000000FORS000002088Xencor, Inc.98401F105US98401F105706/12/2025To approve the proposed amendment and restatement of the Company's 2023 Equity Incentive Plan to increase the number of authorized shares reserved for issuance thereunder by 3,000,000 shares;COMPENSATIONISSUER598436.0000000FOR598436.000000FORS000002088Xencor, Inc.98401F105US98401F105706/12/2025To approve, on an advisory (non-binding) basis, the compensation of the Company's named executive officers, as disclosed in the accompanying Proxy Statement;SECTION 14A SAY-ON-PAY VOTESISSUER598436.0000000FOR598436.000000FORS000002088Immuneering Corporation45254E107US45254E107306/13/2025Election of three Class I Directors: Ann E. BermanDIRECTOR ELECTIONSISSUER314533.0000000FOR314533.000000FORS000002088Immuneering Corporation45254E107US45254E107306/13/2025Election of three Class I Directors: Diana F. Hausman, M.D.DIRECTOR ELECTIONSISSUER314533.0000000FOR314533.000000FORS000002088Immuneering Corporation45254E107US45254E107306/13/2025Election of three Class I Directors: Thomas J. Schall, Ph.D.DIRECTOR ELECTIONSISSUER314533.0000000FOR314533.000000FORS000002088Immuneering Corporation45254E107US45254E107306/13/2025Ratify the appointment of RSM US LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025.AUDIT-RELATEDISSUER314533.0000000FOR314533.000000FORS000002088Monte Rosa Therapeutics, Inc.61225M102US61225M102706/13/2025To elect three Class I director nominees to our board of directors, to serve until the Company's 2028 annual meeting of stockholders and until their successor has been duly elected and qualified, or until their earlier death, resignation or removal: Christine Siu, MBADIRECTOR ELECTIONSISSUER1011007.0000000FOR1011007.000000FORS000002088Monte Rosa Therapeutics, Inc.61225M102US61225M102706/13/2025To elect three Class I director nominees to our board of directors, to serve until the Company's 2028 annual meeting of stockholders and until their successor has been duly elected and qualified, or until their earlier death, resignation or removal: Kimberly L. Blackwell, M.D.DIRECTOR ELECTIONSISSUER1011007.0000000FOR1011007.000000FORS000002088Monte Rosa Therapeutics, Inc.61225M102US61225M102706/13/2025To elect three Class I director nominees to our board of directors, to serve until the Company's 2028 annual meeting of stockholders and until their successor has been duly elected and qualified, or until their earlier death, resignation or removal: Jan Skvarka, Ph.D., MBADIRECTOR ELECTIONSISSUER1011007.0000000FOR1011007.000000FORS000002088Monte Rosa Therapeutics, Inc.61225M102US61225M102706/13/2025To ratify the appointment of Deloitte & Touche, LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025; andAUDIT-RELATEDISSUER1011007.0000000FOR1011007.000000FORS000002088Regeneron Pharmaceuticals, Inc.75886F107US75886F107506/13/2025Election of Directors: Bonnie L. Bassler, Ph.D.DIRECTOR ELECTIONSISSUER304057.0000000FOR304057.000000FORS000002088Regeneron Pharmaceuticals, Inc.75886F107US75886F107506/13/2025Election of Directors: Michael S. Brown, M.D.DIRECTOR ELECTIONSISSUER304057.0000000FOR304057.000000FORS000002088Regeneron Pharmaceuticals, Inc.75886F107US75886F107506/13/2025Election of Directors: Leonard S. Schleifer, M.D., Ph.D.DIRECTOR ELECTIONSISSUER304057.0000000FOR304057.000000FORS000002088Regeneron Pharmaceuticals, Inc.75886F107US75886F107506/13/2025Election of Directors: George D. Yancopoulos, M.D., Ph.D.DIRECTOR ELECTIONSISSUER304057.0000000FOR304057.000000FORS000002088Regeneron Pharmaceuticals, Inc.75886F107US75886F107506/13/2025Ratification of the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025.AUDIT-RELATEDISSUER304057.0000000FOR304057.000000FORS000002088Regeneron Pharmaceuticals, Inc.75886F107US75886F107506/13/2025Proposal to approve, on an advisory basis, executive compensation.SECTION 14A SAY-ON-PAY VOTESISSUER304057.0000000FOR304057.000000FORS000002088Regeneron Pharmaceuticals, Inc.75886F107US75886F107506/13/2025Proposal to approve an amendment to the Company's Certificate of Incorporation to declassify the board of directors.SHAREHOLDER RIGHTS AND DEFENSESISSUER304057.0000000FOR304057.000000FORS000002088Regeneron Pharmaceuticals, Inc.75886F107US75886F107506/13/2025Amendments to the Company's Certificate of Incorporation to Eliminate Supermajority Vote Requirements Proposal to approve an amendment to Article IV, Section 2(e)(8) of the Certificate of IncorporationCORPORATE GOVERNANCEISSUER304057.0000000FOR304057.000000FORS000002088Regeneron Pharmaceuticals, Inc.75886F107US75886F107506/13/2025Amendments to the Company's Certificate of Incorporation to Eliminate Supermajority Vote Requirements Proposal to approve an amendment to Article VI of the Certificate of Incorporation.CORPORATE GOVERNANCEISSUER304057.0000000FOR304057.000000FORS000002088Apogee Therapeutics, Inc.03770N101US03770N101906/17/2025Election of Class II Directors for terms expiring in 2028: Lisa Bollinger, M.D.DIRECTOR ELECTIONSISSUER587295.0000000FOR587295.000000FORS000002088Apogee Therapeutics, Inc.03770N101US03770N101906/17/2025Election of Class II Directors for terms expiring in 2028: Tomas KiselakDIRECTOR ELECTIONSISSUER587295.0000000FOR587295.000000FORS000002088Apogee Therapeutics, Inc.03770N101US03770N101906/17/2025Election of Class II Directors for terms expiring in 2028: Nimish ShahDIRECTOR ELECTIONSISSUER587295.0000000FOR587295.000000FORS000002088Apogee Therapeutics, Inc.03770N101US03770N101906/17/2025Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the year ending December 31, 2025.AUDIT-RELATEDISSUER587295.0000000FOR587295.000000FORS000002088Apogee Therapeutics, Inc.03770N101US03770N101906/17/2025Vote on the frequency of future advisory votes to approve our named executive officers compensation.SECTION 14A SAY-ON-PAY VOTESISSUER587295.0000000ONE YEAR587295.000000FORS000002088Aura Biosciences, Inc.05153U107US05153U107906/17/2025To elect two Class I directors to our Board of Directors, to serve until the 2028 annual meeting of stockholders and until their successor has been duly elected and qualified, or until their earlier death, resignation or removal: Elisabet de los Pinos, Ph.D.DIRECTOR ELECTIONSISSUER349606.0000000FOR349606.000000FORS000002088Aura Biosciences, Inc.05153U107US05153U107906/17/2025To elect two Class I directors to our Board of Directors, to serve until the 2028 annual meeting of stockholders and until their successor has been duly elected and qualified, or until their earlier death, resignation or removal: Giovanni Mariggi, Ph.D.DIRECTOR ELECTIONSISSUER349606.0000000FOR349606.000000FORS000002088Aura Biosciences, Inc.05153U107US05153U107906/17/2025To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025.AUDIT-RELATEDISSUER349606.0000000FOR349606.000000FORS000002088Bicycle Therapeutics Plc088786108US088786108806/17/2025To re-elect Alessandro Riva as a director, who retires in accordance with the Articles of Association.DIRECTOR ELECTIONSISSUER1168468.0000000FOR1168468.000000FORS000002088Bicycle Therapeutics Plc088786108US088786108806/17/2025To re-elect Stephen Sands as a director, who retires in accordance with the Articles of Association.DIRECTOR ELECTIONSISSUER1168468.0000000FOR1168468.000000FORS000002088Bicycle Therapeutics Plc088786108US088786108806/17/2025To approve, on advisory basis, the compensation of our named executive officers, as disclosed in the proxy statement.SECTION 14A SAY-ON-PAY VOTESISSUER1168468.0000000FOR1168468.000000FORS000002088Bicycle Therapeutics Plc088786108US088786108806/17/2025To ratify the appointment of PricewaterhouseCoopers LLP, a limited liability partnership organized under the laws of England, as our U.S. independent registered public accounting firm for the year ending December 31, 2025.AUDIT-RELATEDISSUER1168468.0000000FOR1168468.000000FORS000002088Bicycle Therapeutics Plc088786108US088786108806/17/2025To re-appoint PricewaterhouseCoopers LLP, a limited liability partnership organized under the laws of England, as our U.K. statutory auditors, to hold office until the conclusion of the next annual general meeting of shareholders.AUDIT-RELATEDISSUER1168468.0000000FOR1168468.000000FORS000002088Bicycle Therapeutics Plc088786108US088786108806/17/2025To authorize the Audit Committee to determine our U.K. statutory auditors' remuneration for the year ending December 31, 2025.AUDIT-RELATEDISSUER1168468.0000000FOR1168468.000000FORS000002088Bicycle Therapeutics Plc088786108US088786108806/17/2025To receive and adopt our U.K. statutory annual accounts and reports for the year ended December 31, 2024 (the "2024 U.K. Annual Report").CORPORATE GOVERNANCEISSUER1168468.0000000FOR1168468.000000FORS000002088Bicycle Therapeutics Plc088786108US088786108806/17/2025To approve our directors' remuneration report for the year ended December 31, 2024 (the "directors' remuneration report"), which is set forth as Annex A to the proxy statement.COMPENSATIONISSUER1168468.0000000FOR1168468.000000FORS000002088Bicycle Therapeutics Plc088786108US088786108806/17/2025To approve an amendment to our Amended and Restated 2020 Equity Incentive Plan, which amendment is set forth as Annex C to the proxy statement.COMPENSATIONISSUER1168468.0000000AGAINST1168468.000000AGAINSTS000002088Biogen Inc.09062X103US09062X103706/17/2025Election of Directors. To elect the 11 nominees identified in the accompanying Proxy Statement to our Board of Directors to serve for a one-year term extending until our 2026 annual meeting of stockholders and their successors are duly elected and qualified: Caroline D. DorsaDIRECTOR ELECTIONSISSUER89744.0000000AGAINST89744.000000AGAINSTS000002088Biogen Inc.09062X103US09062X103706/17/2025Election of Directors. To elect the 11 nominees identified in the accompanying Proxy Statement to our Board of Directors to serve for a one-year term extending until our 2026 annual meeting of stockholders and their successors are duly elected and qualified: Maria C. FreireDIRECTOR ELECTIONSISSUER89744.0000000FOR89744.000000FORS000002088Biogen Inc.09062X103US09062X103706/17/2025Election of Directors. To elect the 11 nominees identified in the accompanying Proxy Statement to our Board of Directors to serve for a one-year term extending until our 2026 annual meeting of stockholders and their successors are duly elected and qualified: William A. HawkinsDIRECTOR ELECTIONSISSUER89744.0000000FOR89744.000000FORS000002088Biogen Inc.09062X103US09062X103706/17/2025Election of Directors. To elect the 11 nominees identified in the accompanying Proxy Statement to our Board of Directors to serve for a one-year term extending until our 2026 annual meeting of stockholders and their successors are duly elected and qualified: Susan K. LangerDIRECTOR ELECTIONSISSUER89744.0000000AGAINST89744.000000AGAINSTS000002088Biogen Inc.09062X103US09062X103706/17/2025Election of Directors. To elect the 11 nominees identified in the accompanying Proxy Statement to our Board of Directors to serve for a one-year term extending until our 2026 annual meeting of stockholders and their successors are duly elected and qualified: Jesus B. MantasDIRECTOR ELECTIONSISSUER89744.0000000AGAINST89744.000000AGAINSTS000002088Biogen Inc.09062X103US09062X103706/17/2025Election of Directors. To elect the 11 nominees identified in the accompanying Proxy Statement to our Board of Directors to serve for a one-year term extending until our 2026 annual meeting of stockholders and their successors are duly elected and qualified: Lloyd MinorDIRECTOR ELECTIONSISSUER89744.0000000FOR89744.000000FORS000002088Biogen Inc.09062X103US09062X103706/17/2025Election of Directors. To elect the 11 nominees identified in the accompanying Proxy Statement to our Board of Directors to serve for a one-year term extending until our 2026 annual meeting of stockholders and their successors are duly elected and qualified: Menelas PangalosDIRECTOR ELECTIONSISSUER89744.0000000FOR89744.000000FORS000002088Biogen Inc.09062X103US09062X103706/17/2025Election of Directors. To elect the 11 nominees identified in the accompanying Proxy Statement to our Board of Directors to serve for a one-year term extending until our 2026 annual meeting of stockholders and their successors are duly elected and qualified: Monish PatolawalaDIRECTOR ELECTIONSISSUER89744.0000000FOR89744.000000FORS000002088Biogen Inc.09062X103US09062X103706/17/2025Election of Directors. To elect the 11 nominees identified in the accompanying Proxy Statement to our Board of Directors to serve for a one-year term extending until our 2026 annual meeting of stockholders and their successors are duly elected and qualified: Eric K. RowinskyDIRECTOR ELECTIONSISSUER89744.0000000AGAINST89744.000000AGAINSTS000002088Biogen Inc.09062X103US09062X103706/17/2025Election of Directors. To elect the 11 nominees identified in the accompanying Proxy Statement to our Board of Directors to serve for a one-year term extending until our 2026 annual meeting of stockholders and their successors are duly elected and qualified: Stephen A. SherwinDIRECTOR ELECTIONSISSUER89744.0000000FOR89744.000000FORS000002088Biogen Inc.09062X103US09062X103706/17/2025Election of Directors. To elect the 11 nominees identified in the accompanying Proxy Statement to our Board of Directors to serve for a one-year term extending until our 2026 annual meeting of stockholders and their successors are duly elected and qualified: Christopher A. ViehbacherDIRECTOR ELECTIONSISSUER89744.0000000FOR89744.000000FORS000002088Biogen Inc.09062X103US09062X103706/17/2025To ratify the selection of PricewaterhouseCoopers LLP as our independent registered public accounting firm for fiscal year ending December 31, 2025AUDIT-RELATEDISSUER89744.0000000FOR89744.000000FORS000002088Biogen Inc.09062X103US09062X103706/17/2025Say on Pay - To hold an advisory vote on executive compensation.SECTION 14A SAY-ON-PAY VOTESISSUER89744.0000000AGAINST89744.000000AGAINSTS000002088Rapport Therapeutics, Inc.75383L102US75383L102606/17/2025To elect Reid Huber, Ph.D., John Maraganore, Ph.D.,and Wendy B. Young, Ph.D. as Class I Directors: Reid Huber, Ph.D.DIRECTOR ELECTIONSISSUER877484.0000000FOR877484.000000FORS000002088Rapport Therapeutics, Inc.75383L102US75383L102606/17/2025To elect Reid Huber, Ph.D., John Maraganore, Ph.D.,and Wendy B. Young, Ph.D. as Class I Directors: John Maraganore, Ph.D.DIRECTOR ELECTIONSISSUER877484.0000000FOR877484.000000FORS000002088Rapport Therapeutics, Inc.75383L102US75383L102606/17/2025To elect Reid Huber, Ph.D., John Maraganore, Ph.D.,and Wendy B. Young, Ph.D. as Class I Directors: Wendy B. Young, Ph.D.DIRECTOR ELECTIONSISSUER877484.0000000FOR877484.000000FORS000002088Rapport Therapeutics, Inc.75383L102US75383L102606/17/2025To ratify the appointment of PricewaterhouseCoopers LLP as Rapport's independent registered public accounting firm for the fiscal year ending December 31, 2025.AUDIT-RELATEDISSUER877484.0000000FOR877484.000000FORS000002088Agios Pharmaceuticals, Inc.00847X104US00847X104606/18/2025To elect each of the two Class III director nominees set forth in the Proxy Statement, each to serve for a three-year term expiring at the 2028 annual meeting of stockholders and until his or her respective successor is duly elected and qualified: Jacqualyn A. Fouse, Ph.D.DIRECTOR ELECTIONSISSUER1057121.0000000FOR1057121.000000FORS000002088Agios Pharmaceuticals, Inc.00847X104US00847X104606/18/2025To elect each of the two Class III director nominees set forth in the Proxy Statement, each to serve for a three-year term expiring at the 2028 annual meeting of stockholders and until his or her respective successor is duly elected and qualified: David Scadden, M.D.DIRECTOR ELECTIONSISSUER1057121.0000000FOR1057121.000000FORS000002088Agios Pharmaceuticals, Inc.00847X104US00847X104606/18/2025To vote, on an advisory basis, to approve the compensation paid to our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER1057121.0000000FOR1057121.000000FORS000002088Agios Pharmaceuticals, Inc.00847X104US00847X104606/18/2025To approve an amendment to the Agios Pharmaceuticals, Inc. 2023 Stock Incentive Plan, to increase the number of shares of common stock available thereunder by 2,500,000 shares.COMPENSATIONISSUER1057121.0000000FOR1057121.000000FORS000002088Agios Pharmaceuticals, Inc.00847X104US00847X104606/18/2025To ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025.AUDIT-RELATEDISSUER1057121.0000000FOR1057121.000000FORS000002088Allogene Therapeutics, Inc.019770106US019770106506/18/2025Election of Directors: Elizabeth BarrettDIRECTOR ELECTIONSISSUER2936094.0000000FOR2936094.000000FORS000002088Allogene Therapeutics, Inc.019770106US019770106506/18/2025Election of Directors: Arie Belldegrun, M.D.DIRECTOR ELECTIONSISSUER2936094.0000000FOR2936094.000000FORS000002088Allogene Therapeutics, Inc.019770106US019770106506/18/2025Election of Directors: David Chang, M.D., Ph.D.DIRECTOR ELECTIONSISSUER2936094.0000000FOR2936094.000000FORS000002088Allogene Therapeutics, Inc.019770106US019770106506/18/2025To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the proxy statement.SECTION 14A SAY-ON-PAY VOTESISSUER2936094.0000000FOR2936094.000000FORS000002088Allogene Therapeutics, Inc.019770106US019770106506/18/2025To ratify the selection by the Audit Committee of the Board of Directors of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2025.AUDIT-RELATEDISSUER2936094.0000000FOR2936094.000000FORS000002088Blueprint Medicines Corporation09627Y109US09627Y109106/18/2025Election of class I directors each to serve for a three-year term, or until their successor has been duly elected and qualified: Jeffrey AlbersDIRECTOR ELECTIONSISSUER1484139.0000000FOR1484139.000000FORS000002088Blueprint Medicines Corporation09627Y109US09627Y109106/18/2025Election of class I directors each to serve for a three-year term, or until their successor has been duly elected and qualified: Mark Goldberg, M.D.DIRECTOR ELECTIONSISSUER1484139.0000000FOR1484139.000000FORS000002088Blueprint Medicines Corporation09627Y109US09627Y109106/18/2025Election of class I directors each to serve for a three-year term, or until their successor has been duly elected and qualified: John Tsai, M.D.DIRECTOR ELECTIONSISSUER1484139.0000000FOR1484139.000000FORS000002088Blueprint Medicines Corporation09627Y109US09627Y109106/18/2025Approval of a non-binding advisory vote on the compensation paid to our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER1484139.0000000FOR1484139.000000FORS000002088Blueprint Medicines Corporation09627Y109US09627Y109106/18/2025Ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025.AUDIT-RELATEDISSUER1484139.0000000FOR1484139.000000FORS000002088CARGO Therapeutics, Inc.14179K101US14179K101606/18/2025To elect three Class II directors to hold office until the 2028 annual meeting of stockholders or until their successors are elected: Abraham BassanDIRECTOR ELECTIONSISSUER454938.0000000FOR454938.000000FORS000002088CARGO Therapeutics, Inc.14179K101US14179K101606/18/2025To elect three Class II directors to hold office until the 2028 annual meeting of stockholders or until their successors are elected: Kapil DhingraDIRECTOR ELECTIONSISSUER454938.0000000FOR454938.000000FORS000002088CARGO Therapeutics, Inc.14179K101US14179K101606/18/2025To elect three Class II directors to hold office until the 2028 annual meeting of stockholders or until their successors are elected: David LubnerDIRECTOR ELECTIONSISSUER454938.0000000FOR454938.000000FORS000002088CARGO Therapeutics, Inc.14179K101US14179K101606/18/2025To ratify the appointment, by the Audit Committee of the Company's Board of Directors, of Deloitte & Touche LLP as the independent registered public accounting firm and independent auditor of the Company for the fiscal year ending December 31, 2025.AUDIT-RELATEDISSUER454938.0000000FOR454938.000000FORS000002088Guardant Health, Inc.40131M109US40131M109906/18/2025Election of Class I Directors: Vijaya GaddeDIRECTOR ELECTIONSISSUER558518.0000000FOR558518.000000FORS000002088Guardant Health, Inc.40131M109US40131M109906/18/2025Election of Class I Directors: Roberto MignoneDIRECTOR ELECTIONSISSUER558518.0000000FOR558518.000000FORS000002088Guardant Health, Inc.40131M109US40131M109906/18/2025Election of Class I Directors: Myrtle PotterDIRECTOR ELECTIONSISSUER558518.0000000FOR558518.000000FORS000002088Guardant Health, Inc.40131M109US40131M109906/18/2025Election of Class I Directors: Musa TariqDIRECTOR ELECTIONSISSUER558518.0000000FOR558518.000000FORS000002088Guardant Health, Inc.40131M109US40131M109906/18/2025Ratification of the appointment of Deloitte & Touche LLP as Guardant Health, Inc.'s independent registered public accounting firm for the year ending December 31, 2025.AUDIT-RELATEDISSUER558518.0000000FOR558518.000000FORS000002088Guardant Health, Inc.40131M109US40131M109906/18/2025Non-binding advisory vote to approve Guardant Health, Inc.'s named executive officer compensation.SECTION 14A SAY-ON-PAY VOTESISSUER558518.0000000FOR558518.000000FORS000002088Nuvalent, Inc.670703107US670703107506/18/2025Election of the following nominees as Class I directors: Grant BogleDIRECTOR ELECTIONSISSUER335007.0000000FOR335007.000000FORS000002088Nuvalent, Inc.670703107US670703107506/18/2025Election of the following nominees as Class I directors: James R. Porter, Ph.D.DIRECTOR ELECTIONSISSUER335007.0000000FOR335007.000000FORS000002088Nuvalent, Inc.670703107US670703107506/18/2025Election of the following nominees as Class I directors: Anna ProtopapasDIRECTOR ELECTIONSISSUER335007.0000000FOR335007.000000FORS000002088Nuvalent, Inc.670703107US670703107506/18/2025To approve, on an advisory basis, the compensation paid to our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER335007.0000000AGAINST335007.000000AGAINSTS000002088Nuvalent, Inc.670703107US670703107506/18/2025To ratify the appointment of KPMG LLP as Nuvalent, Inc.'s independent registered public accounting firm for the fiscal year ending December 31, 2025.AUDIT-RELATEDISSUER335007.0000000FOR335007.000000FORS000002088Rocket Pharmaceuticals, Inc.77313F106US77313F106606/18/2025Election of the ten directors named in the proxy statement to hold office until the annual meeting of stockholders in 2026, or until their respective successors have been duly elected and qualified or until their earlier death, resignation or removal: Roderick Wong, M.D.DIRECTOR ELECTIONSISSUER1106474.0000000FOR1106474.000000FORS000002088Rocket Pharmaceuticals, Inc.77313F106US77313F106606/18/2025Election of the ten directors named in the proxy statement to hold office until the annual meeting of stockholders in 2026, or until their respective successors have been duly elected and qualified or until their earlier death, resignation or removal: Elisabeth Bjork, M.D., Ph.D.DIRECTOR ELECTIONSISSUER1106474.0000000FOR1106474.000000FORS000002088Rocket Pharmaceuticals, Inc.77313F106US77313F106606/18/2025Election of the ten directors named in the proxy statement to hold office until the annual meeting of stockholders in 2026, or until their respective successors have been duly elected and qualified or until their earlier death, resignation or removal: Carsten BoessDIRECTOR ELECTIONSISSUER1106474.0000000FOR1106474.000000FORS000002088Rocket Pharmaceuticals, Inc.77313F106US77313F106606/18/2025Election of the ten directors named in the proxy statement to hold office until the annual meeting of stockholders in 2026, or until their respective successors have been duly elected and qualified or until their earlier death, resignation or removal: Mikael Dolsten, M.D., Ph.D.DIRECTOR ELECTIONSISSUER1106474.0000000FOR1106474.000000FORS000002088Rocket Pharmaceuticals, Inc.77313F106US77313F106606/18/2025Election of the ten directors named in the proxy statement to hold office until the annual meeting of stockholders in 2026, or until their respective successors have been duly elected and qualified or until their earlier death, resignation or removal: Pedro GranadilloDIRECTOR ELECTIONSISSUER1106474.0000000FOR1106474.000000FORS000002088Rocket Pharmaceuticals, Inc.77313F106US77313F106606/18/2025Election of the ten directors named in the proxy statement to hold office until the annual meeting of stockholders in 2026, or until their respective successors have been duly elected and qualified or until their earlier death, resignation or removal: Gotham Makker, M.D.DIRECTOR ELECTIONSISSUER1106474.0000000FOR1106474.000000FORS000002088Rocket Pharmaceuticals, Inc.77313F106US77313F106606/18/2025Election of the ten directors named in the proxy statement to hold office until the annual meeting of stockholders in 2026, or until their respective successors have been duly elected and qualified or until their earlier death, resignation or removal: Fady Malik, M.D., Ph.D.DIRECTOR ELECTIONSISSUER1106474.0000000FOR1106474.000000FORS000002088Rocket Pharmaceuticals, Inc.77313F106US77313F106606/18/2025Election of the ten directors named in the proxy statement to hold office until the annual meeting of stockholders in 2026, or until their respective successors have been duly elected and qualified or until their earlier death, resignation or removal: Piratip PratumsuwanDIRECTOR ELECTIONSISSUER1106474.0000000FOR1106474.000000FORS000002088Rocket Pharmaceuticals, Inc.77313F106US77313F106606/18/2025Election of the ten directors named in the proxy statement to hold office until the annual meeting of stockholders in 2026, or until their respective successors have been duly elected and qualified or until their earlier death, resignation or removal: Gaurav Shah, M.D.DIRECTOR ELECTIONSISSUER1106474.0000000FOR1106474.000000FORS000002088Rocket Pharmaceuticals, Inc.77313F106US77313F106606/18/2025Election of the ten directors named in the proxy statement to hold office until the annual meeting of stockholders in 2026, or until their respective successors have been duly elected and qualified or until their earlier death, resignation or removal: David P. SouthwellDIRECTOR ELECTIONSISSUER1106474.0000000FOR1106474.000000FORS000002088Rocket Pharmaceuticals, Inc.77313F106US77313F106606/18/2025Ratification of the appointment of EisnerAmper LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025;AUDIT-RELATEDISSUER1106474.0000000FOR1106474.000000FORS000002088Rocket Pharmaceuticals, Inc.77313F106US77313F106606/18/2025Consider and act upon a non-binding, advisory vote on the compensation of our named executive officers;SECTION 14A SAY-ON-PAY VOTESISSUER1106474.0000000FOR1106474.000000FORS000002088Veeva Systems Inc.922475108US922475108406/18/2025To elect the following to serve as directors until the annual meeting to be held in 2026 or until their successors are duly elected and qualified: Tim CabralDIRECTOR ELECTIONSISSUER154484.0000000FOR154484.000000FORS000002088Veeva Systems Inc.922475108US922475108406/18/2025To elect the following to serve as directors until the annual meeting to be held in 2026 or until their successors are duly elected and qualified: Mark CargesDIRECTOR ELECTIONSISSUER154484.0000000FOR154484.000000FORS000002088Veeva Systems Inc.922475108US922475108406/18/2025To elect the following to serve as directors until the annual meeting to be held in 2026 or until their successors are duly elected and qualified: Peter P. GassnerDIRECTOR ELECTIONSISSUER154484.0000000FOR154484.000000FORS000002088Veeva Systems Inc.922475108US922475108406/18/2025To elect the following to serve as directors until the annual meeting to be held in 2026 or until their successors are duly elected and qualified: Mary Lynne HedleyDIRECTOR ELECTIONSISSUER154484.0000000FOR154484.000000FORS000002088Veeva Systems Inc.922475108US922475108406/18/2025To elect the following to serve as directors until the annual meeting to be held in 2026 or until their successors are duly elected and qualified: Priscilla HungDIRECTOR ELECTIONSISSUER154484.0000000FOR154484.000000FORS000002088Veeva Systems Inc.922475108US922475108406/18/2025To elect the following to serve as directors until the annual meeting to be held in 2026 or until their successors are duly elected and qualified: Marshall MohrDIRECTOR ELECTIONSISSUER154484.0000000FOR154484.000000FORS000002088Veeva Systems Inc.922475108US922475108406/18/2025To elect the following to serve as directors until the annual meeting to be held in 2026 or until their successors are duly elected and qualified: Gordon RitterDIRECTOR ELECTIONSISSUER154484.0000000FOR154484.000000FORS000002088Veeva Systems Inc.922475108US922475108406/18/2025To elect the following to serve as directors until the annual meeting to be held in 2026 or until their successors are duly elected and qualified: Paul SekhriDIRECTOR ELECTIONSISSUER154484.0000000FOR154484.000000FORS000002088Veeva Systems Inc.922475108US922475108406/18/2025To elect the following to serve as directors until the annual meeting to be held in 2026 or until their successors are duly elected and qualified: Matthew J. WallachDIRECTOR ELECTIONSISSUER154484.0000000FOR154484.000000FORS000002088Veeva Systems Inc.922475108US922475108406/18/2025To ratify the appointment of KPMG LLP as our independent registered public accounting firm for the fiscal year ending January 31, 2026.AUDIT-RELATEDISSUER154484.0000000FOR154484.000000FORS000002088Zai Lab Limited98887Q104US98887Q104006/18/2025THAT, each director nominee identified below is hereby re-elected to serve as a director until the 2026 annual general meeting of shareholders and until his or her successor is duly elected and qualified, subject to his or her earlier resignation or removal: Samantha (Ying) DuDIRECTOR ELECTIONSISSUER513334.0000000FOR513334.000000FORS000002088Zai Lab Limited98887Q104US98887Q104006/18/2025THAT, each director nominee identified below is hereby re-elected to serve as a director until the 2026 annual general meeting of shareholders and until his or her successor is duly elected and qualified, subject to his or her earlier resignation or removal: John D. DiekmanDIRECTOR ELECTIONSISSUER513334.0000000FOR513334.000000FORS000002088Zai Lab Limited98887Q104US98887Q104006/18/2025THAT, each director nominee identified below is hereby re-elected to serve as a director until the 2026 annual general meeting of shareholders and until his or her successor is duly elected and qualified, subject to his or her earlier resignation or removal: Richard GaynorDIRECTOR ELECTIONSISSUER513334.0000000FOR513334.000000FORS000002088Zai Lab Limited98887Q104US98887Q104006/18/2025THAT, each director nominee identified below is hereby re-elected to serve as a director until the 2026 annual general meeting of shareholders and until his or her successor is duly elected and qualified, subject to his or her earlier resignation or removal: Nisa LeungDIRECTOR ELECTIONSISSUER513334.0000000FOR513334.000000FORS000002088Zai Lab Limited98887Q104US98887Q104006/18/2025THAT, each director nominee identified below is hereby re-elected to serve as a director until the 2026 annual general meeting of shareholders and until his or her successor is duly elected and qualified, subject to his or her earlier resignation or removal: William LisDIRECTOR ELECTIONSISSUER513334.0000000FOR513334.000000FORS000002088Zai Lab Limited98887Q104US98887Q104006/18/2025THAT, each director nominee identified below is hereby re-elected to serve as a director until the 2026 annual general meeting of shareholders and until his or her successor is duly elected and qualified, subject to his or her earlier resignation or removal: Scott MorrisonDIRECTOR ELECTIONSISSUER513334.0000000FOR513334.000000FORS000002088Zai Lab Limited98887Q104US98887Q104006/18/2025THAT, each director nominee identified below is hereby re-elected to serve as a director until the 2026 annual general meeting of shareholders and until his or her successor is duly elected and qualified, subject to his or her earlier resignation or removal: Leon O. Moulder, Jr.DIRECTOR ELECTIONSISSUER513334.0000000FOR513334.000000FORS000002088Zai Lab Limited98887Q104US98887Q104006/18/2025THAT, each director nominee identified below is hereby re-elected to serve as a director until the 2026 annual general meeting of shareholders and until his or her successor is duly elected and qualified, subject to his or her earlier resignation or removal: Michel VounatsosDIRECTOR ELECTIONSISSUER513334.0000000FOR513334.000000FORS000002088Zai Lab Limited98887Q104US98887Q104006/18/2025THAT, each director nominee identified below is hereby re-elected to serve as a director until the 2026 annual general meeting of shareholders and until his or her successor is duly elected and qualified, subject to his or her earlier resignation or removal: Peter WirthDIRECTOR ELECTIONSISSUER513334.0000000FOR513334.000000FORS000002088Zai Lab Limited98887Q104US98887Q104006/18/2025THAT, the appointment of KPMG LLP and KPMG as the Company's independent registered public accounting firms and auditors to audit the Company's consolidated financial statements to be filed with the U.S. Securities and Exchange Commission and The Stock Exchange of Hong Kong Limited for the year ending December 31, 2025, respectively, is hereby approved.AUDIT-RELATEDISSUER513334.0000000FOR513334.000000FORS000002088Zai Lab Limited98887Q104US98887Q104006/18/2025THAT, the authority of the Board of Directors to fix auditor compensation for 2025, is hereby approved.AUDIT-RELATEDISSUER513334.0000000FOR513334.000000FORS000002088Zai Lab Limited98887Q104US98887Q104006/18/2025THAT, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the proxy statement, is hereby approved.SECTION 14A SAY-ON-PAY VOTESISSUER513334.0000000AGAINST513334.000000AGAINSTS000002088Zai Lab Limited98887Q104US98887Q104006/18/2025THAT, a general mandate to the Board of Directors to allot and issue ordinary shares and/or ADSs and/or resell treasury shares of up to 10% of the total number of issued ordinary shares of the Company (excluding treasury shares) as of the date of the Annual Meeting until the 2026 annual general meeting of shareholders is hereby approved.CAPITAL STRUCTUREISSUER513334.0000000FOR513334.000000FORS000002088Zai Lab Limited98887Q104US98887Q104006/18/2025THAT, a general mandate to repurchase ordinary shares and/or ADSs of up to 10% of the total number of issued ordinary shares of the Company (excluding treasury shares) as of the date of the Annual Meeting until the 2026 annual general meeting of shareholders is hereby approved.CAPITAL STRUCTUREISSUER513334.0000000FOR513334.000000FORS000002088Centessa Pharmaceuticals Plc152309100US152309100706/20/2025To re-appoint as a director Arjun Goyal, M.D., M.Phil., M.B.A., who retires by rotation in accordance with the Company's articles of association.DIRECTOR ELECTIONSISSUER3358683.0000000FOR3358683.000000FORS000002088Centessa Pharmaceuticals Plc152309100US152309100706/20/2025To re-appoint as a director Samarth Kulkarni, Ph.D., who retires by rotation in accordance with the Company's articles of association.DIRECTOR ELECTIONSISSUER3358683.0000000FOR3358683.000000FORS000002088Centessa Pharmaceuticals Plc152309100US152309100706/20/2025To re-appoint KPMG LLP, a United Kingdom entity, as UK statutory auditors of the Company, to hold office until the conclusion of the next meeting at which the Company's annual accounts and reports are laid before the Company.AUDIT-RELATEDISSUER3358683.0000000FOR3358683.000000FORS000002088Centessa Pharmaceuticals Plc152309100US152309100706/20/2025To ratify the re-appointment of KPMG LLP, a Delaware limited liability partnership, as the Company's independent registered public accounting firm, for the financial year ending December 31, 2025.AUDIT-RELATEDISSUER3358683.0000000FOR3358683.000000FORS000002088Centessa Pharmaceuticals Plc152309100US152309100706/20/2025To authorize the Audit Committee to determine the Company's auditors' remuneration for the financial year ending December 31, 2025.AUDIT-RELATEDISSUER3358683.0000000FOR3358683.000000FORS000002088Centessa Pharmaceuticals Plc152309100US152309100706/20/2025To receive and adopt our UK statutory annual accounts and reports for the financial year ended December 31, 2024 and to note that the Company's directors do not recommend the payment of any dividend for the financial year ended December 31, 2024.CORPORATE GOVERNANCEISSUER3358683.0000000FOR3358683.000000FORS000002088Centessa Pharmaceuticals Plc152309100US152309100706/20/2025To receive and approve, on an advisory basis, the Company's U.K. statutory directors' remuneration report for the financial year ended December 31, 2024, which is set forth as Annex A to the proxy statement.COMPENSATIONISSUER3358683.0000000FOR3358683.000000FORS000002088Centessa Pharmaceuticals Plc152309100US152309100706/20/2025To receive and approve the Directors' Remuneration Policy as set out in the Company's UK statutory directors' remuneration report for the financial year ended December 31, 2024, which is set forth as Annex A to the proxy statement.COMPENSATIONISSUER3358683.0000000FOR3358683.000000FORS000002088Centessa Pharmaceuticals Plc152309100US152309100706/20/2025To generally and unconditionally authorise the directors of the Company or any duly authorised committee of the directors, in accordance with section 551 of the UK Companies Act 2006 (the "Companies Act"), to allot shares in the Company or grant rights to subscribe for or to convert any security into shares in the Company up to an aggregate nominal amount of pounds133,184.CAPITAL STRUCTUREISSUER3358683.0000000FOR3358683.000000FORS000002088Centessa Pharmaceuticals Plc152309100US152309100706/20/2025Subject to the passing of Resolution 9, to empower the Board of Directors to allot equity securities for cash, under section 570 of the Companies Act as if section 561(1) of the Companies Act did not apply to such allotment up to a maximum aggregate nominal amount of pounds133,184.CAPITAL STRUCTUREISSUER3358683.0000000AGAINST3358683.000000AGAINSTS000002088Madrigal Pharmaceuticals, Inc.558868105US558868105706/20/2025Re-election of Class III directors: Julian BakerDIRECTOR ELECTIONSISSUER123264.0000000WITHHOLD123264.000000AGAINSTS000002088Madrigal Pharmaceuticals, Inc.558868105US558868105706/20/2025Re-election of Class III directors: Raymond Cheong, M.D., Ph.D.DIRECTOR ELECTIONSISSUER123264.0000000WITHHOLD123264.000000AGAINSTS000002088Madrigal Pharmaceuticals, Inc.558868105US558868105706/20/2025Re-election of Class III directors: Jacqualyn Fouse, Ph.D.DIRECTOR ELECTIONSISSUER123264.0000000FOR123264.000000FORS000002088Madrigal Pharmaceuticals, Inc.558868105US558868105706/20/2025Re-election of Class III directors: Richard Levy, M.D.DIRECTOR ELECTIONSISSUER123264.0000000WITHHOLD123264.000000AGAINSTS000002088Madrigal Pharmaceuticals, Inc.558868105US558868105706/20/2025To ratify the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025AUDIT-RELATEDISSUER123264.0000000FOR123264.000000FORS000002088Madrigal Pharmaceuticals, Inc.558868105US558868105706/20/2025Advisory vote to approve executive compensationSECTION 14A SAY-ON-PAY VOTESISSUER123264.0000000FOR123264.000000FORS000002088Madrigal Pharmaceuticals, Inc.558868105US558868105706/20/2025Advisory vote to approve the frequency of future advisory votes to approve executive compensationSECTION 14A SAY-ON-PAY VOTESISSUER123264.0000000ONE YEAR123264.000000FORS000002088Protagonist Therapeutics, Inc.74366E102US74366E102906/20/2025To elect the Class III director nominees named below to hold office until the 2028 Annual Meeting of Stockholders and until their successors are duly elected and qualified: Harold E. Selick, Ph.D.DIRECTOR ELECTIONSISSUER861704.0000000FOR861704.000000FORS000002088Protagonist Therapeutics, Inc.74366E102US74366E102906/20/2025To elect the Class III director nominees named below to hold office until the 2028 Annual Meeting of Stockholders and until their successors are duly elected and qualified: Bryan GiraudoDIRECTOR ELECTIONSISSUER861704.0000000FOR861704.000000FORS000002088Protagonist Therapeutics, Inc.74366E102US74366E102906/20/2025To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER861704.0000000FOR861704.000000FORS000002088Protagonist Therapeutics, Inc.74366E102US74366E102906/20/2025To ratify the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for its fiscal year ending December 31, 2025.AUDIT-RELATEDISSUER861704.0000000FOR861704.000000FORS000002088Viridian Therapeutics, Inc.92790C104US92790C104506/20/2025To elect the three Class I director nominees to serve until the 2028 Annual Meeting of Stockholders, and until their successors are duly elected and qualified: Jeff AjerDIRECTOR ELECTIONSISSUER244233.0000000FOR244233.000000FORS000002088Viridian Therapeutics, Inc.92790C104US92790C104506/20/2025To elect the three Class I director nominees to serve until the 2028 Annual Meeting of Stockholders, and until their successors are duly elected and qualified: Chris Cain, Ph.D.DIRECTOR ELECTIONSISSUER244233.0000000FOR244233.000000FORS000002088Viridian Therapeutics, Inc.92790C104US92790C104506/20/2025To elect the three Class I director nominees to serve until the 2028 Annual Meeting of Stockholders, and until their successors are duly elected and qualified: Sarah Gheuens, M.D., Ph.D.DIRECTOR ELECTIONSISSUER244233.0000000FOR244233.000000FORS000002088Viridian Therapeutics, Inc.92790C104US92790C104506/20/2025To ratify the selection of KPMG LLP as the Company's independent registered public accounting firm for the year ending December 31, 2025.AUDIT-RELATEDISSUER244233.0000000FOR244233.000000FORS000002088Viridian Therapeutics, Inc.92790C104US92790C104506/20/2025To approve, on an advisory basis, the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER244233.0000000FOR244233.000000FORS000002088Viridian Therapeutics, Inc.92790C104US92790C104506/20/2025To approve a further amendment and restatement of the Company's Amended and Restated 2016 Equity Incentive Plan, including increasing the number of shares available for issuance thereunder by 8,000,000 shares.COMPENSATIONISSUER244233.0000000AGAINST244233.000000AGAINSTS000002088Viridian Therapeutics, Inc.92790C104US92790C104506/20/2025To approve the Viridian Therapeutics, Inc. 2025 Employee Stock Purchase Plan.COMPENSATIONISSUER244233.0000000FOR244233.000000FORS000002088Structure Therapeutics Inc.86366E106US86366E106406/23/2025Election of the nominees for Class II director named below to hold office until the 2028 annual general meeting of shareholders and their successors are duly elected and qualified, or until their earlier death, resignation or removal: Eric DobmeierDIRECTOR ELECTIONSISSUER259835.0000000FOR259835.000000FORS000002088Structure Therapeutics Inc.86366E106US86366E106406/23/2025Election of the nominees for Class II director named below to hold office until the 2028 annual general meeting of shareholders and their successors are duly elected and qualified, or until their earlier death, resignation or removal: Joanne Waldstreicher, M.D.DIRECTOR ELECTIONSISSUER259835.0000000FOR259835.000000FORS000002088Structure Therapeutics Inc.86366E106US86366E106406/23/2025To ratify the appointment by the Audit Committee of the Board of Directors of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025.AUDIT-RELATEDISSUER259835.0000000FOR259835.000000FORS000002088Structure Therapeutics Inc.86366E106US86366E106406/23/2025To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the proxy statement.SECTION 14A SAY-ON-PAY VOTESISSUER259835.0000000FOR259835.000000FORS000002088Structure Therapeutics Inc.86366E106US86366E106406/23/2025To indicate, on an advisory basis, the preferred frequency of shareholder advisory votes on the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER259835.0000000ONE YEAR259835.000000FORS000002088IDEAYA Biosciences, Inc.45166A102US45166A102506/24/2025To elect two Class III directors to hold office until the 2028 annual meeting of stockholders or until their successors are elected: Jeffery L. Stein. Ph.D.DIRECTOR ELECTIONSISSUER181995.0000000FOR181995.000000FORS000002088IDEAYA Biosciences, Inc.45166A102US45166A102506/24/2025To elect two Class III directors to hold office until the 2028 annual meeting of stockholders or until their successors are elected: Scott W. MorrisonDIRECTOR ELECTIONSISSUER181995.0000000FOR181995.000000FORS000002088IDEAYA Biosciences, Inc.45166A102US45166A102506/24/2025To ratify the selection, by the Audit Committee of the Company's Board of Directors, of PricewaterhouseCoopers LLP, as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2025;AUDIT-RELATEDISSUER181995.0000000FOR181995.000000FORS000002088IDEAYA Biosciences, Inc.45166A102US45166A102506/24/2025To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers as disclosed in the Proxy Statement accompanying this Notice of Annual Meeting of Stockholders.SECTION 14A SAY-ON-PAY VOTESISSUER181995.0000000FOR181995.000000FORS000002088Orchestra Biomed Holdings, Inc.68572M106US68572M106206/24/2025Election of Class II Directors: Chris ClearyDIRECTOR ELECTIONSISSUER298482.0000000FOR298482.000000FORS000002088Orchestra Biomed Holdings, Inc.68572M106US68572M106206/24/2025Election of Class II Directors: Pamela ConnealyDIRECTOR ELECTIONSISSUER298482.0000000FOR298482.000000FORS000002088Orchestra Biomed Holdings, Inc.68572M106US68572M106206/24/2025Election of Class II Directors: David PacittiDIRECTOR ELECTIONSISSUER298482.0000000FOR298482.000000FORS000002088Orchestra Biomed Holdings, Inc.68572M106US68572M106206/24/2025Ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2025.AUDIT-RELATEDISSUER298482.0000000FOR298482.000000FORS000002088Rhythm Pharmaceuticals, Inc.76243J105US76243J105106/24/2025Election of the Class II directors, each to serve for a three year term until the 2028 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified: Jennifer GoodDIRECTOR ELECTIONSISSUER279688.0000000FOR279688.000000FORS000002088Rhythm Pharmaceuticals, Inc.76243J105US76243J105106/24/2025Election of the Class II directors, each to serve for a three year term until the 2028 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified: Edward T. MathersDIRECTOR ELECTIONSISSUER279688.0000000WITHHOLD279688.000000AGAINSTS000002088Rhythm Pharmaceuticals, Inc.76243J105US76243J105106/24/2025Ratification of the appointment of Ernst & Young LLP as the independent registered public accounting firm for the Company for the fiscal year ending December 31, 2025.AUDIT-RELATEDISSUER279688.0000000FOR279688.000000FORS000002088Rhythm Pharmaceuticals, Inc.76243J105US76243J105106/24/2025Approval, on an advisory (non-binding) basis, of the compensation of the named executive officers of the Company.SECTION 14A SAY-ON-PAY VOTESISSUER279688.0000000FOR279688.000000FORS000002088Rhythm Pharmaceuticals, Inc.76243J105US76243J105106/24/2025Approval of an amendment to our Amended and Restated Certificate of Incorporation to provide for exculpation of officers from breaches of fiduciary duty to the fullest extent permitted by the General Corporation Law of the State of Delaware (the "Officer Exculpation Proposal").CORPORATE GOVERNANCEISSUER279688.0000000FOR279688.000000FORS000002088Rhythm Pharmaceuticals, Inc.76243J105US76243J105106/24/2025Approval of an adjournment of the Annual Meeting, if necessary, to solicit additional proxies if there are not sufficient votes at the time of the Annual Meeting to approve the Officer Exculpation Amendment.CORPORATE GOVERNANCEISSUER279688.0000000AGAINST279688.000000AGAINSTS000002088Arvinas, Inc.04335A105US04335A105106/25/2025Election of three Class I directors: Linda BainDIRECTOR ELECTIONSISSUER523134.0000000FOR523134.000000FORS000002088Arvinas, Inc.04335A105US04335A105106/25/2025Election of three Class I directors: John Houston, Ph.D.DIRECTOR ELECTIONSISSUER523134.0000000FOR523134.000000FORS000002088Arvinas, Inc.04335A105US04335A105106/25/2025Election of three Class I directors: Laurie Smaldone Alsup, M.D.DIRECTOR ELECTIONSISSUER523134.0000000FOR523134.000000FORS000002088Arvinas, Inc.04335A105US04335A105106/25/2025To approve, on an advisory basis, the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER523134.0000000FOR523134.000000FORS000002088Arvinas, Inc.04335A105US04335A105106/25/2025Ratification of the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025.AUDIT-RELATEDISSUER523134.0000000FOR523134.000000FORS000002088Kymera Therapeutics, Inc.501575104US501575104406/25/2025To elect two class II directors to our Board of Directors, each to serve until the 2028 Annual Meeting of Shareholders and until his successor has been duly elected and qualified, or until his earlier death, resignation or removal: Jeffrey Albers, J.D., MBADIRECTOR ELECTIONSISSUER1199603.0000000FOR1199603.000000FORS000002088Kymera Therapeutics, Inc.501575104US501575104406/25/2025To elect two class II directors to our Board of Directors, each to serve until the 2028 Annual Meeting of Shareholders and until his successor has been duly elected and qualified, or until his earlier death, resignation or removal: Felix J. Baker, Ph.D.DIRECTOR ELECTIONSISSUER1199603.0000000FOR1199603.000000FORS000002088Kymera Therapeutics, Inc.501575104US501575104406/25/2025To approve, on a non-binding advisory basis, the compensation of our named executive officers; andSECTION 14A SAY-ON-PAY VOTESISSUER1199603.0000000FOR1199603.000000FORS000002088Kymera Therapeutics, Inc.501575104US501575104406/25/2025To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025.AUDIT-RELATEDISSUER1199603.0000000FOR1199603.000000FORS000002088Praxis Precision Medicines, Inc.74006W207US74006W207006/26/2025To elect the Class II Directors to serve until the 2028 Annual Meeting of Stockholders and until their respective successors have been duly elected and qualified: Jeffrey Chodakewitz, M.D.DIRECTOR ELECTIONSISSUER240343.0000000FOR240343.000000FORS000002088Praxis Precision Medicines, Inc.74006W207US74006W207006/26/2025To elect the Class II Directors to serve until the 2028 Annual Meeting of Stockholders and until their respective successors have been duly elected and qualified: Merit Cudkowicz, M.D.DIRECTOR ELECTIONSISSUER240343.0000000FOR240343.000000FORS000002088Praxis Precision Medicines, Inc.74006W207US74006W207006/26/2025To ratify the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025.AUDIT-RELATEDISSUER240343.0000000FOR240343.000000FORS000002088Praxis Precision Medicines, Inc.74006W207US74006W207006/26/2025To approve, on an advisory (non-binding) basis, the compensation of the named executive officers as disclosed in the Company's proxy statement for the 2025 Annual Meeting of Stockholders pursuant to the applicable compensation disclosure rules of the SEC, including the compensation tables and narrative discussion.SECTION 14A SAY-ON-PAY VOTESISSUER240343.0000000AGAINST240343.000000AGAINSTS000002088Revolution Medicines, Inc.76155X100US76155X100006/26/2025To elect four Class II directors to hold office until the 2028 Annual Meeting of Stockholders or until his or her successor is elected: Frank K. Clyburn, Jr.DIRECTOR ELECTIONSISSUER1488405.0000000FOR1488405.000000FORS000002088Revolution Medicines, Inc.76155X100US76155X100006/26/2025To elect four Class II directors to hold office until the 2028 Annual Meeting of Stockholders or until his or her successor is elected: Sandra J. Horning, M.D.DIRECTOR ELECTIONSISSUER1488405.0000000FOR1488405.000000FORS000002088Revolution Medicines, Inc.76155X100US76155X100006/26/2025To elect four Class II directors to hold office until the 2028 Annual Meeting of Stockholders or until his or her successor is elected: Sushil Patel, Ph.D.DIRECTOR ELECTIONSISSUER1488405.0000000FOR1488405.000000FORS000002088Revolution Medicines, Inc.76155X100US76155X100006/26/2025To elect four Class II directors to hold office until the 2028 Annual Meeting of Stockholders or until his or her successor is elected: Thilo Schroeder, Ph.D.DIRECTOR ELECTIONSISSUER1488405.0000000FOR1488405.000000FORS000002088Revolution Medicines, Inc.76155X100US76155X100006/26/2025To ratify the appointment, by the Audit Committee of the Company's Board of Directors, of PricewaterhouseCoopers LLP, as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2025; andAUDIT-RELATEDISSUER1488405.0000000FOR1488405.000000FORS000002088Revolution Medicines, Inc.76155X100US76155X100006/26/2025To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers as disclosed in the Proxy Statement pursuant to the compensation disclosure rules of the Securities and Exchange Commission ("Say-on-Pay").SECTION 14A SAY-ON-PAY VOTESISSUER1488405.0000000FOR1488405.000000FORS000002088United Therapeutics Corporation91307C102US91307C102706/26/2025Election of Directors: Christopher CauseyDIRECTOR ELECTIONSISSUER71496.0000000FOR71496.000000FORS000002088United Therapeutics Corporation91307C102US91307C102706/26/2025Election of Directors: Raymond DwekDIRECTOR ELECTIONSISSUER71496.0000000FOR71496.000000FORS000002088United Therapeutics Corporation91307C102US91307C102706/26/2025Election of Directors: Richard GiltnerDIRECTOR ELECTIONSISSUER71496.0000000FOR71496.000000FORS000002088United Therapeutics Corporation91307C102US91307C102706/26/2025Election of Directors: Ray KurzweilDIRECTOR ELECTIONSISSUER71496.0000000FOR71496.000000FORS000002088United Therapeutics Corporation91307C102US91307C102706/26/2025Election of Directors: Jan MalcolmDIRECTOR ELECTIONSISSUER71496.0000000FOR71496.000000FORS000002088United Therapeutics Corporation91307C102US91307C102706/26/2025Election of Directors: Linda MaxwellDIRECTOR ELECTIONSISSUER71496.0000000FOR71496.000000FORS000002088United Therapeutics Corporation91307C102US91307C102706/26/2025Election of Directors: Nilda MesaDIRECTOR ELECTIONSISSUER71496.0000000FOR71496.000000FORS000002088United Therapeutics Corporation91307C102US91307C102706/26/2025Election of Directors: Judy OlianDIRECTOR ELECTIONSISSUER71496.0000000FOR71496.000000FORS000002088United Therapeutics Corporation91307C102US91307C102706/26/2025Election of Directors: Christopher PatuskyDIRECTOR ELECTIONSISSUER71496.0000000FOR71496.000000FORS000002088United Therapeutics Corporation91307C102US91307C102706/26/2025Election of Directors: Martine RothblattDIRECTOR ELECTIONSISSUER71496.0000000FOR71496.000000FORS000002088United Therapeutics Corporation91307C102US91307C102706/26/2025Election of Directors: Louis SullivanDIRECTOR ELECTIONSISSUER71496.0000000FOR71496.000000FORS000002088United Therapeutics Corporation91307C102US91307C102706/26/2025Election of Directors: Tommy ThompsonDIRECTOR ELECTIONSISSUER71496.0000000FOR71496.000000FORS000002088United Therapeutics Corporation91307C102US91307C102706/26/2025Advisory resolution to approve executive compensation.SECTION 14A SAY-ON-PAY VOTESISSUER71496.0000000FOR71496.000000FORS000002088United Therapeutics Corporation91307C102US91307C102706/26/2025Approval of the amendment and restatement of the United Therapeutics Corporation Amended and Restated 2015 Stock Incentive Plan.COMPENSATIONISSUER71496.0000000FOR71496.000000FORS000002088United Therapeutics Corporation91307C102US91307C102706/26/2025Ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for 2025.AUDIT-RELATEDISSUER71496.0000000FOR71496.000000FORS000002088Pharvaris NVN69605108NL00150005Y406/27/2025Adopt Financial Statements and Statutory ReportsCORPORATE GOVERNANCEISSUER577425.0000000FOR577425.000000FORS000002088Pharvaris NVN69605108NL00150005Y406/27/2025Ratify PricewaterhouseCoopers Accountants N.V. as AuditorsAUDIT-RELATEDISSUER577425.0000000FOR577425.000000FORS000002088Pharvaris NVN69605108NL00150005Y406/27/2025Approve Discharge of DirectorsCORPORATE GOVERNANCEISSUER577425.0000000FOR577425.000000FORS000002088Pharvaris NVN69605108NL00150005Y406/27/2025Authorize Repurchase of Ordinary Shares or Depositary ReceiptsCAPITAL STRUCTUREISSUER577425.0000000FOR577425.000000FORS000002088Pharvaris NVN69605108NL00150005Y406/27/2025Reelect David Meeker as Non-Executive DirectorDIRECTOR ELECTIONSISSUER577425.0000000AGAINST577425.000000AGAINSTS000002088Pharvaris NVN69605108NL00150005Y406/27/2025Reelect Robert Glassman as Non-Executive DirectorDIRECTOR ELECTIONSISSUER577425.0000000FOR577425.000000FORS000002088Pharvaris NVN69605108NL00150005Y406/27/2025Reelect Viviane Monges as Non-Executive DirectorDIRECTOR ELECTIONSISSUER577425.0000000FOR577425.000000FORS000002088